_	Page 1
From:	<u>"Waves Rebecca"</u>
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	1/5/2021 1:21:46 AM
Subject:	Re: UT Austin Contract 2019 4681 For Signature
ar abigai this the n	l, noment for the invoice? how much should i invoice?
irmly	
ecca	
On 4 Jan	2021, at 20:18, Vijalapuram, Jayashree < <u>jayashreev@austin.utexas.edu</u> > wrote:
Rebecca:	
It usually	nd the invoice to Professor Aiken, she will approve and forward it to me for payment. takes 8-10 business days to process the payment. If free contact me with any questions.
< <u>araa2@</u>	Accounting < <u>Ibjaccounting@austin.utexas.edu</u> >, <u>araa2@utexas.edu</u> utexas.edu>, Vijalapuram, Jayashree < <u>jayashreev@austin.utexas.edu</u> > Re: UT Austin Contract 2019 4681 For Signature ecca,
Thank you	u for your kind email. I am copying Jayashree, who can assist with any payment questions.
Jayashree	e, could you please let Rebecca know what is needed for her request?
Best, Jeff	
	ERVE Sr. Grants & Contracts Specialist ity of Texas at Austin LBJ School of Public Affairs Office of Research 512.471.3043 SRH 3.388
Date: Sa To: Jeffre Cc: LBJ	aves Rebecca turday, December 26, 2020 at 10:05 AM ey Meserve < <u>meserve@austin.utexas.edu</u> > Accounting < <u>Ibjaccounting@austin.utexas.edu</u> >, Abigail Aiken < <u>araa2@utexas.edu</u> > Re: UT Austin Contract 2019 4681 For Signature
Dear Jeff,	
I would gr	e to reach out to you concerning this contract. ately appreciate it if you could let me know what is the schedule for payment aso much ards
	2/0/2024

On 6 May 2019, at 20:08, Jeff Meserve <<u>meserve@austin.utexas.edu</u>> wrote:

Dear Rebecca,

Please find attaching the UT Austin services agreement for your work on Dr. Abigail Aiken's grant project. Please review and sign on page 5 of the attached PDF and return to us at your convenience. Please let us know of any questions.

Best,

Jeff Meserve

JEFF MESERVE | Sr. Grants & Contracts Specialist The University of Texas at Austin | LBJ School of Public Affairs | Office of Research | 512.471.3043 | SRH 3.388 <Rebecca_Gomperts.pdf>

This message is from an external sender. Learn more about why this matters.

	Page 1
From:	
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	"Rebecca Gomperts" <
	<u>"Melissa Madera" <mmadera@utexas.edu></mmadera@utexas.edu></u>
Date:	2/5/2021 1:54:44 PM
Subject:	Social Science and Medecine Manuscript Submission

Dear All,

I submitted our manuscript to Social Science and Medicine this morning. Thank you all for taking the time with this research, and offering such thorough and thoughtful comments on the manuscript. I really appreciate it! You should receive an author confirmation from the journal, if you have not already.

Thank you again, I am grateful for all your help on this!!

Hope you all have lovely weekend :)

Best,

	<u> </u>
From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	<u>"Jennifer E Starling" <jstarling@utexas.edu></jstarling@utexas.edu></u>
	"Rebecca Gomperts"
Date:	3/5/2021 7:58:32 PM
Subject:	Fwd: JAMA Network Open JNO21-0447-T Decision Letter

Hi there,

Some positive news from JAMA Network Open-an R&R on our paper!

I took a quick look through all of the comments and I think it's pretty straight forward, although there is quite a lot of it! I'll start working on it next week and then I'll be in touch with any reviewer points where I need input from you all.

Jenn: there are a few stats things I think I'll need your help with. Would you have time over the next couple of weeks for that? They are asking for the revision back within 3 weeks but have also said that an extension is OK if we ask for it. I think I will need a week's extension since I'm out for Spring Break March 15th-19th. I'll wait to hear if that sounds OK to you before I write back to them.

Thanks so much, this is very exciting! A

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>

------ Forwarded message ------From: <jamanetworkopen@jamanetwork.org Date: Fri, Mar 5, 2021 at 1:55 PM Subject: JAMA Network Open JNO21-0447-T Decision Letter To: <araa2@utexas.edu>

PLEASE REPLY TO CONFIRM RECEIPT OF THIS LETTER

March 5, 2021

Dr Abigail Aiken University of Texas at Austin LBJ School of Public Affairs PO Box Y Austin, Texas 78712

RE: Factors Associated with Accessing Self-Managed Medication Abortion from an Online Telemedicine Service in the United States

Dear Dr Aiken:

We have completed our review of your manuscript "Factors Associated with Accessing Self-Managed Medication Abortion from an Online Telemedicine Service in the United States." We are interested in your paper but not in its current state. We would be interested in evaluating a revised version that

addresses the Comments and Editorial Requirements listed below.

When revising the manuscript, please include an "Author Response Letter" with an itemized, pointby-point response to each item under the following categories, which are listed below my signature in this email:

- Editorial Requirements
- Editor Comments (if included)
- Reviewer Comments

If you decide to revise your manuscript along these lines, please note that the decision regarding publication will be based on our priorities at the time, the quality of your revision, and perhaps additional review. We would like to receive your revised manuscript within 3 weeks. If that timeline is too stringent, please let me know.

After reviewing this letter and all comments, please confirm that you can submit a revision within this time. Or, let us know if you require additional time or do not plan to submit a revised manuscript.

To log in to our online submission system and submit the revised manuscript, click on the link below. You will be required to enter your password. If you are unable to locate your password please click the "Unknown/Forgotten password" link.

https://manuscripts.jamanetworkopen.com/cgi-bin/main.plex? el=A1Np3IxL6A5BACL5I1A9ftdnDtOXMQxEkNgGsxCQRM36gZ

Please do not share this email with anyone.

Please feel free to contact me if you have any questions.

Thank you for the privilege of reviewing your work.

Sincerely yours,

Olugbenga Ogedegbe, MD, MS, MPH Associate Editor - JAMA Network Open <u>https://jamanetwork.com</u>

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential, or proprietary information, and may not be redistributed in any way without the sender's consent.

EDITORIAL REQUIREMENTS

AUTHOR RESPONSE LETTER

Please itemize and indicate how you have addressed each of the items and comments below in a detailed response letter accompanying your revised manuscript. Include the original comment or specific reference to each comment along with page numbers and sections or line numbers for each item/comment as they appear in the new clean version without tracked changes. Such itemization will facilitate a timely and efficient review of your revision.

REVISED MANUSCRIPT

The text of the revised manuscript should be double spaced and all pages should be numbered.

Two versions: (1) Submit your revised manuscript text file in Word, with revisions marked using the "track changes" or "edit" feature. (2) Also submit a clean version with all changes accepted.

On the title page(s), include the title and subtitle; names, academic degrees, and affiliations of all authors; date of the revision; and a word count for text only (ie, not including the title, abstract, acknowledgments, references, tables, and figure legends).

TEXT WORD LENGTH

Limit the length of the text of your revised manuscript (not including title, abstract, references, and acknowledgment) to 3000 words.

CORRESPONDING AUTHOR

Identify a corresponding author and include that author's address, telephone numbers, and email address on the title page and in the JAMA Network Open manuscript submission screen.

COAUTHORS

All coauthors' complete names and email addresses, in the correct order as they appear in the manuscript, are required to be listed in the manuscript submission system.

AUTHORSHIP FORMS

Each author will be sent an email with instructions for submitting the Authorship Forms, with information about authorship responsibility, funding and conflicts of interests, and a publishing agreement.

NOTE: If your manuscript is accepted, all authorship forms must be obtained at the time of revision before we can move forward with publication. We ask that you provide an accurate, current email address of each coauthor in the manuscript submission system when you submit your revision.

AUTHOR CONFLICT OF INTEREST DISCLOSURES

Please verify and confirm that all conflict of interest disclosure information for you and all coauthors is accurate, complete, up-to-date, and reported in the Acknowledgment section of the manuscript in a manner that is consistent with that reported in the disclosures of potential conflicts of interest section of the journal's Authorship Form.

Our policy requires that all authors disclose:

• Any potential conflicts of interest involving the work under consideration for publication (during the time involving the work, from initial conception and planning to present);

• Any relevant financial activities outside the submitted work (during the 3 years prior to submission); And any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what is written in the submitted work (based on all relationships that were present during the 3 years prior to submission).

Potential conflicts of interest include but are not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers' bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. For example, authors of a manuscript about hypertension should report all financial relationships they have with all manufacturers of products used in the management of hypertension, not only those relationships with companies whose specific products are mentioned in the manuscript.

Authors without potential conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests. If you are uncertain about what constitutes a relevant financial interest or relationship, please let me know. Each author will be sent an email with further instructions for submitting the Authorship Form, which includes the ICMJE Disclosure of Potential Conflicts of Interest section.

KEY POINTS

In the manuscript, include a separate section called "Key Points" before the Abstract.

This feature provides a quick structured synopsis of the findings of your manuscript (required only for research and review manuscripts), following 3 key points: Question, Findings, and Meaning. Limit this section to 75-100 words or less.

Question: Focused question based on the study hypothesis or goal/purpose. Limit to 1 sentence.

Findings: Results of the study/review. Include the design (eq. clinical trial, cohort study, case-control study, meta-analysis, systematic review). Focus on primary outcome(s) and finding(s). Do not emphasize secondary outcomes. Report basic numbers only but state if results are statistically significant or not significant; do not include results of statistical tests or measures of variance (see example below). Limit to no more than 1-2 sentences.

Meaning: Key conclusion and implication based on the primary finding(s). Limit to 1 sentence.

TWEET

Please submit a Tweet of no more than 257 characters that conveys the essential message of your paper, which we will then edit and publish through JAMA Network Open's Twitter account to promote your article. A field for the Tweet will be available on the manuscript revision submission form. Please also provide your Twitter handle if you have one. Note: We may add an image and hashtags (a word or phrase preceded by a hash or pound sign and used to identify messages on a specific topic).

ABSTRACT

Submit a structured abstract of no more than 350 words using Abstracts for Reports of Original Data. See Instructions for Authors at

https://jamanetwork.com/journals/jamanetworkopen/pages/instructions-for-authors#SecAbstracts.

--ACKNOWLEDGMENT SECTION--

FUNDING/SUPPORT

All financial and material support for the research and/or the work reported in the manuscript should be clearly and completely identified in the Acknowledgment. If the work was not funded, please state "no funding".

ROLE OF FUNDER/SPONSOR STATEMENT

Using the exact language enclosed in the following quotation marks, the specific role of the funding organization or sponsor in each of the following should be specified: "design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication." The work should be clearly and completely identified in the Acknowledgment section of the manuscript.

NON-AUTHOR CONTRIBUTIONS to Data Collection, Analysis, or Writing/Editing Assistance All persons who have made substantial contributions to the work reported in this manuscript (eg, data collection, analysis, or writing or editing assistance) but who do not fulfill the authorship criteria should be named with their specific contributions in an Acknowledgment section of the manuscript. Provide complete names, affiliations, academic degrees, roles/contributions, and indication if compensation was received for all persons named in the Acknowledgment. Please confirm that you have obtained written permission to include the names of individuals in the Acknowledgment section of the manuscript (you do not need to submit copies of such permission to the journal).

ACCESS TO DATA AND DATA ANALYSIS

Using the exact language enclosed in the following quotation marks, provide a statement from 1 author (eg, the principal investigator), or no more than 2 authors, that she or he "had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis" and include this in the Acknowledgment section of the manuscript.

For all reports containing original data, the names and affiliations of all authors (or other individuals) who conducted and are responsible for the data analysis must be indicated in the Acknowledgment section of the manuscript. If the individual who conducted the analysis is not named as an author, a detailed explanation of his/her contributions and reasons for his/her involvement with the data analysis should be included.

MEETING PRESENTATION

If you are planning to present this work at a major meeting, please confirm the date and time of your planned meeting presentation so that we may consider possible publication to coincide with your presentation, and include this information in the designated field on the manuscript submission screen when you upload your revised manuscript.

ORIGINALITY OF CONTENT

Please verify that all information and materials in the manuscript are original. JAMA Network Open generally does not republish text, tables, figures, or other material from other publishers, except in rare circumstances. If you believe that you must include content that is owned by a third party, please let us know.

--REPORTING REQUIREMENTS--

ETHICAL REVIEW OF STUDY

Add a statement to the Methods section on review and approval of the study by an IRB or ethics committee, or institutional or regulatory determined waiver/exemption of such review.

INFORMED CONSENT OF STUDY PARTICIPANTS

Add a statement to the Methods section on how informed consent (oral or written) was obtained from study participants, or note if a waiver/exemption of such consent was granted by an IRB or ethics committee or regulatory authority.

REPORTING RACE/ETHNICITY

If race and/or ethnicity is reported, add information to the Methods section indicating who classified individuals, whether options were defined by the investigator or participant, and why race and/or ethnicity was assessed in the study.

REPORTING SEX

Report the sex distribution of study participants or samples in the Results section, including studies of humans and preclinical studies of tissues, cells, or animals, if appropriate. If data from participants of only 1 sex are reported, or participants of only 1 sex are included in the study, explain why the other sex is not reported or included, except for studies of diseases/disorders that are sex-specific.

IDENTIFIABLE PATIENTS AND PERMISSION

Provide written permission from all individuals who are identifiable in any photograph, case description, pedigree, video, or audio file. You will be sent an email with further instructions for submitting the Patient Permission Form.

USE OF CAUSAL LANGUAGE

Causal language (including use of terms such as "effect," "efficacy," "cause," and "x increased y") should be used only for randomized trials. For all other study designs (including meta-analyses of randomized trials), methods and results should be described in terms of association or correlation (eg, "x associated with an increase in y") and should avoid cause-and-effect wording.

Avoid use of the words "predict" and "predictive of" for reports of observational studies assessing independent and dependent variables, unless your study design is a diagnostic/prognostic study and has used an appropriate approach to quantifying predictive performance such as (but not limited to) split sampling, cross-validation, or bootstrapping.

PRESENTATION OF STATISTICS AND DATA

Provide a brief description of all statistical tests used in the study and levels of statistical significance.

For reports of original data, present numerical results (eg, absolute numbers, proportions, rates, ratios, or differences) with appropriate indicators of uncertainty, such as confidence intervals.

For baseline data and descriptive studies only, use means and standard deviations (SDs) for normally distributed data and medians and ranges or interquartile ranges (IQRs) for data that are not normally distributed. Avoid relying solely on statistical hypothesis testing, such as the use of P values, which fails to convey important quantitative information.

When P values are provided, they should be exact and expressed to 2 digits to the right of the decimal point, or to 3 digits if <.01.

Please provide an assessment of missing values and participants lost to follow-up.

All units of measure should be expressed in conventional units, accompanied by conversion factors to System International (SI) units (see Instructions for Authors at:

https://jamanetwork.com/journals/jamanetworkopen/pages/instructions-forauthors#SecUnitsofMeasure).

PERMISSION FOR PERSONAL COMMUNICATION

Provide written permission from all individuals named in personal communications (oral or written) stating that they agree to be named and that the information cited in the personal communication is accurate.

REFERENCES

See Instructions for Authors (<u>https://jamanetwork.com/journals/jamanetworkopen/pages/instructions-for-authors#SecReferences</u>) for guidance on manuscript reference style and format.

--TABLES, FIGURES, AND ONLINE SUPPLEMENTAL FILES--

Please limit your paper to include a maximum of 5 tables and/or figures, which will be included in the main article. For other tables, figures, and supporting materials that are important to the understanding and interpretation of the manuscript and have not been previously published elsewhere, please provide these materials as a supplemental document for online-only material. If the manuscript is accepted, these materials will be posted online (unedited) at the time of publication, at the discretion of the editors.

Do not indicate in the text of the manuscript where tables and figures should be placed.

TABLES

Tables should be constructed in Word using single spacing and the table editor feature and be placed at the end of the manuscript file. Do not embed tables as images in the manuscript file or upload tables in image formats. Each unit of information must be in its own cell. Do not use tabs or spaces to set up tables. See the Table Creation section in the Instructions for Authors at:

https://jamanetwork.com/journals/jamanetworkopen/pages/instructions-for-authors#SecTables

FIGURES

Please give each figure its own descriptive title of no more than 10-15 words, as well as an explanatory figure legend. Do not submit figures with more than 4 panels unless otherwise justified.

Each figure should be loaded as a separate file.

See Figure Files Requirements for Publication in the Instructions for Authors at:

https://jamanetwork.com/journals/jamanetworkopen/pages/instructions-forauthors# SecFigures

IMPORTANT: For all figures displaying bar graphs, line graphs and statistical plots, provide graphs

output directly from the software used to create these in an editable VECTOR file format, such as .wmf, .eps, .pdf, or as an Excel graph, if created in Excel. If you provide .pdf files, be sure that these are in VECTOR file formal, not Raster file format. Raster (picture) files, such as .jpg or .tif are not acceptable. All statistical graphs in accepted manuscripts are recreated in-house.

Provide axis labels (numbers and units of measure) for all statistical graphs.

IMPORTANT: Photographs, clinical images, photomicrographs, gel electrophoresis, and the like that include labels, arrows, or other markers must be submitted in 2 versions: one version with the markers and one without. Provide an explanation for all labels, arrows, or other markers in the figure legend. The Figure field in the File Description tab of the manuscript submission form allows for uploading of 2 versions of the same figure.

ONLINE SUPPLEMENTAL FILES

Online-only material should be submitted in a single Word document with pages numbered consecutively. Each element included in the online-only material should be cited in the text of the main manuscript (eg, eTable in the Supplement) and numbered in order of citation in the text (eg, eTable 1, eTable 2, eFigure 1, eFigure 2, eMethods). The first page of the online-only document should list the number and title of each element included in the document.

For additional instructions for preparing online-only materials, please see guidelines for Online-Only Supplements at:

https://jamanetwork.com/journals/jamanetworkopen/pages/instructions-for-authors#SecOnline-OnlySupplementsandMultimedia

JAMA Network Open is dedicated to publishing high quality science, presented clearly and accessible to readers around the world. Articles published in JAMA Network Open should be understandable to clinicians as well as to other scientists. Authors who do not usually write for this audience should consider engaging a technical editor to assist them in the presentation of their work. Authors who are not conversant in English should consider using the services of a certified English translator. Properly and clearly written papers have a greater chance of being published and being widely viewed once published.

EDITOR'S SPECIFIC COMMENTS:

There are several issues that the authors should address, the most important of which is the assertion that race is a major factor associated with increased use of this service. As noted by reviewer #1, the effects of race should and must be untangled from the myriad of factors studied; it is important to account for collinearity and paramount to show that magnitude of the effects of the other factors. Simply mentioning race does not really mean anything other than falsely equivocating causality without untangling the underlying factors that are proxies for race. For example, would be important to untangle the relationship between race and social deprivation in the zip codes where that have the highest request; thesame is true for the proportion of healthcare facilitates in the counties and zip codes with highest density of Black and Brown populations. Finally, you studies many factors but only presented four - is there a reason for this? Would be important to show the demographics in Table 1 particularly of race and ethnicity to podia the reader with a sense of the proportion of Blacks and Hispanics that used the service compared to whites.

ADDITIONAL COMMENTS:

Change title to, "Factors associated with use of an Online Telemedicine Service to Access Medical Abortion in the United States"

Provide a Structured Abstract per the journal's format. See https://jamanetwork.com/journals

/jamanetworkopen/pages/instructions-for-authors#SecAbstracts Include Exposure

Abstract, Results: The number of patients and summary demographic information (eg, baseline characteristics of study participants) should be reported in the first line of the Results section.

Please correct rates in abstract reported for Louisiana.

Key Points, Findings: Include the design, cross-sectional Key Points, Meaning: Please edit to focus on study findings, (individual reported factors and geographic distance at a county level)

Throughout: Avoid use of causal language not justified by this study design: Causal language (including use of terms such as "effect," "efficacy," "cause," and "x increased y") should be used only for randomized trials. For all other study designs (including meta-analyses of randomized trials), methods and results should be described in terms of association or correlation (eg, "x associated with an increase in y") and should avoid cause-and-effect wording.

Introduction: Please edit last sentence to avoid use of causal language.

Methods: Indicate how this report follows the STROBE reporting guideline for cross-sectional studies. See <u>http://www.equator-network.org/reporting-guidelines/strobe</u>/

Results (main text): Summary demographic information (eg, baseline characteristics of study participants) should be reported in the first line of the Results section.

Please review and correct rates/100,000 as relevant.

Discussion: Avoid use of jargon ie. "doubled down" Edit to avoid attribution of geographic associations as relevant to individual decisions.

Discussion: Provide separate sections for Limitations and Conclusions.

Tables: Any notes following the table should have an accompanying footnote symbol within the table to indicate where the information is applicable.

Statistical graphs in the main manuscript, technical: All statistical graphs in accepted manuscripts are re-created in-house using Adobe Illustrator. To facilitate preparation for publication if this manuscript is accepted, please provide graphs output directly from the software used to create them in an editable vector file format, such as .wmf or .eps, or as Excel graphs (including the linked data file), if created in Excel. Raster (picture) files, such as .jpg or .tif, output directly or embedded in vector files, are not acceptable. Figures inserted in PowerPoint or Word are not acceptable.

REVIEWER COMMENTS:

If the reviewers have opted to reveal their identity, please refrain from contacting them directly.

The following individuals involved in review of your submission have agreed to reveal their identity: Blair G Darney (Reviewer #1); Donald D McIntire (Reviewer #2).

Reviewer #1

Overall comments to author

1) Thank you for the opportunity to review this well-written paper. My comments are primarily clarification issues, with some requests for revisions to the Discussion section

Key points

2) Line 38: It seems to me that you present data about distance as a barrier and about race but not together. So can you really say that "these barriers [distance] disproportionately impact people of color" based on your data ?

Abstract

3) Line 49: Design: the term request is a bit confusing, does this mean they ordered meds? The pills obtained or requested an appointment? A bit more clarity here would be helpful.

4) Line 56-57: Why were these two items the distance to clinic and race considered the most important hypothetical factors thought to increase demand? In the methods there are other elements that are explored, you can make a statement here in the abstract to show this is only a couple of the factors you explored.

5) Line 66: clarify this is per 100,000 reproductive-aged women?

6) Conclusion: again, this goes a bit beyond your data. Online telemedicine may be partly a response to access barriers but that is not what you measured - you measured that distance is associated with more requests. And proportion non-white likewise - but these are distinct findings, not distance*race, for example (or I have missed something?). And does the distance barrier disproportionately impact people of color? Or do you mean different barriers here? Can you present some some data that help unpack the possible relationship between race/ethnicity density and distance

7) Line 68 "partly a response" - this sounds causal - is that the intent? Change to "associated with"?

Introduction

8) Line 74-75: "fraught with challenges"? Just simply state that "...in many states, access to abortion in clinics or hospital settings is limited" ?

9) Line 79-80: if you get into Hyde seems important o also state that XX states use state funds to pay for abortions for Medicaid-eligible individuals?

10) Line 82-87: this paragraph does not guite flow - need to explain why the REMS are in place for mife (the theoretical, if non-evidence based, reason for the REMS). "Perceived need for oversight not supported by evidence" or something like that?

11) Line 93-94: change ""a national phenomenon" to "at the population level"?

12) Line 102-106: study purpose. Any hypotheses to state here? Clarify what the local/county factors are (e.g. distance)

Methods

13) Line 1132: consider deleting "age" throughout - say "gestation of 10 weeks" ? "Age" anthropomorphizes the fetus.

14) Line 115: cite for WHO medication abortion protocol?

15) Line 188: recognize signs of potential complications and when to seek care? Is the knowing when to see care in a health facility important or relevant?

16) Line 122: while stopping the study period pre-COVID seems cleaner and reasonable, I was curious about "necessitated some temporary changes to the service model" - why? Model seems perfectly suited to COVID. Is this about delays in drug supply related to the pandemic? 17) Line 165: poverty line - is this FPL - Federal Poverty Level.

18) Line 166-167: this measurement is a bit crude. Counties and zip codes do not overlap. Did you aggregate zip codes up to counties? What about zip codes that are in more than 1 county? I got confused about where you have zip code, where you have county, and how accurate the distance measures are. Distance analysis seems very granular but actually does not seem to be. Please clarify.

19) Line 179: specify how you are operationalizing "increased requests" - increased relative to what? It seems like it is counts per 10,000 - so increased counts compared to some baseline? I got a bit confused (and see Fig 3 confusion as well) Ah! Line 184-186 I see - perhaps revise this paragraph to make outcome more clear up front?

20) Line 179: Clarify this is at the county level? Explicitly state the unit of analysis and N for the model

21) Line 180: not sure negative binomial needs to be capitalized

22) Line 190: I thought you had zip code?

Results

23) Lines 202-204: I'm curious about whether there is threat of social desirability bias in responses that could determine access to the service (somebody who can be with them during abortion, etc).24) Line 225-226: and see below Table 2 - this was not clear reading Table 2.

25) Line 230: Save speculation for Discussion. Also, isn't this study likely overpowered?

26) Line 232: state-level intercepts - OK magnitude is bigger but help reader interpret that number, what does it represent?

27) Line 232: "more restrictive abortion policies" - is this in your study measures or you just know this? Seems the latter. This needs to be explained to help the reader interpret the Figure and state estimates.

28) Table 1.

a. In the title, should it be N (not n) - isn't this the entire sample?

b. Table can be reduced by presenting only one response option (yes?) for binary variables (e.g. Respondent had an US prior to abortion request :15.5%)

c. Do you not have data on education level? Just curious as it is always a key variable. Ditto rural /urban.

d. Reorder Table 1 to present requestor/client demographics first (age, parity) the clinical data? I'm not used to seeing age towards the bottom of a table

29) Table 2

a. How to interpret distance - clarify how you got 47 miles (Line 225) and help reader interpret estimate since distance is not a proportion - so interpretation can't be change in request for a 10% change in proportion as for other variables. Clear in text 225-226 but not in Table)

b. Ditto poverty line (See above)

30) Figure 2.

a. Delete "Map showing" from title.

b. It would be helpful in Discussion to have some point of reference for these rates - how do they compare to know /published abortion rates. And what if they were annual instead of 24 mo rates? 31) Figure 3

a. I got very confused trying to interpret this Figure. Please help reader understand what we are looking at. Tell the reader what the state-elvel intercept means. Please define terms better - this is density of requests to Aid Access, so what does 0.05 mean?

b. Make clear this is the county-level rate model?

c. Is the 10% change really "adjusted" - which implies adjusted for covariates. It is scaled - would that be more accurate? I got confused between a multivariable, adjusted model and the scaling.

d. Title says "predicting" - did you do out of sample prediction? Estimating?

Discussion

32) Please summarize your findings, including key data points, in the first paragraph

33) Line 244-245: is "states with the most burdensome abortion restrictions" ever defined?

34) Line 245-249: this is important but move down (One notable exception....increased request rate.") - getting into the weeds in the summary paragraph

35) Line 250: is a higher density or a relatively higher density (back to my confusion with Fig 3)
36) Line 252: people of color - this makes sense but do your data say this? Where is the law/policy independent variable? Is state a proxy for it? Are restrictive states ever defined?
37) Line 254-260: move this paragraph down

38) Line 260: Can you suggest some hypotheses here? Why might racial minorities need increased access to self manage abortion? What would future studies be trying to answer if focused more on causality?

39) Line 264-266: How/where does Hyde fit here? And what about Medicaid states, does it make sense to discuss Hyde as a state-level impact (although a federal policy)? I was unclear as to how Hyde is framed in Discussion and Introduction - no explicit mention of Medicaid states, that Hyde plays out as a state policy despite being federal policy.

40) Line 265: Please use Roe vs Wade to be complete

41) Line 271-275: this seems like Key point #1 - Suggest leading paragraph with your key points based on your results, then support the assertion with literature (as written you present a lot of context then end with your results) $\frac{2/8}{2024}$

42) Line 277-279: key point #2. Is it relevant to cite evidence about SMA in legal contexts from global settings?

43) Line 287-290: key point #3

44) Line 288: You should consider including that as far as Aid Access know they have not had any serious complications. Again, these medications appear to be safe (even though the source is technically not legal)

45) Lines 296-308: not clear how this links to your results. Focus the conclusion on your data, stay close to the data. Repeat your key findings and implications. Again, state restrictions are not defined or incorporated into the analysis - this needs t be defined up front if you want to draw conclusions about state level restrictions

46) Line 302-304: Is this a call for providers to state that they are prescribing meds for miscarriage when in fact it is for induced termination? Please clarify

47) Does the ongoing Gynuity study impact your results or interpretation in any way?

48) I expected a more developed Discussion of race/ethnicity given the conclusions about race

49) Could the Discussion be focused on the 3 key points (if these are in fact your key points:

a. Increase in SMA in context of declining abortion rates

b. Some chose SMA even when they have access (SMA is not just an access issue)

c. But increase in SMA can also indicate poor access and highlights disparities in access to facility services

Reviewer #1 (Explain how the manuscript can be improved to follow the reporting guidelines.):

would be useful to ask authors to submit STROBE if they ave not already

Reviewer #2

"Factors Associated with Accessing Self-Managed Medication Abortion from an Online Telemedicine Service in the United States"

The most telling information of this report is Figure 1. Distance and cost are not surprising. Of the top ten reasons only three are "process" and the other seven are "fear and convenience". It depends on your position on abortion in general as to whether one finds this alarming or comforting. Some may not find convenience a plus. Some will find this heartening. With that understanding the authors need to assess their position on this highly charged issue and ensure that the presentation doesn't obscure the facts. This reviewer would recommend the authors reread the piece and lessen the implications of a possible perceived opinion. There is very good information in this report, but it could be ignored if there is a perceived agenda. Some greater explanation and evaluation of safety should be emphasized as well. There is a glancing reference to safety on line 280 (which should be expanded) and hospital miscarriage protocols on line 304. This will be an important concern to the expanded use of self-management.

Let me re-emphasize that this is good information, well described, and an interesting read. Don't let the a possibly perceived notion of favor diminish the message.

Reviewer #3

Personally, I think this article is generally good and is useful to abortion. Maybe the adverse reactions of patients after their self-managed medication abortion can be considered in further study

From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	<u>"Jennifer E Starling" <jstarling@utexas.edu></jstarling@utexas.edu></u>
	<u>"Rebecca Gomperts"</u>
	<u>"Rebecca Gomperts" <</u>
Date:	3/8/2021 8:49:49 AM
Subject:	Author forms for JAMA Network Open paper

Hi Jenn and Rebecca,

Following on from my last email about the R&R at JAMA Network Open, I wanted to also check that you both received an email asking you to complete an authorship form and disclose any conflicts of interest?

We need to complete these before we submit the revision. As far as I'm aware, the only COIs we have are the grants I need to report (which I've put on my form) and Rebecca's position as Founder and Director of AA.

Once you've completed your form, please send me the PDF copy you will receive by email from the journal.

Let me know of any questions, and thanks so much! A

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>

From: <u>"Waves Rebecca" <</u>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 3/9/2021 2:27:15 AM

Subject: Fwd: Authorship Form Received for JNO21-0447-T

Attachments: authorship_e_form_jno21-0447-t_gomperts_emvmku.pdf

Begin forwarded message:

From: jamanetworkopen@jamanetwork.org Subject: Authorship Form Received for JNO21-0447-T Date: 9 March 2021 at 06:46:07 CET To:

Reply-To: jamanetworkopen@jamanetwork.org

March 9, 2021

Dear Dr Gomperts,

Thank you for submitting your Authorship form for JAMA Network Open. Your authorship form will be reviewed for accuracy and completeness. If there are any omissions, the form will be returned to you for correction and resubmission. A PDF copy of the form is attached for your reference.

Sincerely yours,

Editorial Staff

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

The JAMA Network Journals' Authorship Responsibility, Funding and Conflicts of Interest, and Publishing Agreement for Coauthor

Each author must read and complete the following sections:

- 1. Authorship Responsibility, Criteria, and Contributions
- 2. Disclosure of Potential Conflicts of Interest
- 3. Publishing Agreement
- 4. Confirmation

JAMA Network Open

Manuscript # JNO21-0447-T

Manuscript Title: Factors Associated with Accessing Self-Managed Medication Abortion from an Online Telemedicine Service in the United States

Author Name: Rebecca Gomperts

Corresponding Author: Abigail Aiken

Phone:

Email:

Step 1. Authorship Responsibility, Criteria, and Contributions. Each author should meet all criteria below (A, B, C, and D) and should indicate general and specific contributions by reading criteria A, B, C, and D and checking the appropriate boxes. A contribution statement based on this form will be published with the final version of your article; please ensure the contributions are accurate.

A. I certify that

- The manuscript represents original and valid work and that neither this manuscript nor one with substantially similar content under my authorship has been published or is being considered for publication elsewhere, except as described in the journal's submission form and cover letter submitted with the manuscript, and copies of closely related manuscripts have been provided; and
- I agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; and
- If requested, I will provide the data or will cooperate fully in obtaining and providing the data on which the manuscript is based for examination by the editors or their assignees; and
- For papers with more than 1 author, I agree to allow the corresponding author to serve as the primary correspondent with the editorial office, to review the edited manuscript and proof, and to make decisions regarding release of information in the manuscript to the media, federal agencies, or both; or, if I am the only author, I will be the corresponding author and agree to serve in the roles described above.
- \blacksquare B. I have given final approval of the submitted manuscript.

C. I have participated sufficiently in the work to take public responsibility for (check 1 of 2 below)

- o part of the content.
- the whole content.

D. To qualify for authorship, you must check at least 1 box for each of the 3 categories of contributions listed below.

I have made substantial contributions to the intellectual content of the paper as described below.

- 1. Check at least 1 of 2 below
- $\hfill\square$ concept and design
- ✓ acquisition, analysis, or interpretation of data
- 2. Check at least 1 of 2 below
- □ drafting of the manuscript
- ✓ critical revision of the manuscript for important intellectual content
- 3. Check at least 1 below
- statistical analysis
- ☐ obtained funding
- 🗖 administrative, technical, or material support
- \blacksquare supervision
- no additional contributions
- other

Step 2. Disclosure of Potential Conflicts of Interest

The purpose of this section is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The section includes the questions from the ICMJE Form for Disclosure of Potential Conflicts of Interest and is divided into 5 subsections.

Authors are expected to provide detailed information about all relevant financial interests, activities, relationships, and affiliations (other than those affiliations listed in the title page of the manuscript) including, but not limited to, employment, affiliation, funding and grants received or pending, consultancies, honoraria or payment, speakers bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

• 2A. The work under consideration for publication.

This subsection asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party—that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support

the work, such as a government granting agency, charitable foundation, or commercial sponsor, check "Yes."

• 2B. Relevant financial activities outside the submitted work.

This subsection asks about your financial relationships with entities in the biomedical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations, or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

• 2C. Intellectual property.

This subsection asks about patents and copyrights, whether pending, issued, licensed, and/or receiving royalties.

• 2D. Relationships not covered above.

Use this subsection to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: Government agency, foundation, commercial sponsor, academic institution, etc Grant: A grant from an entity, generally (but not always) paid to your organization Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations Non-Financial Support:

Other: Anything not covered under the previous 3 boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc

• 2E. Disclosure statement.

Step 2A. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc)? Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. If you have more than 1 entity, press the "Add" button to add a row. Excess rows can be removed by pressing the "Remove" button. If you have selected the "Other" checkbox, a "Comment" will be required.

No

Step 2B. Relevant Financial Activities Outside the Submitted Work

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. If you have more than 1 entity, press the "Add" button to add a row. Excess rows can be removed by pressing the "Remove" button. If you have selected the "Other" checkbox, a "Comment" will be required. You should report relationships that were **present during the 36 months prior to publication**.

Yes

1. aid access other

salary

 women on waves other salary

Step 2C. Intellectual Property—Patents and Copyrights

Do you have any patents, whether planned, pending, or issued, broadly relevant to the work? Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions.

No

Step 2D. Relationships Not Covered Above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, the journal will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, the journal may ask authors to disclose further information about reported relationships.

Step 2E. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement in the box below after you click the "Generate Disclosure Statement" button. Any subsequent changes will also update the disclosure statement automatically after clicking the "Submit" button.

Dr Gomperts reports other from aid access salary and other from women on waves salary outside the submitted work.

Step 3. Publishing Agreement. The corresponding author has indicated that this work is eligible for an open access CC-BY license, which requires transfer of a publication license to the journal.

License rights: Immediate open access on journal website on the day of publication, access to a PDF copy of the published article, retention of copyright, and the granting of a CC-BY license that permits others to distribute, remix, tweak, and build on the work, even commercially, without permission—provided that credit is given to the original authors and journal.

All authors must select only 1 of the following: A, or B, or C.

• A. Publication License. In consideration of the action of the American Medical Association (AMA) in reviewing and editing this submission (manuscript, tables, figures, video, audio, and other supplemental files for publication), I hereby transfer, assign, or otherwise convey first publication rights exclusively to the AMA, in the event that such work is published by the AMA, in addition to the attributes of a CC-BY license.

• B. Federal Employment. I was an employee of the US federal government or that of another nation when this work was conducted and prepared for publication; therefore, it is not protected by the Copyright Act.

C. Work for Hire. I am employed by an institution that considers this submission a "work made for hire" and therefore I cannot transfer a publication license.

Name of Institution:

First Name of Authorized Representative:

Last Name of Authorized Representative:

Email Address of Authorized Representative:

Step 4. Confirmation. Confirm that all information provided is accurate by checking the box below and then enter your complete name **as it appears at the top of this form** and date of confirmation in the fields below.

✓ I certify that all information I have provided is accurate.

Complete Name: rebecca gomperts

Date: 09032021

local_p_id: 140724 time: 1615268766 ip address:

	Page 1
From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	<u>"Jennifer E Starling" <jstarling@utexas.edu></jstarling@utexas.edu></u>
	"Rebecca Gomperts"
Date:	4/1/2021 11:29:18 AM
Subject:	Fwd: JNO21-0447R Receipt of Revised Manuscript by JAMA Network Open
Attachments:	JNO21-0447R_Merged_PDF.pdf

The revision is in! (PDF attached for your records). Fingers crossed for a positive outcome... Thanks so much, A

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: araa2@utexas.edu

------ Forwarded message ------From: <jamanetworkopen@jamanetwork.org> Date: Thu, Apr 1, 2021 at 11:03 AM Subject: JNO21-0447R Receipt of Revised Manuscript by JAMA Network Open To: <<u>araa2@utexas.edu</u>>

Dear Dr Aiken:

On April 1, 2021, we received your revised manuscript, "Factors Associated with use of an Online Telemedicine Service to Access Self-managed Medical Abortion in the United States," (Manuscript #JNO21-0447R). We will contact you as soon as this revision has been evaluated.

You may check the status of this manuscript by selecting the Check Manuscript Status link on the following Web page. You will be required to enter your password. If you are unable to locate your password please click the "Unknown/Forgotten password".

Please do not share this email with anyone.

https://manuscripts.jamanetworkopen.com/cgi-bin/main.plex? el=A1Np5IxL6B7BACL7F7A9ftd7QDIyxHxDfhyh2iV1tKAZ

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the sender's consent.

Thank you for considering JAMA Network Open for publication of your work.

Sincerely,

Michaela Mark Editorial Assistant JAMA Network Open jamanetworkopen@jamanetwork.org https://jamanetwork.com

1 2 3 4	Factors Associated with use of an Online Telemedicine Service to Access Self-managed Medical Abortion in the United States
5 6 7 8	Abigail R.A. Aiken, MD, PhD ^{1,2,*} , Jennifer E. Starling, PhD ³ , Rebecca Gomperts, MD, PhD ⁴
8 9	¹ Associate Professor, LBJ School of Public Affairs, University of Texas at Austin, Austin, TX, 78712
10	² Faculty Associate, Population Research Center, University of Texas at Austin, Austin, TX, 78712
11	³ Statistician, Mathematica Policy Research Inc., Cambridge, MA, 02139
12	⁴ Founder and Director, Aid Access
13 14	*Corresponding author:
15	LBJ School of Public Affairs
16	University of Texas at Austin
17	Austin, TX, 78712
18	
19	araa2@utexas.edu
20 21	Date of Revision: March 31 st 2021

- 22 23 24 Manuscript Word Count: 3,000

25 Key Points

26

27 Question: What factors are associated with accessing self-managed medication abortion using

28 online telemedicine in the United States?

29

- **30** Findings: This cross-sectional study of 57,506 people in 2,458 counties examined individual reasons
- 31 for requesting self-managed abortion, as well as state- and county-level factors and rate of requests.
- 32 At the individual level, the cost of in-clinic care was the most commonly cited factor. At the county
- 33 level, a 47 mile increase in distance to the nearest clinic was significantly associated with a 41%
- 34 increase in requests, while a 10% increase in the population living in poverty was significantly
- associated with a 20% increase in requests.

36

- 37 Meaning: Clinic access barriers at the individual level and both distance to an abortion clinic and
 38 poverty at the county level are associated with higher demand for self-managed abortion.
- 39

40

41

43 Abstract (350)

- 44 **Importance:** Evidence shows that people in the United States are self-managing abortions outside
- 45 the formal healthcare system using medications obtained through online telemedicine. However,
- 46 little is known about this practice, including potential motivating factors.
- 47 **Objective:** To examine individual reasons for accessing medication abortion through online
- 48 telemedicine, as well as associations between state- and county-level factors and rate of requests.
- 49 Design: A population-based study examining all requests through the service's online consultation
 50 form between March 20th 2018 and March 20th 2020.
- 51 Setting: The sole online telemedicine organization in the US.
- 52 **Participants:** All people who made a request to the online telemedicine service.
- 53 Main Outcomes and Measures: We examined individual-level reasons for accessing the service
- 54 and the rate of requests per 100,000 reproductive-aged women by state. We then used zip code data
- 55 provided by requestors to examine county-level factors hypothesized to increase demand for self-
- 56 management: distance to a clinic, calculated using location data on US abortion clinics, and the
- 57 population proportion identifying as a racial/ethnic minority, living below the FPL, and with
- 58 broadband internet access, calculated using Census data.
- 59 **Results:** During the two-year study period, 57,506 people in 2,458 counties in 50 states requested
- 60 self-managed medication abortion; 52% were aged 20-29 years, 50% had children, and 99% were 10
- 61 weeks pregnant or less. The most common reasons cited by requestors were inability to afford in-
- 62 clinic care (74%), privacy (49%), and clinic distance (40%). States with the highest rate of requests
- 63 were Louisiana (202.7 per 100,000) and Mississippi (199.9 per 100,000). At the county-level, a one
- 64 standard deviation (47 mile) increase in distance to the nearest clinic was significantly associated with
- 65 a 41% increase in requests (IRR =1.41 95% C.I. 1.31 1.51, p<0.001), and a 10% increase in the
- 66 population living below the FPL was significantly associated with a 20% increase in requests (IRR
- 67 =1.20, 95% C.I. 1.13-1.28, p<0.001).
- 68 **Conclusions and Relevance:** Demand for self-managed medication abortion using online
- 69 telemedicine is associated with clinic access barriers at the individual level and with distance to an
- 70 abortion clinic and poverty at the county level. State and federal legislation could address these
- 71 access barriers.

72 Introduction

73

74	Self-managed medication abortion is the practice of using mifepristone and misoprostol, or
75	misoprostol alone, to conduct a medication abortion outside of the formal healthcare setting. ¹ This
76	practice may be increasing in the United States for two main reasons. First, in many states, access to
77	abortion in the clinical setting is limited. ² At the state level, TRAP (Targeted Regulation of Abortion
78	Provider) laws have forced clinics to close ³ , while state-mandated requirements such as pre-abortion
79	ultrasounds, waiting periods, and parental consent have placed significant and sometimes
80	insurmountable burdens on individuals seeking clinical abortion care. ^{4,5} At the federal level, the
81	Hyde Amendment, which bans federal funding for almost all abortions, may put clinical care out of
82	financial reach in states that do not use state Medicaid dollars to cover abortion care. ⁶
83	
84	Second, there is growing evidence that medication abortion provided without ultrasound and with
85	minimal oversight from healthcare professionals is safe and effective. ^{7,8} Since its approval,
86	mifepristone has been subject to a REMS (Risk Evaluation Management Strategy), which restricts its
87	use in ways not supported by evidence, including an in-person dispensing requirement. Healthcare
88	professionals have called for the FDA to remove the REMS and enable mifepristone to be obtained
89	from pharmacies following remote provider consultation.9 There is thus a growing movement that
90	views self-managed medication abortion as part of the spectrum of abortion care.
91	
92	Little is known, however, about who uses self-managed medication abortion in the U.S., or the
93	factors that influence the need or desire to self-manage. Insights have come from mixed-methods
94	studies in Texas and from abortion clinics in major cities, where women discuss self-managing using

95 a variety of methods and cite myriad reasons, including both barriers to clinic access and personal

preference.^{10,11} Few studies have engaged in quantitative analysis of self-management at the national
level, except for one assessing life-time prevalence¹² and another finding that demand for medication
self-management exists in every state.¹³

99

100 Until recently, access to self-managed medication abortion in the U.S. has been mainly through pharmacies in Mexico, social networks, or online pharmacies¹⁴ which are often perceived as 101 suspicious by people seeking pills⁵, despite usually offering genuine medications.¹⁵ However, access 102 103 changed dramatically in 2018, when Aid Access, the first online telemedicine service to offer abortion medications to people living anywhere in the U.S., was launched.¹⁶ Using data from this 104 105 service, we examine the individual-level characteristics and motivations of people who made 106 requests for abortion medications, the rate of requests by state, and the relationship between the rate 107 of requests at the county-level and factors that might be associated with increased demand for self-108 management.

109

110 Methods

People make requests to Aid Access by filling out an online consultation form. A doctor reviews the form to check for contraindications and a reported gestation of 10 weeks or fewer. Mifepristone and misoprostol are then prescribed according to the World Health Organization (WHO)-recommended medication abortion protocol¹⁷ and mailed by a partner organization. The Aid Access helpdesk is available to users any time during and after their abortion. Trained helpdesk members provide email instructions for how to use the medications as well as information about recognizing complications that may require in-person medical attention.

We analyzed all online consultation forms received by Aid Access between March 20th 2018 and 119 120 March 20th 2020. These dates represent the first two years of service operation, from official launch 121 to the emergence of COVID-19, which necessitated temporary changes to the service model. 122 Consultation forms contained information about age, parity, state of residence, circumstances of 123 pregnancy, gestation at the time of request, whether or not gestation had been determined by 124 ultrasound, reasons for not having an ultrasound, contraindications to medication abortion (allergy 125 to medications, IUD in place, chronic adrenal failure, inherited porphyria), distance to a hospital, 126 presence of a support person, and motivations for accessing the service. Those making the request 127 could decline to answer any question that did not determine medical eligibility. They also provided 128 information about their location for mailing purposes.

129

130 Motivations for accessing the service were asked about using the question "Please share with us the 131 reasons why you are requesting treatment through this online service". Answer options were based on prior insights from qualitative and quantitative studies^{5,11,18} and included an "other" option for 132 133 specifying motivations not explicitly included. The options listed included: cost of clinical services; 134 distance to a clinic; difficulty finding childcare; difficulty taking time away from work or school; legal 135 restrictions (such as being required to view an ultrasound); experienced or perceived stigma or 136 judgement; intimidation or harassment by protestors; inability to maintain confidentiality from 137 family members when accessing clinic services; fear of negative consequences from a controlling or 138 abusive partner; the comfort of the home environment; preferring autonomy during the abortion 139 process; feeling empowered by self-management; the privacy of the home environment; and the 140 ability to have a support person present during the abortion. Respondents could choose as many 141 motivations as they felt applied to their situation.

142

2/8/2024

143 Reasons for not obtaining an ultrasound prior to making a request were asked about using the 144 question "Please share with us why you did not obtain an ultrasound" and included a range of 145 answer options: inability to afford an ultrasound, certainty about gestation based on last menstrual 146 period, fear of pregnancy being discovered by others by attending a clinic, inability to get to a clinic 147 due to distance or lack of transport, inability to take time off school or work to visit a clinic, and 148 uncertainty about where to obtain an ultrasound. An "other" option was included to capture 149 motivations explicitly listed. Respondents could choose as many reasons as they felt applied to their 150 situation.

151

152 In addition to examining characteristics and motivations at the individual-level, we also examined 153 per capita requests to Aid Access at the state level. We measured the rate of requests in each state 154 per 100,000 women of reproductive age to visualize heterogeneity in demand across states. We then 155 conducted an analysis of factors associated with increased requests to Aid Access at the county-level. 156 We used zip code data from consultation forms to create a count of Aid Access requests per 10,000 157 women of reproductive age in each county, mapping zip codes to counties based on centroid 158 latitude and longitude. Reproductive-age population for each county was obtained from the US 159 Census Bureau's 2019 data¹⁹ and is defined as 15-44 years.

160

We also obtained information on county-level spatial and demographic covariates that we hypothesized might be related to requests for medication self-management, including average distance across zip codes in each county to the nearest abortion clinic, and the proportion of the county's population that: has broadband internet access; is non-white; and lives below the Federal Poverty Level (FPL). We calculated clinic distance for each county by averaging the distance in miles from each zip code in the county to the zip code of the nearest abortion clinic, using the Great

2/8/2024

167	Circle Distance Formula. ²⁰ We obtained information on abortion clinic location using three separate
168	sources which are updated regularly, the Abortion Care Network (ACN) clinic list, UCSF's Abortion
169	Clinic Database, and Ineedana.com, compiled by A Team Tech ^{21,22} , which we cross-referenced to
170	ensure maximum inclusion and accuracy. We calculated the proportion of each county's population
171	with broadband internet access from the Federal Communications Commission Mapping
172	Broadband Health in America project's open-source data ²³ , and the proportion of each county's
173	population of women of reproductive age that identifies as a racial/ethnic minority using the most
174	recent available data (2019) from the US Census Bureau, Population Division. ¹⁹ We calculated the
175	proportion of each county's population living below the FPL using data from the US Census
176	Bureau's Small Area Income and Poverty Estimates data. ²⁴
177	
178	To explore the factors associated with increased requests to Aid Access per 10,000 reproductive-
179	aged women compared to state-level averages, we fit a multi-level negative binomial model to the
180	county-level request data (N=2,458), where the response variable is the reproductive age population-
181	adjusted total request count for each county and the explanatory variables are the county-level
182	spatial and demographic covariates described above. We selected variables using a step-wise
183	procedure and used variance inflation factors to guard against collinearity. We also tested for
184	interactions between each of these variables and used likelihood ratio tests to select the best model
185	fit. To account for the distinct state contexts in which the counties are nested, including both state
186	abortion policy context as defined by the Guttmacher Institute's state policy classification system ²⁵
187	and other unmeasured state-specific factors, we allowed model intercepts to vary at the state level.
188	For ease of interpretability, we re-scaled the county-level regression coefficient estimates and
189	confidence intervals to represent expected change in requests associated with one standard deviation

190	in clinic distance (47 miles), and 10% changes in the percent of the population that identifies as a
191	racial/ethnic minority, has broadband access, and lives below the FPL.
192	
193	We used R statistical software (Version 3.5.3, R Foundation for Statistical Computing, Vienna,
194	Austria) to conduct all data analysis and the 'mpath' package to fit our models. ²⁶ We consider
195	significance at the 0.05 level. Aid Access provided all data in a fully de-identified format. Researchers
196	had access only to the state and zip code aspects of mailing information. At the time of accessing the
197	service, respondents consented to the fully anonymized use of their data for research purposes. The
198	study received ethical approval from the Institutional Review Board at the University of Texas at
199	Austin. The principles of the STROBE reporting guideline for cross-sectional studies were followed.
200	
201	Results
202	Between March 20th 2018 and March 20th 2020, 57,506 people requested medication abortion from
203	Aid Access and Table 1 shows their demographic and clinical characteristics. 52% were aged
204	between 20 and 29 years old, with 20% aged under 20 years, and half had children. At the time of
205	making the request, 44% were 6 weeks pregnant or less, 56% were between 7 and 10 weeks, and less
206	than 1% were over 10 weeks. 54% had experienced a contraceptive failure. The majority (85%) had
207	not had an ultrasound scan, the most common reasons being inability to afford one (56%) and
208	certainty about gestation based on last menstrual period (33%). Most (96%) were within an hour's
209	drive to a hospital and had somebody who could be with them during their abortion. Less than 1%
210	had any contraindication and 99% felt sure about their decision.
211	
212	The most common reason for seeking medication abortion via Aid Access was inability to afford an

213 in-clinic abortion, cited by 74% of people making requests (Figure 1). Almost half (49%) were afraid

214 of a partner or family member finding out if they tried to go to the clinic, 40% said the nearest clinic 215 was too far away, and 38% were unable to take time away from work or school to go to a clinic. 216 While the most common reasons were barriers to clinic access, preferences for self-managed 217 abortion were also cited: 28% percent said they would be more comfortable at home, and 27% said 218 self-managing at home would be more convenient. Figure 1 shows the full range of motivations. 219 220 Requests to Aid Access came from all 50 states and Figure 2 shows the rate of requests by state, per 221 100,000 women of reproductive age. Louisiana has the highest rate of requests (202.7 per 100,000), 222 followed by Mississippi (199.9 per 100,000), Wyoming (173.2 per 100,000), and Alabama (166.1 per 223 100,000). Vermont has the lowest rate of requests (36.7 per 100,000), followed by Connecticut (41.8 224 per 100,000) Oregon (43.7 per 100,000), and California (44.6 per 100,000). 225 County-level factors associated with a higher rate of requests to Aid Access include distance to the 226 227 nearest abortion clinic and the proportion of the population living below the FPL (Table 2). The

228 mean distance to the nearest clinic across all counties is 56.5 miles (standard deviation 47.4 miles).

229 On average, a 47 mile (one standard deviation) increase in distance to the nearest clinic is associated

230 with an 41.0% increase in Aid Access requests (95% CI 31.0%- 51.0%, p<0.001), while a 10%

increase in population living below the FP is associated with a 20.0% increase in requests (95% C.I.

232 13.0% - 28.0%, p<0.001). The interaction between clinic distance and the proportion living below

233 the FPL is associated with a 12.0% lower rate of requests (95% CI 16.0% - 8.0%, p<0.001).

234

Figure 3 shows the magnitude of the state-level intercepts, which are scaled to represent the baseline

236 expected request rate per 100,000 women of reproductive age for each state under the reference

237 level for all other covariates in the model (i.e. mean clinic distance, and all county-level

characteristics set to zero). The magnitude of the state-level intercepts was larger in states with more restrictive abortion policy climates²⁵—the top five being Louisiana, Mississippi, Nevada, Kansas, and Wyoming—suggesting that such policies, as well as other state-specific factors, are associated with increased rates of self-management. The magnitude of the intercepts was smaller in states with more supportive policy climates²⁵, the lowest being Vermont, Massachusetts, Oregon, California, and Connecticut.

244

245 Discussion

Our study offers the first examination of requests for self-managed medication abortion using online telemedicine in the U.S and the factors associated with these requests. We show that clinic access barriers, most notably the cost of an in-clinic abortion, are major reasons cited by those making requests. We also find evidence that these individual-level barriers are reflected at the state level, where the highest rates of requests are found in states with more restrictive abortion policy climates, and at the county level, where longer average distance to the nearest abortion clinic, and a higher proportion living in poverty are associated with an increased rate of requests.

253

254 Our findings suggest a strong influence of barriers to in-clinic abortion access, including cost and 255 clinic distance, on demand for self-managed abortion. In light of the declining abortion rate in the 256 U.S., these findings lend support to the possibility there has been a shift in the location of some abortions to outside of the clinic setting and thus an increase in self-managed abortions.²⁷ Policies 257 restricting access to in-clinic abortion have accelerated over the last decade,²⁸ and there is evidence 258 that in-clinic abortion rates have decreased most in states with more restrictions.²⁹ Moreover, the 259 Midwest and the South have seen a 6% and 9% decline in clinic numbers, respectively,³⁰ resulting in 260 increased distance to an abortion clinic and an associated decline in the in-clinic abortion rate.³¹ 261

262 These patterns mirror our findings that cost and distance to a clinic are associated with increased263 demand for self-management.

264

265 At the individual level, three-quarters of those making requests to Aid Access cited cost as a 266 motivating factor and at the county level we found an association between the proportion of people 267 living below the FPL and increased requests. The interaction we examined between poverty and 268 clinic distance also shows that while closer clinic distance is associated with a decrease in requests to 269 Aid Access, this association does not hold for people living in poverty. In other words, in places 270 where people cannot afford the cost of an in-clinic abortion, closer clinics do not improve access. 271 On top of the difficulties poverty exacerbates, such as finding information, taking time away from 272 work and childcare, and keeping multiple state-mandated clinic appointments, one of the most 273 significant financial obstacles is likely to be lack of Medicaid abortion coverage under the Hyde 274 Amendment.³² While 16 states do use state Medicaid funds to pay for abortion care, most (34) do 275 not^{33} , and many of these same states also prohibit ACA health insurance plans from covering 276 abortion.³⁴ Although the state-level intercepts in our model account for more than policy differences, 277 we note that the states with restrictions on insurance and Medicaid coverage tend to have higher 278 baseline request rates. These policies mean that most people must pay out-of- pocket for abortion 279 care, and while abortion funds play a critical role in making this possible, our findings suggest that 280 self-management also fills a key access gap.

281

We note, however, that barriers to clinic access were not the sole or primary motivation among all individuals. Some also cited preferences for the comfort and convenience of using abortion medications at home. Such preferences are also commonly reported in other countries where selfmanaged abortion is provided using online telemedicine.¹⁴ Moreover, studies have demonstrated

286 high levels of effectiveness and safety, with very few reported serious adverse events.^{7,14} Self-

287 managed abortion as a preference thus calls attention to the need for a wider spectrum of abortion

288 care models that center individual autonomy and preferences.

289

290 Limitations

The main limitation of our study is that there are other routes to self-managed medication abortion in the U.S., we well as other types of self-management. Our results may therefore not be generalizable beyond the population using online telemedicine. Furthermore, our methodological approach lends itself to exploring associations rather than establishing causality. Nonetheless, we hope that future work will examine in more detail the factors linked with higher rates of selfmanaged medication abortion we have highlighted.

297

298 Conclusion

299 With many states planning further restrictions on in-clinic abortion and the possibility that *Roe v*. 300 Wade is severely diminished by the Supreme Court, we can expect to see demand for self-managed 301 medication abortion increase further. The temporary adjustment to the mifepristone REMS during 302 the COVID-19 pandemic spurred some states increase access to medication abortion by introducing no-test protocols, telemedicine consultation, and medications by mail.³⁵ These innovations also have 303 304 the potential to expand access for those living in poverty by negating the costs of in-person clinic 305 attendance and paying for medical tests. Yet other states have kept in place laws that prohibit telemedicine and in some cases moved to further restrict clinic access,³⁶ with consequent increases in 306 307 demand for self-management.³⁷ For clinicians, this increased demand for self-managed abortion 308 means being equipped to provide follow-up to those who might require it, including being informed on ACOGs position on self-management³⁸ and on the lack of reporting requirements to protect 309

Page 16

310 patient confidentiality.³⁹ For policymakers, it means serious consideration of the consequences of

311 laws that make in-clinic abortion less accessible and the expansion of medication abortion access to

312 help overcome existing barriers and meet people's preferences.

313

314 Acknowledgements

315 ARAA conceived of the original research question. All authors contributed to the study design. RG 316 provided the de-identified Aid Access data. JES designed the statistical models, conducted the 317 statistical analyses, and prepared the tables and figures. ARAA and JES did the initial data 318 interpretation and wrote the first draft of the manuscript. All authors contributed to final data 319 interpretation, revised the manuscript for important intellectual content, and approved the final 320 version of the manuscript. No medical writers or Editors were involved in the creation of the 321 manuscript. All authors agree to be accountable for all aspects of the work. ARAA had full access to 322 all the data in the study and takes responsibility for the integrity of the data and the accuracy of the 323 data analysis. ARAA reports grant support from the Society of Family Planning (Grant # SFPRF12-324 MA1) and received infrastructure support from the National Institutes of Health (Grant # 325 P2CHD042849). RG is the Founder and Director of Aid Access and Women on Waves. ARAA and 326 JES declare no competing interests. None of the sources of funding had any involvement in the 327 design and conduct of the study; the collection, management, analysis, and interpretation of the data; 328 the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for 329 publication.

330 References

331

- 332 1. World Health Organization Guidelines. WHO recommendations on self-care interventions:
- 333 Self-management of medical abortion. 25th June 2020.
- 334 https://www.who.int/publications/i/item/WHO-SRH-20-11 (Accessed January 12th 2021).

335

2. Nash E, Donovan MK. Ensuring access to abortion at the State Level: Selected Examples and
Lessons. *Guttmacher Policy Review*. 2019;22.

338

339 3. Gerdts C, Fuentes L, Grossman D et al. Impact of clinic closures on women obtaining abortion

340 services after implementation of a restrictive law in Texas. Am J Public Health. 2016 May;106(5):857-

341 64.

- 342
- 343 4. Jerman J, Frohwirth L, Kavanaugh ML, Blades N. Barriers to abortion care and their consequenc-

344 es for patients traveling for services: qualitative findings from two states. Perspect Sexual Reprod Health.

345 2017 Jun;49(2):95-102.

346

5. Aiken AR, Broussard K, Johnson DM, Padron E. Motivations and experiences of people seeking
medication abortion online in the United States. *Perspect Sexual Reprod Health.* 2018 Dec;50(4):157-63.

349

- 350 6. Dennis A, Manski R, Blanchard K. Does Medicaid coverage matter? A qualitative multi-state
- 351 study of abortion affordability for low-income women. J Health Care Poor Underserved. 2014; 25 (4):

352 1571-85.

353	7. Aiken AR, Digol I, Trussell J, Gomperts R. Self reported outcomes and adverse events after med-
354	ical abortion through online telemedicine: population based study in the Republic of Ireland and
355	Northern Ireland. BMJ. 2017 May 16;357.
356	
357	8. Aiken AR, Lohr P, Lord J, Ghosh N, Starling J. Effectiveness, safety and acceptability of no-test
358	medical abortion provided via telemedicine: a national cohort study. BJOG. 2021. Early View:
359	Online Ahead of Print.
360	
361	9. Mifeprex REMS Study Group. Sixteen years of overregulation: time to unburden Mifeprex.
362	NEJM. 2017:790-794.
363	
364	10. Fuentes L, Baum S, Keefe-Oates B et al. Texas women's decisions and experiences regarding
365	self-managed abortion. BMC Womens Health. 2020;20(1):1-2.
366	
367	11. Grossman D, Holt K, Peña M et al. Self-induction of abortion among women in the United
368	States. Reprod Health Matters. 2010 Jan 1;18(36):136-46.
369	
370	12. Ralph L, Foster DG, Raifman S et al. Prevalence of Self-Managed Abortion Among Women of
371	Reproductive Age in the United States. JAMA Netw Open. 2020 Dec 1;3(12):e2029245
372	
373	13. Aiken AR, Starling JE, van der Wal A et al. Demand for self-managed medication abortion
374	through an online telemedicine Service in the United States. Am J Public Health. 2020 Jan;110(1):90-7.
375	

376	14. Moseson H, Herold S, Filippa S, Barr-Walker J, Baum SE, Gerdts C. Self-managed abortion: a
377	systematic scoping review. Best Pract Res Clin Obstet Gynaecol. 2020 Feb 1;63:87-110.
378	
379	15. Murtagh C, Wells E, Raymond EG, Coeytaux F, Winikoff B. Exploring the feasibility of obtain-
380	ing mifepristone and misoprostol from the internet. Contraception. 2018 Apr 1;97(4):287-91.
381	
382	16. Aiken, AR. Erosion of women's reproductive rights in the United States. BMJ. 2019: 14444.
383	
384	17. World Health Organization (WHO). Medical Management of Abortion. 2018.
385	https://apps.who.int/iris/bitstream/handle/10665/278968/9789241550406-eng.pdf?ua=1. (Ac-
386	cessed March 24 th 2021).
387	
388	18. Aiken AR, Broussard K, Johnson DM, Padron E, Starling JE, Scott JG. Knowledge, interest, and
389	motivations surrounding self-managed medication abortion among patients at three Texas clinics.
390	Am J Obstet Gynecol. 2020 Mar 3.
391	
392	19. US Census Bureau, Population Division. Annual County Resident Population Estimates by Age,
393	Sex, Race, and Hispanic Origin: April 1, 2010 to July 1, 2019. https://www2.census.gov/programs-
394	surveys/popest/datasets/2010-2019/counties/asrh/cc-est2019-alldata.csv (Accessed January 12 th
395	2021).
396	
397	20. Wallace JR. R Package 'gdist': Geodesic distance (great circle distance) between points.
398	https://rdrr.io/cran/Imap/man/gdist.html (Accessed January 12th 2021).
399	

400 21. A Team Tech LLC. https://ineedana.com (Accessed January 12th 2021).

- 402 22. Advancing New Standards in Reproductive Health (ANSIRH), Abortion Facility Database. Uni-
- 403 versity of California, San Francisco. September 2019.
- 404
- 405 23. Federal Communications Commission. FCC's Mapping Broadband Health in America.
- 406 https://www.fcc.gov/health/maps/methodology. (Accessed January 12th 2021).
- 407
- 408 24. US Census Bureau. Small Area Income and Poverty Estimates data:
- 409 https://www.census.gov/data-tools/demo/saipe/#/?map_geoSelector=aa_c (Accessed January
- 410 12th 2021).
- 411
- 412 25. Nash E. Guttmacher Institute Policy Analysis. State Abortion Policy Landscape: From Hostile to
- 413 Supportive. August 2019. https://www.guttmacher.org/article/2019/08/state-abortion-policy-
- 414 <u>landscape-hostile-supportive#</u> (Accessed March 24th 2021).
- 415
- 416 26. Wang Z. R Package 'mpath'. Dec 13th 2020. https://cran.r-
- 417 project.org/web/packages/mpath/mpath.pdf (Accessed January 12th 2021).
- 418
- 419 27. Foster DG. Dramatic decreases in US abortion rates: public health achievement or failure? Am J
- 420 *Public Health.* 2017;107(12):1860–1862.
- 421
- 422 28. Guttmacher Institute News in Context. Last Five Years Account for More Than One-quarter of
- 423 All Abortion Restrictions Enacted Since Roe. January 13th 2016.

424 https://ww	w.guttmacher.org/	article/2016/	/01/last-five-	years-account-more-one-	quarter-all
----------------	-------------------	---------------	----------------	-------------------------	-------------

- 425 abortion-restrictions-enacted-roe (Accessed January 12th 2021).
- 426
- 427 29. Brown BP, Hebert LE, Gilliam M, Kaestner R. Association of Highly Restrictive State Abortion

428 Policies With Abortion Rates, 2000-2014. JAMA Netw Open. 2020;3(11):e2024610.

- 429
- 430 30. Jones R, Witwer E, Jerman J. Abortion Incidence and Service Availability in the United States,
- 431 2017. Guttmacher Institute Report. September 2019. https://www.guttmacher.org/report/abortion-
- 432 incidence-service-availability-us-2017 (Accessed January 12th 2021).
- 433

434 31. Brown BP, Hebert LE, Gilliam M, Kaestner R. Distance to an Abortion Provider and Its Asso-

435 ciation with the Abortion Rate: A Multistate Longitudinal Analysis. *Perspect Sex Reprod Health.* 2020
436 Dec 17.

- 437
- 438 32. Donovan MK, "In Real Life: Federal Restrictions on Abortion Coverage and the Women They
- 439 Impact," *Guttmacher Policy Review*, 2017; 20: 1-7.
- 440
- 441 33. Salganicoff A, Sobel L, Ramaswamy A. The Hyde Amendment and Coverage for Abortion Ser-
- 442 vices. Kaiser Family Foundation Issue Brief. March 5th 2021. https://www.kff.org/womens-health-
- 443 policy/issue-brief/the-hyde-amendment-and-coverage-for-abortion-services/ (Accessed March 24th
- 444 2021).
- 445
- 446

447	34. Kaiser Family	y Foundation Issue Brief	. How State Policies Shap	be Access to Abortion Coverage

- 448 Feb 10th 2020. <u>https://www.kff.org/womens-health-policy/issue-brief/interactive-how-state-</u>
- 449 policies-shape-access-to-abortion-coverage/ (Accessed March 24th 2021).
- 450
- 451 35. Upadhyay UD, Schroeder R, Roberts SC. Adoption of no-test and telehealth medication abor-
- 452 tion care among independent abortion providers in response to COVID-19. *Contraception: X.* 2020453 Jan 1;2:100049.
- 454
- 455 36. White K, Kumar B, Goyal V, Wallace R, Roberts SCM, Grossman D. Changes in Abortion in
- 456 Texas Following an Executive Order Ban During the Coronavirus Pandemic. *JAMA*. 2021 Feb
- 457 16;325(7):691-693.
- 458
- 459 37. Aiken AR, Starling JE, Gomperts R, Tec M, Scott JG, Aiken CE. Demand for self-managed
- 460 online telemedicine abortion in the United States during the coronavirus disease 2019 (COVID-19)
- 461 pandemic. Obstet Gynecol. 2020 Oct;136(4):835.
- 462
- 463 38. The American College of Obstetricians and Gynecologists (ACOG) Position Statement on De-
- 464 criminalization of Self-Induced Abortion. 2017 https://www.acog.org/clinical-information/policy-
- 465 and-position-statements/2017/decriminalization-of-self-induced-abortion (Ac-
- 466 cessed January $12^{th} 2021$).

- 468 39. If/When/How Lawyering for Reproductive Justice Factsheet. Patient Confidentiality and Self-
- 469 managed Abortion: A Guide to Protecting Patients and Yourself. https://www.ifwhenhow.org/wp-

- 470 content/uploads/2020/04/20_04_Final_SMA_TheLaw_COVID-19_FactSheet_PDF.pdf (Ac-
- 471 cessed January 12th 2021).

472 473 474 Table 1: Characteristics of people requesting medication abortion from Aid Access between March 20th 2018 and March 20th 2020 (N=57,506)

Characteristic	Frequency (Percent)
Age	
Under 20	11,283 (19.6)
20-24	16,056 (27.9)
25-29	13,884 (24.1)
30-34	9,317 (16.2)
35-39	5,077 (8.8)
40-44	1,606 (2.8)
45 and over	283 (0.5)
Number of children	
0	28,754 (50.0)
1	11,288 (19.6)
2	9,592 (16.7)
3+	7,872 (13.7)
Gestation	
6 weeks or less	25,100 (43.6)
Between 7 and 10 weeks	32,399 (56.3)
More than 10 weeks	7 (0.1)
Circumstances of pregnancy*	
Contraceptive failure	30,766 (53.5)
Contraceptive non-use	23,891 (41.6)
Sexual assault	2,848 (4.9)
Ultrasound before abortion request	
Yes	8,895 (15.5)
No	48,611 (84.5)
Reason for no ultrasound**	, , , ,
Cannot afford to pay for one	27,436 (56.4)
Don't need one since feel sure of gestation	16,244 (33.4)
Afraid someone will find out if go to a clinic to get one	15,350 (31.6)
Cannot get to a clinic to get one (distance, lack of transport)	11,557 (23.8)
No time to get one	4,863 (10.0)
Not sure where to get one	4,725 (9.7)
Other reason	1,105 (2.3)
Contraindication to medication abortion	, , , , , , , , , , , , , , , , , , ,
Yes	340 (0.6)
No	57,166 (99.4)
Within a 60 min drive to a hospital	
Yes	55,383 (96.3)
No	2,123 (3.7)
Somebody to be present during abortion	
Yes	55,449 (96.4)
No	2,057 (3.6)
Feelings about decision	

OK with decision	56,960 (99.1)
Troubled by decision	546 (0.9)

475 476 477 *1 missing response **Respondents could choose more than one response

Covariate	IRR (95% CI)	P-value
Clinic distance z-score (average miles to nearest abortion clinic, standardized)*	1.41 (1.31, 1.51)	< 0.001
Proportion of population below Federal Poverty Level ^{**}	1.20 (1.13, 1.28)	< 0.001
Proportion of population that is ra- cial/ethnic minority**	0.99 (0.95, 1.02)	0.499
Proportion of population with broadband internet access***	1.01 (1.00, 1.02)	0.058
Interaction between clinic distance and proportion of population below Federal Poverty Level.**	0.88 (0.84, 0.92)	< 0.001
Interaction between Federal Poverty Lev- el and racial/ethnic minority propor- tions.**	0.92 (0.77, 1.09)	0.335

478 Table 2: County-level factors associated with requests to Aid Access (N=2,458)
479

480 * Mean distance to a clinic is 56 miles, with standard deviation 47 miles. The estimate represents the

481 expected associated change in requests for a one standard deviation increase in clinic distance.

482 ** Adjusted so that the estimate represents the expected change in requests for a 0.1 change in pro-

483 portion.

484

80 Percent of people citing request reason 73.5 60 -49.3 40.4 37.6 40 28.2 27.6 27.0 26.2 22.9 19.5 17.1 20 15.1 6.9 3.4 0.7 0 5/8/508 or perceived stigma Ca_{hhot} afford an abortion in a clinic -Fear of partner or family finding out Cannot get time off work or school Don't want to deal with protestors Wa_{nt} to _{keep my abortion private} | Ne_{arest} clinic is too far away | More _{comfortable at home} -W_{ant} to have family/friend with me Empowering to _{Self-manage} | More convenient at home Risk of abuse from partner State Policy barriers Cannot find childcare Other -

Figure 1: Reasons for requesting self-managed medication abortion using online telemedicine, N=57,506.

Figure 2. Requests for Abortion Medications to Aird Access by State Between March 20th 2018 and March 20th 2020.





Figure 3: State–level baseline expected requests (intercepts) per 100,000 women of reproductive age for multi–level negative binomial regression model.



Abigail Aiken" <araa2@utexas.edu> Naves Rebecca" Mira Michels-Gualtieri" 2/5/2021 6:53:35 AM e: Abstract was Accepted! 5, 2021 at 7:15 AM Abigail Aiken <<u>araa2@utexas.edu</u>> wrote: at, Mira, congratulations! The poster looks excellent as well. enjoy the conference! or 5, 2021 at 5:24 AM Waves Rebecca > wrote: lations! Apr 2021, at 04:06, Mira Michels-Gualtieri wrote:</araa2@utexas.edu>
Waves Rebecca" Mira Michels-Gualtieri" /5/2021 6:53:35 AM e: Abstract was Accepted! ! 5, 2021 at 7:15 AM Abigail Aiken <araa2@utexas.edu> wrote: at, Mira, congratulations! The poster looks excellent as well. enjoy the conference! or 5, 2021 at 5:24 AM Waves Rebecca ations!</araa2@utexas.edu>
<u>Aira Michels-Gualtieri</u>
/5/2021 6:53:35 AM e: Abstract was Accepted! 5, 2021 at 7:15 AM Abigail Aiken < <u>araa2@utexas.edu</u> > wrote: at, Mira, congratulations! The poster looks excellent as well. enjoy the conference! or 5, 2021 at 5:24 AM Waves Rebecca > wrote: lations!
e: Abstract was Accepted! 5, 2021 at 7:15 AM Abigail Aiken < <u>araa2@utexas.edu</u> > wrote: at, Mira, congratulations! The poster looks excellent as well. enjoy the conference! or 5, 2021 at 5:24 AM Waves Rebecca > wrote: lations!
9, 2021 at 7:15 AM Abigail Aiken < <u>araa2@utexas.edu</u> > wrote: at, Mira, congratulations! The poster looks excellent as well. enjoy the conference! or 5, 2021 at 5:24 AM Waves Rebecca
5, 2021 at 7:15 AM Abigail Aiken < <u>araa2@utexas.edu</u> > wrote: at, Mira, congratulations! The poster looks excellent as well. enjoy the conference! or 5, 2021 at 5:24 AM Waves Rebecca> wrote: lations!
at, Mira, congratulations! The poster looks excellent as well. enjoy the conference! or 5, 2021 at 5:24 AM Waves Rebecca
or 5, 2021 at 5:24 AM Waves Rebecca
lations!
Apr 2021, at 04:06, Mira Michels-Gualtieri
becca, and Abigail,
e you're having a nice weekend!
ed to let you know that I was accepted to the NESS Conference (hosted by Harvard al School!). I'll be presenting at the end of April.
ts for your help in making this happen! I attached my poster if you want to check it
ng you all the best and a huge hug,
<i>A</i> ichels-Gualtieri ⁻ College Class of 2021 e, Technology, and Society (STS) r/hers
els-Gualtieri.Miralah.Summary.pdf>

Page 2

University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>

Page 1

From: <u>"JE Starling" <jstarling@utexas.edu></u>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 4/5/2021 5:50:44 PM

Subject: Re: JAMA Network Open JNO21-0447R Decision Letter

Aaaaaa this is wonderful news!!! Thank you for sharing!

Sent from my iPhone

On Apr 5, 2021, at 7:18 PM, Abigail Aiken <araa2@utexas.edu> wrote:

Very good news from JAMA network open! I will find out the expected date of publication and circle back shortly. Thanks so much to you both for making this work possible!

All best,

А

------ Forwarded message ------From: <jamanetworkopen@jamanetwork.org> Date: Mon, Apr 5, 2021 at 3:01 PM Subject: JAMA Network Open JNO21-0447R Decision Letter To: <araa2@utexas.edu>

PLEASE REPLY TO CONFIRM RECEIPT OF THIS LETTER

April 5, 2021

Dr Abigail Aiken University of Texas at Austin LBJ School of Public Affairs PO Box Y Austin, Texas 78712

RE: Factors Associated with use of an Online Telemedicine Service to Access Self-managed Medical Abortion in the United States

Dear Dr Aiken:

We have completed our review of your manuscript and are pleased to accept it for publication in JAMA Network Open. Your manuscript is accepted with the understanding that its contents, all or in part, have not been published elsewhere and will not be disseminated before its publication in JAMA Network Open. Also, please remember that you should not disclose the fact that your manuscript has been accepted to anyone, except coauthors and contributors and as noted below, without permission of the editor.

Any information you may receive about the proposed publication date of your article is tentative and should be kept confidential. The publication date will be confirmed several weeks before publication. Prepublication distribution of the accepted manuscript without permission is prohibited. Do not use social media to post information or "tweet" about your article before publication. Many authors work with their institution's media relations department to send out press releases about their publications. However, please note that the news media should not release any information about your article until 10 AM Central Time on the day of its publication. There is a strict embargo until then. If you or your media relations department needs help in coordinating press conferences or releases, please contact the JAMA Network Media Relations Department at mediarelations@jamanetwork.org.

An edited version of your manuscript will be sent to you for final approval. It is likely that you will also receive questions about the text, tables, or figures. Your manuscript is accepted, therefore, with the understanding that it may later be necessary to consider some changes in text or ancillary material.

NOTE: Please verify and confirm that all conflict of interest disclosure information for you and all coauthors is accurate, complete, and up-to-date and is reported in the Acknowledgment section of the manuscript in a manner consistent with that reported in each author's disclosures of potential conflicts of interest section of the journal's Authorship Form. JAMA Network Open's policy requires that all authors disclose any potential conflicts of interest involving the work under consideration for publication (during the time involving the work, from initial conception and planning to present); any relevant financial activities outside the submitted work (during the 3 years prior to submission); and any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what is written in the submitted work (based on all relationships that were present during the 3 years prior to submission).

First and last authors (ie, those listed first and last in the article byline) may claim 10 CME credits (AMA PRA Category 1 Credit) after publication of articles in JAMA Network Journals. First and last authors will receive a subsequent email from the CME provider after the article is published with instructions about claiming CME credits.

Your article will be published under an open access license. An invoice will be sent to you after this letter of acceptance is sent.

After your article is published, we will send you and all co-authors an email with a link to your article that you can share with others and in which you can view article metrics such as numbers of views, news and social media coverage, and eventually citations.

After publication, your article may receive online comments. We encourage you to respond and engage in that online conversation.

We appreciate your submitting the manuscript for our consideration and look forward to seeing it published in JAMA Network Open.

Sincerely yours,

Olugbenga Ogedegbe, MD, MS, MPH Associate Editor - JAMA Network Open <u>https://jamanetwork.com</u>

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential, or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>

	Page 1
From:	<u>"Melissa Madera" <mmadera@utexas.edu></mmadera@utexas.edu></u>
To:	<u>"Rebecca Gomperts"</u>
CC:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
Date:	4/29/2021 1:29:27 PM
Subject:	Re: Trying out an Aid Access consultation
	much, Rebecca! I'll drop you a note as soon as I've completed it (sometime in the next few n Florida so there shouldn't be a problem based on my state of residence.
Best, Mel	
On Thu, Ap of course	or 29, 2021 at 12:46 PM Rebecca Gomperts wrote:
	now when you completed it and i will process it, please not that for the 10 states where a now US doctors providing the process is different than the states where i provide
warmly rebecca	
On 29	Apr 2021, at 18:43, Abigail Aiken < <u>araa2@utexas.edu</u> > wrote:
Hi dea	ar,
would with th	a is writing up the results of the interviews with people who used Aid Access and she like to have some context for what the consultation process, follow-ups, and emails ne service look like. Could she submit a test consultation so that she can get a feel for ocess herself?
Thank A	s so much and hope you're very well!
Assoc LBJ S Unive Princi Webs	il R.A. Aiken, MD, MPH, PhD siate Professor chool of Public Affairs rsity of Texas at Austin pal Investigator, <u>Project SANA</u> ite: <u>abigailaiken.github.com</u> : <u>araa2@utexas.edu</u>

--Melissa Madera, Ph.D. Research Fellow & Senior Project Manager <u>Project SANA</u> LBJ School of Public Affairs University of Texas at Austin Founder & Director, <u>The Abortion Diary Podcast</u>

Page 1
From: <u>"Waves Rebecca"</u>
To: jayashreev@austin.utexas.edu
CC: <u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
Date: 5/7/2021 5:01:55 AM
Subject: Invoice research
Attachments: invoice research.pdf

Dear Jayashree

Hereby I would like to submit the invoice for the research for Prof Aiken Warm regards

rebecca

AidAccess Mooslackengasse 17, Vienna, 1190 Austria

May 7-2021

Invoice

To whom it might concern

Hereby I would like to send the invoice for my work for the work for the research for Prof. Abigail Aiken.

I worked 24 hours in preparing the data at \$250 per hour.

Please reimburse 6000 USD to:

- Name: Aid Access
- IBAN:
- Bank: Bank Austria
- BIC: BKAUATWW

Thank you

Dr. Rebecca Gomperts

mn

Director Aid Access

	Page 1
From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	<u>"Waves Rebecca"</u> ≥
Date:	5/21/2021 7:29:10 AM
Subject:	Re: Copy of final paper in JAMA
Attachments:	Aiken et al. 2021 Aid Access .pdf
	Here it is, attached. Iblished online today at 10:00am CT.
Associate Profe LBJ School of F University of Te Principal Invest	Public Affairs exas at Austin igator, <u>Project SANA</u> laiken.github.com
On Fri, May 21, Dear Abigail	2021 at 6:52 AM Waves Rebecca
Would it be p Thanks sood	possible for you to send me a copy of the final paper that was published in Jama? In much
Warmly Rebecca	
On 22 Apr	⁻ 2021, at 00:44, Abigail Aiken < <u>araa2@utexas.edu</u> > wrote:
new autho	I'll just clarify that in the proofs that I send back. They may want you to complete a or form, so please look out for a possible request coming by email. r getting back to me so quickly!
On Wed, A	Apr 21, 2021 at 5:34 PM Waves Rebecca
Dear A Sorry I	
Warmly Rebecc	
On 2	2 Apr 2021, at 00:10, Abigail Aiken < <u>araa2@utexas.edu</u> > wrote:
Hi de	ear,
	A Network Open has sent me the page proofs for our Aid Access paper and they isking for them to be sent back within 24hrs (i.e. tomorrow, April 22nd).

They have a query about your author form (attached). In Step 2B, you mention "other" under both Aid Access and Women on Web. They are asking about what "other" refers to?

Could you send me a brief explanation that I could send back to them before the end of the day tomorrow?

Thank you so much and apologies for the quick turnaround on this, A $\boldsymbol{x}\boldsymbol{x}$

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>

<Gomperts JAMA Network Open Authorship Form.pdf>

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>



Factors Associated With Use of an Online Telemedicine Service to Access Self-managed Medical Abortion in the US

Abigail R. A. Aiken, MD, PhD; Jennifer E. Starling, PhD; Rebecca Gomperts, MD, PhD

Abstract

IMPORTANCE People in the US have been seeking self-managed abortions outside the formal health care system using medications obtained through online telemedicine. However, little is known about this practice, including potential motivating factors.

OBJECTIVE To examine individual reasons for accessing medication abortion through an online telemedicine service as well as associations between state- and county-level factors and the rate of requests.

DESIGN, SETTING, AND PARTICIPANTS This population-based cross-sectional study examined all requests for self-managed medication abortion through an online consultation form available from Aid Access, a telemedicine service in the US, between March 20, 2018, and March 20, 2020.

MAIN OUTCOMES AND MEASURES Individual-level reasons for accessing the telemedicine service were examined as well as the rate of requests per 100 000 women of reproductive age by state. Zip code data provided by individuals making requests were used to examine county-level factors hypothesized to be associated with increased demand for self-managed abortion: distance to a clinic (calculated using location data for US abortion clinics) and the population proportion identifying as a member of a racial/ethnic minority group, living below the federal poverty level, and having broadband internet access (calculated using census data).

RESULTS During the 2-year study period, 57 506 individuals in 2458 counties in 50 states requested self-managed medication abortion; 52.1% were aged 20 to 29 years (mean [SD] age, 25.9 [6.7] years), 50.0% had children, and 99.9% were 10 weeks' pregnant or less. The most common reasons cited by individuals making requests were the inability to afford in-clinic care (73.5%), privacy (49.3%), and clinic distance (40.4%). States with the highest rate of requests were Louisiana (202.7 per 100 000 women) and Mississippi (199.9 per 100 000 women). At the county level, an increase of 1 SD (47 miles) in distance to the nearest clinic was significantly associated with a 41% increase in requests (incidence rate ratio, 1.41; 95% CI, 1.31-1.51; P < .001), and a 10% increase in the population living below the federal poverty level was significantly associated with a 20% increase in requests (incidence rate ratio, 1.20; 95% CI, 1.13-1.28; P < .001).

CONCLUSIONS AND RELEVANCE In this cross-sectional study, clinic access barriers were the most commonly cited reason for requesting self-managed medication abortion using an online telemedicine service. At the county level, distance to an abortion clinic and living below the federal poverty level were associated with a higher rate of requests. State and federal legislation could address these access barriers.

JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

Key Points

Question What factors are associated with use of an online telemedicine service for accessing self-managed medication abortion in the US?

Findings In this cross-sectional study of 57 506 individuals in 2458 counties, the cost of in-clinic care was the most commonly cited reason for accessing self-managed abortion using online telemedicine. At the county level, a 47-mile increase in distance to the nearest clinic was significantly associated with a 41% increase in requests, and a 10% increase in the population living below the federal poverty level was significantly associated with a 20% increase in requests.

Meaning In this study, clinic access barriers were the most common reason for accessing self-managed medication abortion, and both distance to an abortion clinic and living below the federal poverty level were associated with higher demand for self-management.

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

May 21, 2021

1/11

Introduction

Self-managed medication abortion is the practice of using mifepristone and misoprostol or misoprostol alone to conduct a medication abortion outside the formal health care setting.¹ This practice may be increasing in the US for 2 main reasons. First, in many states, access to abortion in the clinical setting is limited.² At the state level, Targeted Regulation of Abortion Provider (TRAP) laws have forced clinics to close,³ and state-mandated requirements, such as pre-abortion ultrasonography, waiting periods, and parental consent have placed substantial and sometimes insurmountable burdens on individuals seeking clinical abortion care.^{4,5} At the federal level, the Hyde Amendment, which bans federal funding for almost all abortions, may put clinical care out of financial reach in states that do not use state Medicaid dollars to cover abortion care.⁶

Second, there is increasing evidence that medication abortion provided without ultrasonography and with minimal oversight from health care professionals is safe and effective.^{7,8} Since its approval, mifepristone has been subject to a risk evaluation management strategy (REMS), which restricts its use in ways not supported by evidence, including an in-person dispensing requirement. Health care professionals have called for the US Food and Drug Administration to remove the REMS and enable mifepristone to be obtained from pharmacies after remote consultation with a provider.⁹ Thus, an increasing number of individuals view self-managed medication abortion as part of the spectrum of abortion care.

Little is known, however, about who uses self-managed medication abortion in the US or the factors associated with the need or desire to self-manage. Insights have come from mixed-methods studies in Texas and from abortion clinics in major cities where individuals discuss self-management using a variety of methods and cite myriad reasons, including barriers to clinic access and personal preference.^{10,11} Few studies have engaged in quantitative analysis of self-management at the national level, including 1 study that assessed lifetime prevalence¹² and another that assessed the demand for medication self-management and found that there was demand in every state.¹³

Until recently, access to self-managed medication abortion in the US has been mainly through pharmacies in Mexico, social networks, or online pharmacies.¹⁴ Online pharmacies are often viewed with suspicion by individuals seeking medication⁵ despite the medications usually being authentic.¹⁵ However, access changed markedly in 2018, when Aid Access, the first online telemedicine service to offer abortion medications to individuals living anywhere in the US, was launched.¹⁶ Using data from this service, we examined the individual-level characteristics and motivations of individuals who made requests for abortion medications, the rate of requests by state, and the factors associated with the rate of requests at the county level.

Methods

This cross-sectional study examined all requests for a self-managed medication abortion through Aid Access between March 20, 2018, and March 20, 2020. Individuals make requests to Aid Access by filling out an online consultation form. A doctor reviews the form to check for contraindications and a reported gestation of 10 weeks or less. Mifepristone and misoprostol are then prescribed according to the World Health Organization-recommended medication abortion protocol¹⁷ and mailed by a partner organization. The Aid Access help desk is available to users at any time during and after an abortion. Trained help desk members provide email instructions for use of the medications and information about recognizing complications that may require in-person medical attention. Aid Access provided all data for this study in a fully deidentified format. Researchers had access only to the state and zip code aspects of mailing information. At the time of accessing the service, respondents consented to the fully anonymized use of their data for research purposes. Written informed consent was obtained from all individuals. The study received ethical approval from the institutional review board at The University of Texas at Austin. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

The study dates represent the first 2 years of service operation, from official launch to the beginning of the COVID-19 pandemic in the US, which necessitated temporary changes to the service model. Consultation forms contained information about age, parity, state of residence, circumstances of pregnancy, gestation at the time of request, whether gestation had been determined by ultrasonography, reasons for not undergoing ultrasonography, contraindications to medication abortion (eg, allergy to medications, intrauterine device in place, chronic adrenal failure, and inherited porphyria), distance to a hospital, presence of a support person, and motivations for accessing the service. Those making the request could decline to answer any question that did not determine medical eligibility. These individuals also provided information about their location for mailing purposes.

Motivations for accessing the service were sought using the request, "Please share with us the reasons why you are requesting treatment through this online service." Answer options were based on prior insights from qualitative and quantitative studies^{5,11,18} and included an "other" option for specifying motivations not explicitly listed. The options listed included cost of clinical services, distance to a clinic, difficulty finding childcare, difficulty taking time away from work or school, legal restrictions (such as being required to view ultrasonography findings), experienced or perceived stigma or judgment, intimidation or harassment by protestors, inability to maintain confidentiality (eg, preference to avoid informing family members) when accessing clinic services, fear of negative consequences from a controlling or abusive partner, the comfort of the home environment, preferring autonomy during the abortion process, feeling empowered by self-management, the privacy of the home environment, and the ability to have a support person present during the abortion. Respondents could choose as many motivations as they believed applied to their situation.

Reasons for not undergoing ultrasonography before making a request were sought using the request, "Please share with us why you did not obtain an ultrasound." A range of answer options were provided, including inability to afford ultrasonography, certainty about gestation based on the date of the last menstrual period, fear of pregnancy being discovered by others by attending a clinic, inability to get to a clinic because of distance or lack of transportation, inability to take time off school or work to visit a clinic, and uncertainty about where to access ultrasonography. An "other" option was included to capture motivations not explicitly listed. Respondents could choose as many reasons as they believed applied to their situation.

In addition to examining characteristics and motivations at the individual level, we examined per capita requests to Aid Access at the state level. We measured the rate of requests in each state per 100 000 women of reproductive age to visualize heterogeneity in demand across states. We then conducted an analysis of factors associated with increased requests to Aid Access at the county level. We used zip code data from consultation forms to create a count of Aid Access requests per 10 000 women of reproductive age in each county, mapping zip codes to counties based on centroid latitude and longitude. The population of women of reproductive age in each county was obtained from US Census Bureau 2019 data,¹⁹ and reproductive age was defined as 15 to 44 years.

We also obtained information on county-level spatial and demographic covariates that we hypothesized might be associated with requests for medication self-management, including mean distance across zip codes in each county to the nearest abortion clinic and the proportion of the county's population that had broadband internet access, was non-White, and lived below the federal poverty level (FPL). To determine the clinic distance for each county, we calculated the mean distance in miles from each zip code in the county to the zip code of the nearest abortion clinic using the Great Circle Distance Formula.²⁰ We obtained information on abortion clinic locations using 3 separate sources that are updated regularly: ineedana.com (compiled by A Team Tech),²¹ the Abortion Care Network clinic list, and the University of California, San Francisco, abortion clinic database.²² We cross-referenced these data to ensure maximum inclusion and accuracy. We calculated the proportion of each county's population with broadband internet access using opensource data from the Federal Communications Commission Mapping Broadband Health in America project ²³ and the proportion of each county's population of women of reproductive age identifying

JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

May 21, 2021 3/11

as members of a racial/ethnic minority group using the most recent available data (2019) from the US Census Bureau, Population Division.¹⁹ We calculated the proportion of the population living below the FPL in each county using data from the US Census Bureau's Small Area Income and Poverty Estimates.²⁴

Statistical Analysis

To explore the factors associated with increased requests to Aid Access per 10 000 women of reproductive age compared with state-level mean requests, we fit a multilevel negative binomial model to the county-level request data (N = 2458), in which the response variable was the reproductive-age population-adjusted total request count for each county and the explanatory variables were the county-level spatial and demographic covariates described above. We selected variables using a stepwise procedure and used variance inflation factors to guard against collinearity. We also tested for interactions between each of these variables and used likelihood ratio tests to select the best model fit. To account for the distinct state contexts in which the counties are nested, including both state abortion policy context as defined by the Guttmacher Institute state policy classification system²⁵ and other unmeasured state-specific factors, we allowed model intercepts to vary at the state level. For ease of interpretability, we rescaled the county-level regression coefficient estimates and 95% Cls to represent the expected change in requests associated with 1 SD in clinic distance (47 miles) and 10% change in the percentage of the population identifying as members of a racial/ethnic minority group, having broadband access, and living below the FPL.

We used R statistical software, version 3.5.3 (R Project for Statistical Computing) to conduct all data analysis and the mpath package to fit our models.²⁶ We considered a < .05 to indicate statistical significance.

Results

Between March 20, 2018, and March 20, 2020, 57 506 individuals requested a medication abortion from Aid Access; **Table 1** shows their demographic and clinical characteristics. A total of 52.1% of these individuals were aged 20 to 29 years, and 19.6% were younger than 20 (mean [SD] age, 25.9 [6.7]); 50.0% had children. At the time requests were made, 99.9% reported being pregnant for 10 weeks or less; gestation was 6 weeks or less for 43.6%, between 7 and 10 weeks for 56.3%, and more than 10 weeks for 0.1%. A total of 53.5% had experienced a contraceptive failure. Most individuals (84.5%) had not undergone ultrasonography, with the most common reasons being inability to afford it (56.4%) and certainty about gestation based on date of last menstrual period (33.4%). Most individuals (96.3%) were within an hour's drive to a hospital, and 96.4% had a companion who could be with them during the abortion. A total of 0.6% of individuals had any contraindication, and 99.1% felt sure about their decision.

The most common reason for seeking a medication abortion through Aid Access was inability to afford an in-clinic abortion, cited by 73.5% of individuals making requests (**Figure 1**). Almost half (49.3%) were afraid of a partner or family member finding out if they tried to go to a clinic, 40.4% reported that the nearest clinic was too far away, and 37.6% were unable to take time away from work or school to go to a clinic. Although the most common reasons involved barriers to clinic access, preferences for self-managed abortion were also cited: 28.2% responded that they would be more comfortable at home, and 27.0% said self-managing at home would be more convenient.

Requests to Aid Access came from all 50 states. **Figure 2** shows the rate of requests by state per 100 000 women of reproductive age. Louisiana had the highest rate of requests (202.7 per 100 000 women), followed by Mississippi (199.9 per 100 000 women), Wyoming (173.2 per 100 000 women), and Alabama (166.1 per 100 000 women). Vermont had the lowest rate of requests (36.7 per 100 000 women), followed by Connecticut (41.8 per 100 000 women), Oregon (43.7 per 100 000 women), and California (44.6 per 100 000 women).

JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

Table 1. Characteristics of 57 506 Individuals Requesting Medication Abortion From Aid Access Between March 20, 2018, and March 20, 2020

Characteristic	Frequency of requests, No. (%)
Age, y	
<20	11 283 (19.6)
20-24	16 056 (27.9)
25-29	13 884 (24.1)
30-34	9317 (16.2)
35-39	5077 (8.8)
40-44	1606 (2.8)
≥45	283 (0.5)
Children, No.	
0	28754 (50.0)
1	11 288 (19.6)
2	9592 (16.7)
≥3	7872 (13.7)
Gestation	
≤6 wk	25 100 (43.6)
7-10 wk	32 399 (56.3)
>10 wk	7 (0.1)
Circumstances of pregnancy ^a	
Contraceptive failure	30 766 (53.5)
Contraceptive nonuse	23 891 (41.6)
Sexual assault	2848 (4.9)
Ultrasonography performed before abortion request	
Yes	8895 (15.5)
No	48 611 (84.5)
Reason for no ultrasonography ^b	
Cannot afford to pay for one	27 436 (56.4)
Do not need one owing to feeling sure of gestation	16244 (33.4)
Afraid someone will find out if trip to a clinic is made to get one	15 350 (31.6)
Cannot get to a clinic to get one ^c	11 557 (23.8)
No time to get one	4863 (10.0)
Not sure where to get one	4725 (9.7)
Other reason	1105 (2.3)
Contraindication to medication abortion	
Yes	340 (0.6)
No	57 166 (99.4)
Within a 60-min drive to a hospital	
Yes	55 383 (96.3)
No	2123 (3.7)
Another individual can be available and present during the abortion	
Yes	55 449 (96.4)
No	2057 (3.6)
Feelings about decision	
OK with decision	56 960 (99.1)
Troubled by decision	546 (0.9)
^a One missing response.	

^a One missing response.


 $^{\rm b}$ Respondents could choose more than 1 response.


 $^{\rm c}\,$ Reasons include distance and lack of transportation.


G JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

County-level factors associated with a higher rate of requests to Aid Access included distance to the nearest abortion clinic and the proportion of the population living below the FPL (**Table 2**). The mean (SD) distance to the nearest clinic for all counties was 56.5 (47.4) miles. A 47 mile (1 SD) increase in distance to the nearest clinic was associated with a 41.0% increase in Aid Access requests (incidence rate ratio [IRR], 1.41; 95% CI, 1.31-1.51; P < .001). A 10% increase in the population living below the FPL was associated with a 20.0% increase in requests (IRR, 1.20; 95% CI, 1.13-1.28; P < .001). The interaction between clinic distance and the proportion living below the FPL was associated with a 12.0% lower rate of requests (IRR, 0.88; 95% CI, 0.84-0.92; P < .001).

Figure 3 shows the magnitude of the state-level intercepts, which are scaled to represent the baseline expected request rate per 100 000 women of reproductive age for each state under the reference level for all other covariates in the model (ie, mean clinic distance and all county-level







JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

May 21, 2021 6/11

jamanetwork/2021/jno/05_21_2021/zoi210355

2/8/2024 PAGE: 6

characteristics set to 0). The magnitude of the state-level intercepts (SD of the intercepts, 0.33) was larger in states with more restrictive abortion policy climates,²⁵ with the top 5 being Louisiana (76.1), Mississippi (75.8), Nevada (74.7), Kansas (73.2), and Wyoming (71.0). The magnitude of the intercepts was smaller in states with more supportive policy climates,²⁵ with the lowest being Vermont (27.0), Massachusetts (27.2), Oregon (27.6), California (28.5), and Connecticut (28.7).

Discussion


To our knowledge, this study is the first to examine requests for self-managed medication abortion using an online telemedicine service in the US and the factors associated with these requests. We found that clinic access barriers, most notably the cost of an in-clinic abortion, were the reasons most frequently cited by those making requests. We also found that these individual-level barriers were reflected at the state level, where the highest rates of requests were associated with residence in states with more restrictive abortion policy climates, and at the county level, where longer mean distance to the nearest abortion clinic and a higher proportion living below the FPL were associated with an increased rate of requests.

In light of the declining abortion rate in the US, these findings lend support to the possibility that there has been a shift in the location of some abortions to outside the clinic setting and thus an increase in the number of self-managed abortions.²⁷ Policies restricting access to in-clinic abortion have increased over the past decade,²⁸ and some findings suggest that the decrease in the rate of in-clinic abortions has been associated with residence in states with more restrictions.²⁹ Moreover,

Table 2. County-Level Factors Associated With Requests to Aid Access		
Covariate	IRR (95% CI)	P value
Clinic distance z score ^a	1.41 (1.31-1.51)	<.001
Proportion of population living below the FPL ^b	1.20 (1.13-1.28)	<.001
Proportion of population belonging to racial/ethnic minority group ^b	0.99 (0.95-1.02)	.499
Proportion of population with broadband internet access ^b	1.01 (1.00-1.02)	.058
Interaction between clinic distance and proportion of population living below the $\mbox{FPL}^{\rm b}$	0.88 (0.84-0.92)	<.001
Interaction between and proportion of population living below the FPL and belonging to racial/ethnic minority ${\rm group}^{\rm b}$	0.92 (0.77-1.09)	.34

Abbreviations: FPL, federal poverty level; IRR, incidence rate ratio.

- ^a The mean (SD) distance to a clinic was 56 (47) miles. The estimate represents the expected associated change in requests for a 1-SD increase in clinic distance.
- ^b Adjusted so that the estimate represents the expected change in requests for a 0.1-change in proportion.



Baseline expected requests to Aid Access per 100 000 individuals of reproductive age under reference covariate levels are shown. Variability in intercepts (mean, 50.9; SD, 14.8) reflects state-specific policy and other differences that are not captured by covariates.

🖞 JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

May 21, 2021 7/11

the number abortion clinics in the Midwest and South has decreased by 6% and 9%, respectively,³⁰ resulting in increased distance to an abortion clinic and an associated decrease in the in-clinic abortion rate.³¹ These patterns mirror our findings that cost and distance to a clinic were associated with increased demand for self-management. The interaction examined between poverty and clinic distance also showed that although closer clinic distance was associated with a decrease in requests to Aid Access, this association did not hold for people living in below the FPL. In other words, in places where individuals could not afford the cost of an in-clinic abortion, a shorter distance to a clinic was not associated with improved access.

In addition to the difficulties exacerbated by living below the FPL, such as finding information, taking time away from work and childcare, and keeping multiple state-mandated clinic appointments, 1 of the most significant financial obstacles may be the lack of Medicaid coverage for abortion under the Hyde Amendment.³² Although state Medicaid funds can be used to pay for abortion care in 16 states, they cannot be used in 34 states, ³³ and Patient Protection and Affordable Care Act health insurance plans are prohibited from covering abortion in many of these same 34 states.³⁴ Although the state-level intercepts in our model accounted for more than policy differences, we note that the states with restrictions on insurance and Medicaid coverage tended to have higher baseline request rates. These policies mean that most individuals must pay out of pocket for abortion care, and although abortion funds assist with these payments, our findings suggest that self-management also fills a gap in access.

Of note, barriers to clinic access were not the sole or primary motivation for all individuals. Some also cited preferences for the comfort and convenience of using abortion medications at home. Such preferences are also commonly reported in other countries where self-managed abortion is provided using online telemedicine services.¹⁴ Moreover, studies have demonstrated high levels of effectiveness and safety, with few reported serious adverse events.^{7,14} Self-managed abortion as a preference thus calls attention to the need for a wider spectrum of abortion care models that center on individual autonomy and preferences.

With many states planning further restrictions on in-clinic abortion and the possibility that Roe v Wade will be severely diminished by Supreme Court rulings, we may expect to see demand for selfmanaged medication abortion increase. The temporary adjustment to the mifepristone REMS during the COVID-19 pandemic has spurred some states to increase access to medication abortion by introducing no-test protocols, telemedicine consultation, and delivery of medications by mail.³⁵ These innovations also have the potential to expand access for those living below the FPL by negating the costs of in-person clinic attendance and medical tests. However, other states have kept in place laws that prohibit telemedicine consultation and, in some cases, have moved to further restrict clinic access, ³⁶ with associated increases in demand for self-management.³⁷ For clinicians, this increased demand for self-managed abortion means being equipped to provide follow-up to those patients who might require it, including being informed on the American College of Obstetricians and Gynecologists' position on self-management of abortion³⁸ and the lack of reporting requirements to protect patient confidentiality.³⁹ For policy makers, increased demand means that the consequences of laws that make in-clinic abortion less accessible and the expansion of medication abortion access should be considered to help overcome existing barriers and meet patients' preferences.

Limitations

This study has limitations. The main limitation of our study was that other routes to self-managed medication abortion and other types of self-management are available in the US. Therefore, our results may not be generalizable beyond the population using an online telemedicine service. Furthermore, our methodological approach lends itself to exploring associations rather than establishing causality. Nonetheless, we hope that future studies will examine in more detail the factors associated with higher rates of self-managed medication abortion that were revealed in the present study.

JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

May 21, 2021 8/11

Conclusions

In this cross-sectional study, clinic access barriers owing to cost and distance were the most commonly cited barriers by individuals accessing self-managed medication abortion using an online telemedicine service. At the county level, longer distance to an abortion clinic and living below the FPL were associated with increased demand for the service. At the state level, the highest rates of requests to the service were found in states with more restrictive abortion policy climates. Repeal of the Hyde Amendment and permanent removal of the mifepristone REMS may help to address these barriers.

ARTICLE INFORMATION

Accepted for Publication: April 4, 2021.

Published: May 21, 2021. doi:10.1001/jamanetworkopen.2021.11852

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Aiken ARA et al. *JAMA Network Open*.

Corresponding Author: Abigail R. A. Aiken, MD, PhD, LBJ School of Public Affairs, The University of Texas at Austin, Austin, TX, 78712 (araa2@utexas.edu).

Author Affiliations: LBJ School of Public Affairs, The University of Texas at Austin (Aiken); Population Research Center, The University of Texas at Austin (Aiken); Mathematica Policy Research Inc, Cambridge, Massachusetts (Starling); Aid Access, Amsterdam, the Netherlands (Gomperts).

Author Contributions: Dr Aiken had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Aiken, Starling.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Aiken, Starling.

Critical revision of the manuscript for important intellectual content: Aiken, Gomperts.

Statistical analysis: Aiken, Starling.

Obtained funding: Aiken.

Supervision: Aiken, Gomperts.

Conflict of Interest Disclosures: Dr Aiken reported receiving grants from the Society of Family Planning and the National Institutes of Health during the conduct of the study. Dr Gomperts reported being the founder and director of Aid Access and Women on Waves and receiving salary from Aid Access and Women on Waves outside the submitted work. No other disclosures were reported.

Funding/Support: This research was supported by grant SFPRF12-MA1 from the Society of Family Planning (Dr Aiken).

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES

 World Health Organization Guidelines. WHO recommendations on self-care interventions: self-management of medical abortion. 25 June 2020. Accessed January 12, 2021. https://www.who.int/publications/i/item/WHO-SRH-20-11

2. Nash E, Donovan MK. Ensuring access to abortion at the state level: selected examples and lessons. *Guttmacher Policy Review*. 2019;22. March 31, 2021. https://www.guttmacher.org/gpr/2019/01/ensuring-access-abortion-state-level-selected-examples-and-lessons#

3. Gerdts C, Fuentes L, Grossman D, et al. Impact of clinic closures on women obtaining abortion services after implementation of a restrictive law in Texas. *Am J Public Health*. 2016;106(5):857-864. doi:10.2105/AJPH.2016. 303134

4. Jerman J, Frohwirth L, Kavanaugh ML, Blades N. Barriers to abortion care and their consequences for patients traveling for services: qualitative findings from two states. *Perspect Sex Reprod Health*. 2017;49(2):95-102. doi:10. 1363/psrh.12024

JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

5. Aiken ARA, Broussard K, Johnson DM, Padron E. Motivations and experiences of people seeking medication abortion online in the United States. *Perspect Sex Reprod Health*. 2018;50(4):157-163. doi:10.1363/psrh.12073

6. Dennis A, Manski R, Blanchard K. Does medicaid coverage matter? a qualitative multi-state study of abortion affordability for low-income women. *J Health Care Poor Underserved*. 2014;25(4):1571-1585. doi:10.1353/hpu. 2014.0151

7. Aiken ARA, Digol I, Trussell J, Gomperts R. Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland. *BMJ*. 2017; 357:j2011. doi:10.1136/bmj.j2011

8. Aiken AR, Lohr P, Lord J, Ghosh N, Starling J. Effectiveness, safety and acceptability of no-test medical abortion provided via telemedicine: a national cohort study. *BJOG*. Published online February 18, 2021. doi:10.1111/1471-0528.16668

9. Raymond EG, Blanchard K, Blumenthal PD, et al; Mifeprex REMS Study Group. Sixteen years of overregulation: time to unburden Mifeprex. *N Engl J Med*. 2017;376(8):790-794. doi:10.1056/NEJMsb1612526

10. Fuentes L, Baum S, Keefe-Oates B, et al. Texas women's decisions and experiences regarding self-managed abortion. *BMC Womens Health*. 2020;20(1):6. doi:10.1186/s12905-019-0877-0

11. Grossman D, Holt K, Peña M, et al. Self-induction of abortion among women in the United States. *Reprod Health Matters*. 2010;18(36):136-146. doi:10.1016/S0968-8080(10)36534-7

12. Ralph L, Foster DG, Raifman S, et al. Prevalence of self-managed abortion among women of reproductive age in the United States. JAMA Netw Open. 2020;3(12):e2029245. doi:10.1001/jamanetworkopen.2020.29245

13. Aiken ARA, Starling JE, van der Wal A, et al. Demand for self-managed medication abortion through an online telemedicine service in the United States. *Am J Public Health*. 2020;110(1):90-97. doi:10.2105/AJPH.2019.305369

14. Moseson H, Herold S, Filippa S, Barr-Walker J, Baum SE, Gerdts C. Self-managed abortion: a systematic scoping review. *Best Pract Res Clin Obstet Gynaecol*. 2020;63:87-110. doi:10.1016/j.bpobgyn.2019.08.002

 Murtagh C, Wells E, Raymond EG, Coeytaux F, Winikoff B. Exploring the feasibility of obtaining mifepristone and misoprostol from the internet. *Contraception*. 2018;97(4):287-291. doi:10.1016/j.contraception.2017.09.016

16. Aiken ARA. Erosion of women's reproductive rights in the United States. *BMJ*. 2019;366:14444. doi:10.1136/ bmj.14444

17. World Health Organization (WHO). Medical management of abortion. 2018. Accessed March 24, 2021. https://apps.who.int/iris/bitstream/handle/10665/278968/9789241550406-eng.pdf?ua=1

 Aiken ARA, Broussard K, Johnson DM, Padron E, Starling JE, Scott JG. Knowledge, interest, and motivations surrounding self-managed medication abortion among patients at three Texas clinics. *Am J Obstet Gynecol*. 2020; 223(2):238.e1-238.e10. doi:10.1016/j.ajog.2020.02.026

19. US Census Bureau, Population Division. Annual County resident population estimates by age, sex, race, and Hispanic origin: April 1, 2010 to July 1, 2019. Accessed January 12, 2021. https://www2.census.gov/programs-surveys/popest/datasets/2010-2019/counties/asrh/cc-est2019-alldata.csv

20. Wallace JR. gdist: Geodesic distance (great circle distance) between points. Accessed January 12, 2021. https://rdrr.io/cran/Imap/man/gdist.html

21. ineedana.com. Accessed January 12, 2021. https://ineedana.com

22. Advancing New Standards in Reproductive Health (ANSIRH), Abortion Facility Database. University of California, San Francisco. September 2019.

23. Federal Communications Commission. Mapping broadband health in America. Accessed January 12, 2021. https:// www.fcc.gov/health/maps/methodology

24. US Census Bureau. Small Area Income and Poverty Estimates (SAIPE). Accessed January 12, 2021. https:// www.census.gov/data-tools/demo/saipe/#/?map_geoSelector=aa_c

25. Nash E. Guttmacher Institute Policy Analysis. State abortion policy landscape: from hostile to supportive. August 2019. Accessed March 24, 2021. https://www.guttmacher.org/article/2019/08/state-abortion-policy-landscape-hostile-supportive#

26. Wang Z. Package 'mpath'. December 13, 2020. Accessed January 12, 2021. https://cran.r-project.org/web/ packages/mpath/mpath.pdf

27. Foster DG. Dramatic decreases in US abortion rates: public health achievement or failure? *Am J Public Health*. 2017;107(12):1860-1862. doi:10.2105/AJPH.2017.304152

28. Guttmacher Institute News in Context. Last five years account for more than one-quarter of all abortion restrictions enacted since Roe. January 13, 2016. Accessed January 12, 2021. https://www.guttmacher.org/article/2016/01/last-five-years-account-more-one-quarter-all-abortion-restrictions-enacted-roe

JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852

May 21, 2021 10/11

29. Brown BP, Hebert LE, Gilliam M, Kaestner R. Association of highly restrictive state abortion policies with abortion rates, 2000-2014. *JAMA Netw Open*. 2020;3(11):e2024610. doi:10.1001/jamanetworkopen.2020.24610

30. Jones RK, Witwer E, Jerman J. Abortion incidence and service availability in the United States, 2017. Guttmacher Institute Report. September 2019. Accessed January 12, 2021. https://www.guttmacher.org/report/ abortion-incidence-service-availability-us-2017

31. Brown BP, Hebert LE, Gilliam M, Kaestner R. Distance to an abortion provider and its association with the abortion rate: a multistate longitudinal analysis. *Perspect Sex Reprod Health*. 2020;52(4):227-234. doi:10.1363/psrh.12164

32. Donovan MK. In real life: federal restrictions on abortion coverage and the women they impact. *Guttmacher Policy Review*. 2017;20:1-7.

33. Salganicoff A, Sobel L, Ramaswamy A. The Hyde Amendment and coverage for abortion services. Kaiser Family Foundation Issue Brief. March 5, 2021. Accessed March 24, 2021. https://www.kff.org/womens-health-policy/ issue-brief/the-hyde-amendment-and-coverage-for-abortion-services/

34. Kaiser Family Foundation Issue Brief. Interactive: how state policies shape access to abortion coverage. Feb 10, 2020. Accessed March 24, 2021. https://www.kff.org/womens-health-policy/issue-brief/interactive-how-state-policies-shape-access-to-abortion-coverage/

35. Upadhyay UD, Schroeder R, Roberts SC. Adoption of no-test and telehealth medication abortion care among independent abortion providers in response to COVID-19. *Contracept X*. 2020;2:100049.

36. White K, Kumar B, Goyal V, Wallace R, Roberts SCM, Grossman D. Changes in abortion in Texas following an executive order ban during the coronavirus Pandemic. *JAMA*. 2021;325(7):691-693. doi:10.1001/jama. 2020.24096

37. Aiken ARA, Starling JE, Gomperts R, Tec M, Scott JG, Aiken CE. Demand for self-managed online telemedicine abortion in the United States during the coronavirus disease 2019 (COVID-19) pandemic. *Obstet Gynecol*. 2020; 136(4):835-837. doi:10.1097/AOG.00000000004081

38. American College of Obstetricians and Gynecologists. Position statement on decriminalization of self-induced abortion. Published 2017. Accessed January 12, 2020. https://www.acog.org/clinical-information/policy-and-position-statements/2017/decriminalization-of-self-induced-abortion

39. Self-managed abortion, the law, and COVID-19 factsheet. Accessed January 12, 2021. https://www. ifwhenhow.org/wp-content/uploads/2020/04/20_04_Final_SMA_TheLaw_COVID-19_FactSheet_PDF.pdf

JAMA Network Open. 2021;4(5):e2111852. doi:10.1001/jamanetworkopen.2021.11852



From: jnjournals@jamanetwork.org

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

CC: <u>"Jennifer E Starling" <jstarling@mathematica-mpr.com></u> <u>"Rebecca Gomperts"</u> Date: 5/23/2021 9:02:15 PM

Subject: Congratulations on your publication in JAMA Network Open



Dear Dr Aiken:

Thank you for sending *JAMA Network Open* your manuscript and congratulations on its publication. Below is a link to the article, which is now live on the *JAMA Network Open* website. Feel free to share the link with colleagues, and most importantly your family and friends.

Article: Factors Associated With Use of an Online Telemedicine Service to Access Self-managed Medical Abortion in the US Publication Date: 05-21-2021

On the online version of your article, there is a small panel at the top of the page that shows some early metrics such as views and media and social media coverage. These metrics and citations will accumulate and grow throughout this year and thereafter. Below is an example of what the metrics panel looks like:



JAMA Network Open is committed to making your author experience a positive one and to maximizing the impact and reach of your article. If you have any questions or concerns, please let us know at <u>JAMA Network Open</u>.

Best Regards,

Frederick P. Rivara, MD, MPH

Editor in Chief, JAMA Network Open



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click <u>here</u> to unsubscribe from these emails.

From: <u>"Rebecca Gomperts"</u>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

CC: <u>"Jennifer E Starling" <jstarling@utexas.edu></u>

Date: 6/2/2021 1:45:58 AM

Subject: Re: Coverage summary

thanks sooo much!!

On 1 Jun 2021, at 22:38, Abigail Aiken <<u>araa2@utexas.edu</u>> wrote:

Hi there,

Here's a summary of the coverage for our JAMA article :)

Article here: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780272

https://abcnews.go.com/Health/cost-care-distance-clinics-drives-demand-managed-abortion/story?id=77826875

https://msmagazine.com/2021/05/27/order-abortion-pills-medication-abortion-online-affordabilityprivacy-convenience-aid-access/

https://www.kxan.com/state-of-texas/state-of-texas-legal-challenges-likely-for-abortion-lawidentity-thieves-target-unemployment-benefits/

https://www.politico.com/news/2021/05/31/supreme-court-abortion-fda-491375

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>

	Page 1
From:	
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	<u>"Melissa Madera" <mmadera@utexas.edu></mmadera@utexas.edu></u>
	<u>"Rebecca Gomperts"</u>
Date:	6/17/2021 10:24:17 AM
Subject:	Fwd: Decision on your submission to SSM - Qualitative Research in Health

Hi Abigail, Melissa, and Rebecca-

Below is the decision from SSM Qualitative Research in Health regarding the telemedicine in-depth interviews financial hardship paper. Overall, I think the comments are very helpful! I'm working on drafting the response and incorporating revisions, and I will send out a draft for everyone to look over once I am finished. If anyone has any specific comments they have thoughts on, please let me know! I am around on email or a phone call anytime :)

Hope everyone is doing well, and I look forward to talking soon.

<u>B</u>est,

------ Forwarded message ------From: **SSM - Qualitative Research in Health** <<u>em@editorialmanager.com</u>> Date: Thu, Jun 10, 2021 at 5:05 PM Subject: Decision on your submission to SSM - Qualitative Research in Health To:

Manuscript Number: SSMQR-D-21-00036

Dear

We have completed our evaluation of your manuscript. As you can see, the reviewers are split on your manuscript. I was would like to encourage you to take reviewer 1's suggestions seriously and aim for a stronger and more original contribution. The reviewers recommend reconsideration following revision, and we invite you to resubmit your manuscript after addressing the comments below. Please resubmit your revised manuscript by Aug 09, 2021.

When revising your manuscript, please consider all issues mentioned in the reviewers' comments carefully: please outline every change made in response to their comments and provide suitable rebuttals for any comments not addressed. Please note that your revised submission may need to be re-reviewed.

To submit your revised manuscript, please log in as an author at <u>https://www.editorialmanager.com</u> /ssmqr/, and navigate to the "Submissions Needing Revision" folder under the Author Main Menu.

Kind regards,

Dr. Stefan Timmermans Editor-in-Chief

Zachary Griffen Editorial Assistant

Editor and Reviewer comments:

Reviewer #1:

This manuscript draws on a unique dataset that has the potential to fill an important knowledge gap. There is little qualitative data and analysis on people who self-manage their abortions in the US. I think, however, that the authors do not hit the mark in mining the unique aspects of these data. Much of the findings are not specific to telemedicine abortion nor, in several cases, even to abortion care. Below, I offer some concerns about the framing, methods, and results.

On the overall framing of the manuscript, there is some circularity. The introduction, for example, starts with the presumption that people choose telemedicine when clinical care is out of reach—but then the study purpose is to understand how finances matter to someone's decision to use telemedicine. This is circular. My second concern with the framing that people are choosing between in-clinic and telemedicine care is the timeline participants describe. All of the participants quoted describe first seeking an in-clinic abortion and then, only after determining that they cannot afford inclinic care, seeking a telemedicine abortion. This is not so much, then, a choice between two options: there is one option (in-clinic) that becomes out of reach and then a second option (telemedicine). The framing, however, presents participants as having a simultaneous choice between the two. I don't think the authors place enough of the emphasis for the distress participants experience on Medicaid abortion bans. The reason the cost of an in-clinic abortion is consequential is because insurance doesn't cover abortion (in most states). If abortion were not an out of pocket service—and were like most health care—the price differential between telemedicine and in-clinic abortion would not be a factor in decision making.

In the Methods, I would like to know:

* Was the interview audio only? Or was there also video? What about text?

* How many different people conducted interviews? What was the quality control on ensuring that all interviews had similar level of investigation/probing?

* How many coders were there? What was their relationship to the interviewers?

* Why was inter-rater relatability assessed? That seems to conflict with grounded theory methods, which are not premised on agreement. Inter-rate relatability seems relevant to deductive coding, but the authors do not describe that.

* What were the domains of the interview guide?

Broadly, the results did not break new ground as I think they have the potential to. The literature already demonstrates that finances matter for having an abortion, that people have multiple reasons for abortion, that people already parenting cite their responsibilities to existing children as a reason for seeking an abortion. How does this study extend that knowledge? (As noted above, I don't think the manuscript evidences that finances affect the decision between in-clinic and telemedicine because they are sequential decisions.) Further, I think the emphasis on how finances matter flattens the nuance of participants' decision making and under-utilizes what I imagine is rich data. Qualitative data promises the ability to understand multiple, interactive factors that affect people's decision making. It doesn't make sense that all 80 participants would follow the same decision pathway. Indeed, some of the quotes actually seem to undermine the authors' assertion that financial challenges were the primary motivator for seeking telemedicine abortion (e.g. Carmen who thought it would simply be easier, Steph talked about wanting to avoid protesters and have more privacy) or at least offer additional factors (e.g. protesters). Asserting that finances were the deciding factor suggests that absent financial hardship, all participants would have preferred an in-clinic abortion—but the literature suggests that telemedicine abortion can be a first choice for some people.

I have some ideas of what the authors could do. While the data does not support the authors' contention that cost was what "prompt[ed] participants to seek an alternative pathway to care" (it shows that cost made in-clinic care out of reach), there is an important question about how people who were effectively denied abortion care because of cost had the imagination to find telemedicine. Why didn't they give up when they realized they couldn't afford an in-clinic abortion? There are hints of this in the text (news reports, friends). Examining this process would represent a contribution to the literature and could have practical implications for expanding knowledge of telemedicine options. How does knowledge about telemedicine abortion diffuse? I think fleshing out that process would represent a novel contribution to the literature.



I am thrilled this manuscript is under review. The nuanced understanding that the authors provide of reasons participants sought out self-managed care highlights the critical importance that financial pressures play in the decision(?) to seek more affordable care (through telemedicine) due to the high cost of clinical care. The authors take a structural approach in the framing, analysis, and discussion. They highlight the compounding financial barriers to abortion (health care) access through direct participant quotes. I am particularly impressed by the comprehensive synthesis the authors provide of financial barriers to abortion access (through clinical cost, REMS restrictions, TRAP laws, etc), and their policy suggestions focused on insurance coverage for abortion, which is necessary to make abortion accessible. The authors'

Findings are contextualized within the framework of the US healthcare system, and are applicable beyond self-managed abortion care as they state "The critical piece here is not simply access to medication abortion, but access to services that people can afford". This article will be essential to anyone interested in better understanding the US healthcare system and the role that financial burden play in accessibility of care. Thank you for writing this incredible piece!

A couple of quick suggestions to take or leave:

1. "

May want to consider citing Witwer et al 2020 table 4 https://pubmed.ncbi.nlm.nih.gov

3

/33083783/ Cost range for 2017 in clinic med ab: \$250-\$2000 (Witwer et al. 2020)

2. Were the middle ground states grouped in with hostile states? The "middle ground" categorization is a bit odd (only a few states) and sometimes it is collapsed but I didn't see it noted and was just curious

3. I really appreciated the narratives of mothers and how compounding financial responsibilities played in their decision to self-manage. Many of these narratives were familiar to me as a former clinic worker (wanting the pregnancy but prioritizing the kids they already have, getting pregnant very quickly after giving birth), and I'm wondering if you could include a line to clarify that mothers who have abortion in clinic may struggle with these same difficult decisions but the key importance that may lead to seeking telemedicine abortion outside the clinic is cost (that is how I understood it but I felt like it could be more explicit).

More information and support

You will find information relevant for you as an author on Elsevier's Author Hub: <u>https://www.elsevier.com/authors</u>

FAQ: How can I reset a forgotten password?

https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/ For further assistance, please visit our customer service site: <u>https://service.elsevier.com/app/home</u> /supporthub/publishing/

Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <u>https://www.editorialmanager.com/ssmqr /login.asp?a=r</u>). Please contact the publication office if you have any questions.

From: jnjournals@jamanetwork.org

- To: <u>"Abigail Aiken" <araa2@utexas.edu></u>
- CC: <u>"Jennifer E Starling" <jstarling@mathematica-mpr.com></u> "Rebecca Gomperts"
- Date: 6/24/2021 10:11:30 AM
- Subject: Congratulations on your recent publication in JAMA Network Open



Dear Dr Aiken,

Thank you for submitting your manuscript to JAMA Network Open. Your article has received some attention in the media and we're pleased to provide you a <u>link</u> to some of its news coverage.

Congratulations, and we hope you will consider publishing with us again.

Sincerely yours,

Frederick Rivara, MD, MPH Editor in Chief

From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	<u>"Rebecca Gomperts" <</u>
	<u>"Jennifer E Starling" <jstarling@utexas.edu></jstarling@utexas.edu></u>
	"James Scott" <james.scott@mccombs.utexas.edu></james.scott@mccombs.utexas.edu>
Date:	7/6/2021 9:32:32 AM
Subject:	Media mention for our COVID-19 Aid Access paper

Hi all,

Just sending along a nice mention in Politico of the paper we did this time last year looking at increased demand for Aid Access during COVID-19 in states that restricted in-clinic abortion access: <u>https://www.politico.com/news/2021/07/06/abortion-rights-supreme-court-states-restrictions-497821</u>

Rebecca and Jenn, there's also a mention of our recent JAMA Network Open study, but annoyingly they did not include the link (I'll email to see if they can instate it).

Best to all, A

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>

From: <u>"Melissa Madera" <mmadera@utexas.edu></u>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

CC: <u>"Rebecca Gomperts" <</u>

Date: 8/9/2021 9:29:28 AM

Subject: Re: SSM QHR Manuscript revision

Attachments: SSMQR-D-21-00036_Revised-3.docx

Hey

I think the paper (and all the new bits) looks great. I did have some questions that I went back and added in the intro and analysis section. They are about clarification and consistency. Otherwise, I think it's fantastic.

Best, Mel

On Fri, Aug 6, 2021 at 2:09 PM Abigail Aiken <<u>araa2@utexas.edu</u>> wrote: Hi there.

,

This looks great,

I made a couple of additional edits and caught a few typos in the response to reviewers attached here (all in tracked changes), but I didn't have any changes to the main manuscript.

Let me know if you have any questions about any of the small revisions I made. I'd also suggest one final proof read before you submit on/by the Aug 9th deadline.

Great job and fingers crossed for a positive reception from the journal! A

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>

On Thu, Aug 5, 2021 at 9:26 AM

wrote:

Please see the updated revisions for our Social Science and Medicine Qualitative Health Research submission. Let me know if you have any final questions or comments!

Thanks,

On Fri, Jul 30, 2021 at 1:05 PM Abigail Aiken <<u>araa2@utexas.edu</u>> wrote: Hi all,

you did a great job on this!

Mel and Rebecca: l've given a first round of comments and edits. I know you both are either on vacation or traveling right now. If possible, please hold off on giving your comments until has had a chance to send out an updated version of the manuscript and response

Page 2
to reviewers.
Thanks so much, and best to all, A
Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>
On Thu, Jul 29, 2021 at 1:12 PM wrote: Hi All! Attached is a draft of our revisions of the paper submitted to Social Science and Medicine Qualitative Health Research.
If you have comments or anything you'd like to go over, please let me know! Happy to jump on a zoom call or anything, or take feedback over email. If possible, please let me know any thoughts you might have by August 7th (the final revision is due to the journal Monday August 9th.) I highlighted in track changes a few pieces I thought folks would have specific thoughts on.
Thanks so much! Best,

Melissa Madera, Ph.D. Research Fellow & Senior Project Manager <u>Project SANA</u> LBJ School of Public Affairs University of Texas at Austin Founder & Director, <u>The Abortion Diary Podcast</u>

From: jnjournals@jamanetwork.org

- To: <u>"Abigail Aiken" <araa2@utexas.edu></u>
- CC: <u>"Jennifer E Starling" <jstarling@mathematica-mpr.com></u> <u>"Rebecca Gomperts" <</u> Date: 8/19/2021 9:03:40 PM
- Subject: Update on your publication in JAMA Network Open



Dear Dr Aiken:

In the 3 months since your article, <u>Factors Associated With Use of an</u> <u>Online Telemedicine Service to Access Self-managed Medical</u> <u>Abortion in the US</u>, was published in *JAMA Network Open*, it has attracted readership and attention.

We invite you to click the title of your article in the link above to see your article's reach and usage metrics as shown in this example:



You will see the numbers of times your article has been viewed and cited by other articles. The Altmetric score shows coverage by news and social media. By clicking the Altmetric link, you can explore where your article has been mentioned in the news media, blogs, social media accounts, and more.

Note that the citations metric usually takes 6 months or more to populate.

JAMA Network Open is committed to making your author experience positive and to maximizing the impact and reach of your article. If you have any questions or concerns, please let us know.

Best Regards,


Frederick P. Rivara, MD, MPH Editor in Chief, *JAMA Network Open*



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click here to unsubscribe from these emails.



My comments, and any reviewer comments, are below.

Your accepted manuscript will now be transferred to our production department. We will create a proof which you will be asked to check, and you will also be asked to complete a number of online forms required for publication. If we need additional information from you during the production process, we will contact you directly.

We appreciate you submitting your manuscript to SSM - Qualitative Research in Health and hope you will consider us again for future submissions.

Kind regards,

Dr. Stefan Timmermans Editor-in-Chief

Zachary Griffen Editorial Assistant

SSM - Qualitative Research in Health

Editor and Reviewer comments:

More information and support

FAQ: When and how will I receive the proofs of my article? https://service.elsevier.com/app/answers/detail/a_id/6007/p/10592/supporthub/publishing /related/

You will find information relevant for you as an author on Elsevier's Author Hub: <u>https://www.elsevier.com/authors</u>

FAQ: How can I reset a forgotten password?


https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/ For further assistance, please visit our customer service site: <u>https://service.elsevier.com</u> /app/home/supporthub/publishing/

Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <u>https://www.editorialmanager.com/ssmqr/login.asp?a=r</u>). Please contact the publication office if you have any questions.

Melissa Madera, Ph.D. Research Fellow & Senior Project Manager <u>Project SANA</u> LBJ School of Public Affairs University of Texas at Austin Founder & Director, <u>The Abortion Diary Podcast</u>

--



This message is from an external sender. Learn more about why this matters.

From: <u>"Abigail Aiken" <araa2@utexas.edu></u>

To: <u>"JE Starling" <jstarling@utexas.edu></u>

CC: <u>"Abigail Aiken" <araa2@utexas.edu></u> <u>"Rebecca Gomperts"</u> Date: 9/14/2021 12:28:43 PM

Subject: Re: More news coverage!

Thanks so much! Also this: <u>https://www.washingtonpost.com/world/2021/09/14/abortion-pills-texas/</u> :) :)

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: araa2@utexas.edu

On Tue, Sep 14, 2021 at 10:55 AM JE Starling <<u>jstarling@utexas.edu</u>> wrote: Hi there -

Saw this article this morning - it mentions our paper, thought I'd pass it along in case you hadn't seen it yet. :-)

https://www.yahoo.com/lifestyle/abortion-pills-booming-worldwide-grow-102041837.html

Have a great day! Jenn

	raye i
From:	"Clarissa-Jan Lim"
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
CC:	<u>Gomperts</u>
Date:	9/15/2021 7:13:54 AM
Subject:	Re: Aid Access Media Request

Thank you so much, Abigail, it was great talking to you too!

Dr. Gomperts, I'm Clarissa-Jan Lim, a reporter with BuzzFeed News. I'm doing some reporting on medication abortion access in light of Texas's new law and would love to speak with you — is there any time this week that works for you? I understand you're in Europe; happy to work around your schedule.

Page 1

On Tue, Sep 14, 2021 at 2:26 PM Abigail Aiken <<u>araa2@utexas.edu</u>> wrote: Hi Clarissa,

It was great talking with you just now. As promised, I'm following up to share some research studies that might be useful for your coverage. Hope these are helpful! If you end up citing any of them, inclusion of the links to the original papers in your story would be deeply appreciated.

I've also looped in Dr. Gomperts here since I know you also had some questions about the workings of the service.

Thanks, and all the best, Abigail

1. This paper looks at the number of requests to Aid Access over the first two years of the service (57,506). It's worth noting that requests have been increasing over time as well: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780272

The paper also shows that the states with the highest numbers of requests tend to be those with the most restrictive abortion policies (including Texas), and that the cost of in-clinic care and distance to a clinic are strong motivators among those who self-manage using the service. Since SB 8 is going to increase both the cost of in-clinic care and distance to a clinic, it's therefore very likely that the need for self-managed abortion will also increase.

2. This paper looks at the safety and effectiveness of self-managed medication abortion using online telemedicine and finds results on par with the clinic setting: <u>https://www.bmj.com/content</u>/357/bmj.j2011

Overall, 94.7% reported successfully ending their pregnancy without clinical intervention to help empty the uterus.

3. This study shows what happened to requests to Aid Access in the wake of the several weekslong abortion ban in Texas back in March 2020 when the COVID pandemic first emerged. We saw that requests to the service from Texas almost doubled following the ban on clinic provision: <u>https://journals.lww.com/greenjournal/Fulltext/2020/10000</u>

/Demand for Self Managed Online Telemedicine.29.aspx

This study gives us a window on what is likely to happen now that a much longer hiatus in clinical services looks likely with SB 8.

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Website: <u>abigailaiken.github.com</u> Email: <u>araa2@utexas.edu</u>

				, 2021 at 3:25 PM Clarissa-Jan Lim oking forward to it.	wrote:
C	Gr	ea an	t! I'm ks ai	11, 2021 at 4:24 PM Abigail Aiken < <u>araa2@utexas.edu</u> > wrote: at at arguments nd talk to you soon,	
	As LB Un Pri We	so sJ : nive inc eb:	ciate Scho ersity ipal I site:	A. Aiken, MD, MPH, PhD Professor ol of Public Affairs of Texas at Austin Investigator, <u>Project SANA</u> abigailaiken.github.com aa2@utexas.edu	
		Th	anks	ep 11, 2021 at 3:21 PM Clarissa-Jan Lim for getting back to me! Tuesday the 14th at 1pm CT is perfect. What's the best ou at?	wrote: number to
		0		t, Sep 11, 2021 at 4:20 PM Abigail Aiken < <u>araa2@utexas.edu</u> > wrote: Clarissa-Jan,	
			Tha	nks for getting in touch—I'd be happy to speak with you.	
				uld do Tuesday (Sep 14th) or Wednesday (Sep 15th) at 1:00pm CT. \ nose work for you?	Nould either
			Tha Abię	nks and all the best, gail	
			Ass LBJ Univ Prin Web	gail R.A. Aiken, MD, MPH, PhD ociate Professor School of Public Affairs versity of Texas at Austin icipal Investigator, <u>Project SANA</u> osite: <u>abigailaiken.github.com</u> ail: <u>araa2@utexas.edu</u>	
			wro	Fri, Sep 10, 2021 at 6:35 PM Clarissa-Jan Lim te: Thanks, Christie.	
				Abigail — great to meet you. I'm doing some reporting on SB 8 in Texa o speak with you.	as and I'd love
				Are you free for a call next week? My schedule is flexible, happy to wo ours.	rk around
			0	On Fri, Sep 10, 2021 at 7:29 PM Forward Midwifery	
				Wrote: Clarissa-Jan, Abigail Aiken is the research who I mentioned to you CCed here.	and she is
				Abigail, Clarrissa-Jan is reporting on Aid Access for Buzzfeed.	



Clarissa-Jan Lim(she/her) BuzzFeed News

 From:
 "Marit Pearlman Shapiro" <maritps@hawaii.edu>

 To:
 "Waves Rebecca"

 CC:
 "Abigail Aiken" <araa2@utexas.edu>

Date: 10/18/2021 2:24:14 AM

Subject: Re: Systematic review article info request - no test medication abortion

Thanks so much for your reply!

Yes, we are planning on including the first study in our review. Found it on our initial search :)

Abigail has been amazing helping me out with this project already and we have her study as well.

Thank you both! Marit

On Thu, Oct 14, 2021 at 8:46 PM Waves Rebecca wrote: Dear Marit I think this study has looked at that https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111 /1471-0528.15553 But it is difficult because our follow up rates are low. I cc Abigail , she published https://www.bmj.com/content/357/bmj.j2011 and there are data about ultrasounds in this paper but i am not sur if there is anything about differences in outcome as she is now looking into the data of Aid Access and might have looked at that Warm regards Rebecca Gomperts

On 13 Oct 2021, at 23:39, Marit Pearlman Shapiro <<u>maritps@hawaii.edu</u>> wrote:

Hi Dr. Gomperts,

My name is Marit Pearlman Shapiro and I'm the complex family planning fellow at the University of Hawai'i. We are conducting a systematic review of "no test" medication abortions, essentially those done without prior dating sono or exam. I am so impressed with all you've done to provide abortion services around the world -- thank you for all that you do!

We have quite a few of your studies that have made it down to our final list, however the data as published includes both participants who have had ultrasounds and those who have not with their outcomes reported together. Is disaggregated data available for those patients who have had prior sonos and those who haven't? The studies are:

- Provision of medical abortion using telemedicine in Brazil

- 10-year evaluation of the use of medical abortion through telemedicine: a retrospective cohort study (I'm also contacting Dr. Norten)

- Regional differences in surgical intervention following medical termination of pregnancy provided by telemedicine

- Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services

Please let me know if there is anything I can clarify. Thank you again for your important work!

Marit

Marit Pearlman Shapiro Complex Family Planning University of Hawai'i Phone/Whatsapp: +1 213 500 1208

	Page 1
From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	"Rebecca Gomperts"
	evdokia.romanova <
	<u>"Julia Morber"</u> ≥
Date:	11/8/2021 2:29:52 PM
Subject:	Update and forms to sign for our Aid Access safety and effectiveness paper
Attachments:	tlame-author-signatures.pdf
	COI disclosure form.docx

Hi everyone,

I have some good news about our Aid Access safety and effectiveness paper—we got an invitation to revise and resubmit at The Lancet Regional Health Americas! This is a great journal and it's open access, which will help our work to have a wide reach.

I'm working on the requested revisions now, but I also need your help with some forms that we have to sign and send back with the revised paper.

Attached you will find:

1) An ICMJE form. **We each need to fill out one of these**. Please fill out the date and your name, and then complete the tables asking about grant funding and other conflicts of interest. Please note that you only have to list these if they are plausibly related to the topic of our study (self-managed abortion). You will all need to declare your relationship to Aid Access plus any other work you do that relates to self-managed abortion.

2) An author signature form. **We only need one of these** and all you need to do is fill out your title and name, highest degree, date, and signature sign at the end of the second page. We all need to sign the same copy, **so please circulate among each other before you send back to me.**

If you could please send back these forms to me by the end of the week (Friday Nov 12th) that would be much appreciated!

Thanks so much, and best to all, Abigail

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

Page 2 THE LANCET Regional Health Americas

Author statements

Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with your submission, scan and email to: americas@lancet.com.

Manuscript title:

Corresponding author:

Article type:

I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on my behalf, in the relevant form set out at www.elsevier.com/copyright; and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the governing law of England and Wales.

Does your manuscript have a reference number? No 📮 Yes 📮 If yes, enter number here:

Does your manuscript have a handling editor? No 📮 Yes 📮 If yes, enter name here:

Authors' contributions

Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data analysis, data interpretation, writing etc. If all authors contributed equally, please state this. The information provided here must match the contributors' statement in the manuscript. We require that more than one author has verified the underlying data. Please state the named authors who have accessed verified the underlying data.

THE LANCET Regional Health Americas

Role of the funding source

Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. The information provided here must match the role of the funding source statement in the manuscript. If you are the corresponding author please state that all authors had full access to the full data in the study and accept responsibility to submit for publication.

Conflicts of interest

Please complete the ICMJE conflict of interest form, which is available at http://download.thelancet.com/flatcontentassets/authors/icjme-coiform.pdf. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Case Reports, Clinical Pictures, and Adverse Drug Reactions. Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Regional Health – Americas.

I agree with: the plan to submit to *The Lancet Regional Health – Americas;* the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

Title and name:	Highest degree:	Signature:	Date:
Title and name:	Highest degree:	Signature:	Date:
Title and name:	Highest degree:	Signature:	Date:
Title and name:	Highest degree:	Signature:	Date:
Title and name:	Highest degree:	Signature:	Date:
Title and name:	Highest degree:	Signature:	Date:
Title and name:	Highest degree:	Signature:	Date:
Title and name:	Highest degree:	Signature:	Date:
Title and name:	Highest degree:	Signature:	Date:
Title and name:	Highest degree:	Signature:	Date:

Corresponding author declaration

I <u>[Signature]</u>, the corresponding author of this manuscript, certify that the contributors' and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.

ICMJE DISCLOSURE FORM

Date: ___

Your Name:

Manuscript Title: Safety and Effectiveness of Self-Managed Medication Abortion Provided Using Online Telemedicine in the United States: A Population Based Study

Manuscript number (if known): TLRHAMERICAS-D-21-00321_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	None	
13	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

____ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	"Forward Midwifery"
CC:	<u>"Hanna, John D."</u>
	<u> "Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	"Rebecca Gomperts"
Date:	11/12/2021 2:53:53 PM
Subject:	Re: Story on self-managed/medication abortions

Hi Christie,

Thanks for checking in--the paper is currently under review right now, so alas we don't have data to share yet.

But, the study John mentioned looking at what happened to requests the last time abortion was banned in Texas definitely gives us a good sense of what we can expect to see this time around. If you do cite that study in your piece, John, a link to the full article would be greatly appreciated (<u>https://journals.lww.com/greenjournal/Fulltext/2020/10000</u>/Demand for Self Managed Online Telemedicine.29.aspx).

Thanks so much, Abigail

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

On Fri, Nov 12, 2021 at 1:09 PM Forward Midwifery wrote: Hi Abigail,

You have not yet published on data since 9/1/21, correct? Just wanted to check in for John and his story (see email below).

Thanks! Christie



On Fri, Nov 12, 2021 at 7:12 AM Hanna, John D. wrote:

Christie, Dr. Gomperts,

My story on self-managed medication abortion is close to publication, and I wanted to touch base with you on one issue to clarify:

When Christie and I talked, as I recall, Aid Access did not have hard numbers on how interest/usage had increased since Texas SB 8 took effect at the start of September. Is that still the case?

I am aware of the study earlier this year using Aid Access data about the increase in demand when Texas and other states shut down clinics early in the coronavirus pandemic and I've not seen anything more recent, outside of some data shared by Plan C about visits to its website.

If anything has changed in that regard, please let me know.

Thanks for all your help.

John Hanna Correspondent

Associated Press 300 S.W. 10th Ave. Room 37H-E Topeka, Kan., 66612

785-234-5654 (office) 785-608-5060 (cell)

The information contained in this communication is intended for the use of the designated recipients named above. If the reader of this communication is not the intended recipient, you are hereby notified that you have received this communication in error, and that any review, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication is strictly prohibited. If you have received this communication error, please notify The Associated Press immediately by telephone at +1-212-621-1500 and delete this email. Thank you.

	Page 1
From:	evdokia.romanova
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	"Julia Morber"
	<u>Gomperts</u>
Date:	11/13/2021 3:07:06 PM
Subject:	Re: Fwd: Submission Confirmation for TLRHAMERICAS-D-21-00321R1

Thank you so much Abigail! Congratulations on your amazing work! Warmly, Dunia

Sent from ProtonMail for iOS

On Sat, Nov 13, 2021 at 21:30, Abigail Aiken <<u>araa2@utexas.edu</u>> wrote:

Hi all,

I just sent our revised manuscript back to the journal! Attached here please find the submission PDF for your records.

Thanks so much and fingers crossed for a good outcome! Abigail

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

------ Forwarded message ------From: **The Lancet Regional Health - Americas Team** <<u>em@editorialmanager.com</u>> Date: Sat, Nov 13, 2021 at 2:28 PM Subject: Submission Confirmation for TLRHAMERICAS-D-21-00321R1 To: Abigail Rosemary Anne Aiken <<u>araa2@utexas.edu</u>>

Reference: TLRHAMERICAS-D-21-00321R1 Title: Safety and Effectiveness of Self-Managed Medication Abortion Provided Using Online Telemedicine in the United States: A Population-Based Study *The Lancet Regional Health - Americas*

Dear Dr. Abigail Rosemary Anne Aiken,

This message is to acknowledge that we have received your revised manuscript for reconsideration for publication in *The Lancet Regional Health - Americas*.

You may check the status of your manuscript by logging into the Editorial Manager as an author at <u>https://www.editorialmanager.com/tlrhamericas/</u>.

Thank you for submitting your work to The Lancet Regional Health - Americas.

Kind regards, *The Lancet Regional Health - Americas*

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. <u>(Remove my information/details</u>). Please contact the publication office if you have any questions.

Page 1
"Rebecca Gomperts"
"Alice Ollstein"
<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
11/25/2021 6:45:51 AM
Re: connecting on U.S. distribution

dear alice thank you so much for your email

I am ccing abigail aiken as she is analysing the data of aid access and can answer your questions Warm regards Rebecca Gomperts

On 22 Nov 2021, at 19:20, Alice Ollstein wrote:

Good afternoon! I'm reaching out to see if you could talk for a couple minutes today or tomorrow about how Aid Access is preparing for the potential fall of Roe vs. Wade in the U.S. next year, and what kind of demand you're seeing now. Please let me know as soon as you can, Best, Alice Miranda Ollstein POLITICO

From: <u>"Waves Rebecca"</u>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 1/15/2022 7:06:07 AM

Subject: Fwd: Authorship Form Received for JNO21-13290-T

Attachments: authorship_e_form_jno21-13290-t_gomperts_eqfhjf.pdf

Begin forwarded message:

From: jamanetworkopen@jamanetwork.org Subject: Authorship Form Received for JNO21-13290-T Date: 15 January 2022 at 14:05:16 CET To:

Reply-To: jamanetworkopen@jamanetwork.org

January 15, 2022

Dear Dr Gomperts,

Thank you for submitting your Authorship form for JAMA Network Open. Your authorship form will be reviewed for accuracy and completeness. If there are any omissions, the form will be returned to you for correction and resubmission. A PDF copy of the form is attached for your reference.

Sincerely yours,

Editorial Staff

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

The JAMA Network Journals' Authorship Responsibility, Funding and Conflicts of Interest, and Publishing Agreement for Coauthor

Each author must read and complete the following sections:

- 1. Authorship Responsibility, Criteria, and Contributions
- 2. Disclosure of Potential Conflicts of Interest
- 3. Publishing Agreement
- 4. Confirmation

JAMA Network Open

Manuscript # JNO21-13290-T

Manuscript Title: Requests for Self-Managed Medication Abortion in Texas After Senate Bill 8

Author Name: Rebecca Gomperts

Corresponding Author: Abigail Aiken

Phone:

Email:

Step 1. Authorship Responsibility, Criteria, and Contributions. Each author should meet all criteria below (A, B, C, and D) and should indicate general and specific contributions by reading criteria A, B, C, and D and checking the appropriate boxes. A contribution statement based on this form will be published with the final version of your article; please ensure the contributions are accurate.

A. I certify that

- The manuscript represents original and valid work and that neither this manuscript nor one with substantially similar content under my authorship has been published or is being considered for publication elsewhere, except as described in the journal's submission form and cover letter submitted with the manuscript, and copies of closely related manuscripts have been provided; and
- I agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; and
- If requested, I will provide the data or will cooperate fully in obtaining and providing the data on which the manuscript is based for examination by the editors or their assignees; and
- For papers with more than 1 author, I agree to allow the corresponding author to serve as the primary correspondent with the editorial office, to review the edited manuscript and proof, and to make decisions regarding release of information in the manuscript to the media, federal agencies, or both; or, if I am the only author, I will be the corresponding author and agree to serve in the roles described above.
- B. I have given final approval of the submitted manuscript.
- C. I have participated sufficiently in the work to take public responsibility for (check 1 of 2 below)
- o part of the content.
- the whole content.
- D. To qualify for authorship, you must check at least 1 box for each of the 3 categories of contributions listed below.

I have made substantial contributions to the intellectual content of the paper as described below.

- 1. Check at least 1 of 2 below
- ✓ acquisition, analysis, or interpretation of data
- 2. Check at least 1 of 2 below
- drafting of the manuscript
- ☑ critical revision of the manuscript for important intellectual content
- 3. Check at least 1 below

- statistical analysis
- □ obtained funding
- $\hfill\square$ administrative, technical, or material support
- supervision
- ✓ no additional contributions
- other

Step 2. Disclosure of Potential Conflicts of Interest

The purpose of this section is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The section includes the questions from the ICMJE Form for Disclosure of Potential Conflicts of Interest and is divided into 5 subsections.

Authors are expected to provide detailed information about all relevant financial interests, activities, relationships, and affiliations (other than those affiliations listed in the title page of the manuscript) including, but not limited to, employment, affiliation, funding and grants received or pending, consultancies, honoraria or payment, speakers bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

• 2A. The work under consideration for publication.

This subsection asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party—that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation, or commercial sponsor, check "Yes."

• 2B. Relevant financial activities outside the submitted work.

This subsection asks about your financial relationships with entities in the biomedical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations, or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

• 2C. Intellectual property.

This subsection asks about patents and copyrights, whether pending, issued, licensed, and/or receiving royalties.

• 2D. Relationships not covered above.

Use this subsection to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: Government agency, foundation, commercial sponsor, academic institution, etc Grant: A grant from an entity, generally (but not always) paid to your organization Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc

• 2E. Disclosure statement.

Step 2A. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc)? Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. If you have more than 1 entity, press the "Add" button to add a row. Excess rows can be removed by pressing the "Remove" button. If you have selected the "Other" checkbox, a "Comment" will be required.

No

Step 2B. Relevant Financial Activities Outside the Submitted Work

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. If you have more than 1 entity, press the "Add" button to add a row. Excess rows can be removed by pressing the "Remove" button. If you have selected the "Other" checkbox, a "Comment" will be required. You should report relationships that were **present during the 36 months prior to publication**

No

Step 2C. Intellectual Property—Patents and Copyrights

Do you have any patents, whether planned, pending, or issued, broadly relevant to the work? Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions.

No

Step 2D. Relationships Not Covered Above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain

below):

I am the Founder and Director of Aid Access

At the time of manuscript acceptance, the journal will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, the journal may ask authors to disclose further information about reported relationships.

Step 2E. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement in the box below after you click

Other: Anything not covered under the previous 3 boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency **Licensed:** The patent has been licensed to an entity, whether earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your patent

the "Generate Disclosure Statement" button. Any subsequent changes will also update the disclosure statement automatically after clicking the "Submit" button.

Dr Gomperts reports I am the Founder and Director of Aid Access.

Step 3. Publishing Agreement. The corresponding author has indicated that this work is eligible for an open access CC-BY license, which requires transfer of a publication license to the journal.

License rights: Immediate open access on journal website on the day of publication, access to a PDF copy of the published article, retention of copyright, and the granting of a CC-BY license that permits others to distribute, remix, tweak, and build on the work, even commercially, without permission—provided that credit is given to the original authors and journal.

All authors must select only 1 of the following: A, or B, or C.

• A. Publication License. In consideration of the action of the American Medical Association (AMA) in reviewing and editing this submission (manuscript, tables, figures, video, audio, and other supplemental files for publication), I hereby transfer, assign, or otherwise convey first publication rights exclusively to the AMA, in the event that such work is published by the AMA, in addition to the attributes of a CC-BY license.

© B. Federal Employment. I was an employee of the US federal government or that of another nation when this work was conducted and prepared for publication; therefore, it is not protected by the Copyright Act.

C C. Work for Hire. I am employed by an institution that considers this submission a "work made for hire" and therefore I cannot transfer a publication license.

Step 4. Confirmation. Confirm that all information provided is accurate by checking the box below and then enter your complete name as it appears at the top of this form and date of confirmation in the fields below.

☑ I certify that all information I have provided is accurate.

Complete Name: Rebecca Gomperts

Date: 15-1-2022

local_p_id: 152298 time: 1642251915 ip address:

	Page 1	
From:	"Julia Morber"	
To:	evdokia.romanova	
CC:	"Rebecca Gomperts"	
Date:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u> 2/25/2022 3:52:51 AM	
Subject:		
Congratula	tions Abigail! Well written and super relevant article.	
I will defini	ely share it with everyone I know and on social media.	
Thank you	for letting us be a part of it. I'm really proud to be mentioned!	
Thank you		
All the bes Julia	, ,	
Op vr 18 fe wow!	b. 2022 om 12:51 schreef evdokia.romanova	
•	ulations! g work Abigail!	
thank ye	ou so much again for allowing me to be a part of this process	
warmly, dunia		
Sent from ProtonMail for iOS		
On Thu	Feb 17, 2022 at 22:53, Rebecca Gomperts wrote:	
Cong	ratulations!!	
On	17 Feb 2022, at 15:55, Abigail Aiken < <u>araa2@utexas.edu</u> > wrote:	
Hi	all,	
me	r paper detailing the safety, effectiveness, and acceptability of self-managed dication abortion provided by Aid Access is out today in The Lancet Regional Health: bs://www.sciencedirect.com/science/article/pii/S2667193X22000175	
	ase share the link above on your social media, websites, and with anyone you think ht be interested!	
	anks so much, and congrats to you all! gail	
As	gail R.A. Aiken, MD, MPH, PhD sociate Professor J School of Public Affairs	

University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

From: jnjournals@jamanetwork.org To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

CC: <u>"Jennifer E Starling"</u> <u>"James G Scott" <James.Scott@mccombs.utexas.edu></u> <u>"Rebecca Gomperts"</u>

Date: 2/27/2022 10:02:24 PM

Subject: Congratulations on your publication in JAMA Network Open



Dear Dr Aiken:

Thank you for sending *JAMA Network Open* your manuscript and congratulations on its publication. Below is a link to the article, which is now live on the *JAMA Network Open* website. Feel free to share the link with colleagues, and most importantly your family and friends.

Article: Association of Texas Senate Bill 8 With Requests for Self-managed Medication Abortion Publication Date: 02-25-2022

On the online version of your article, there is a small panel at the top of the page that shows some early metrics such as views and media and social media coverage. These metrics and citations will accumulate and grow throughout this year and thereafter. Below is an example of what the metrics panel looks like:



JAMA Network Open is committed to making your author experience a positive one and to maximizing the impact and reach of your article. If you have any questions or concerns, please let us know at <u>JAMA Network Open</u>.

Best Regards,

Frederick P. Rivara, MD, MPH


Editor in Chief, JAMA Network Open



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click <u>here</u> to unsubscribe from these emails.



Principal Investigator, Project SANA

Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

From: "Rowland, Christopher"

To: <u>"Abigail Aiken" <araa2@utexas.edu></u> <u>"Waves Rebecca"</u>

Date: 5/3/2022 1:12:29 PM

Subject: Re: Washington Post question/interview request about telemedicine and abortion pills access

Abigail,

Yes, absolutely will do -- sorry about the confusing tag-team.

Chris

From: Abigail Aiken <araa2@utexas.edu> Sent: Tuesday, May 3, 2022 3:10 PM To: Waves Rebecca Cc: Abigail Aiken <araa2@utexas.edu>; Rowland, Christopher Subject: Re: Washington Post question/interview request about telemedicine and abortion pills access

CAUTION: EXTERNAL SENDER

Hi Chris,

I spoke with your colleague Laurie just now—would you mind sharing the studies with her as well? If you do cite/use them, a live link to the research papers would be greatly appreciated.

Many thanks and all best, Abigail

On Tue, May 3, 2022 at 5:23 PM Waves Rebecca

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789428 [jamanetwork.com] https://www.sciencedirect.com/science/article/pii/S2667321522000373?via%3Dihub [sciencedirect.com] https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00017-5/fulltext [thelancet.com] https://journals.lww.com/greenjournal/Fulltext/2020/10000 /Demand for Self Managed Online Telemedicine.29.aspx [journals.lww.com]

and the turn away study

https://www.ansirh.org/research/ongoing/turnaway-study [ansirh.org]

warm regards

rebecca

On 3 May 2022, at 16:41, Rowland, Christopher wrote:

Good Morning,

Responding to the news from the Supreme Court abortion decision leak, I am looking at the economic and business factors that are in play for telemedicine, insurance, and abortion pill manufacturers, as the demand for these services undoubtedly will skyrocket.

I saw your excellent December article about this.

Would one of you be available to speak with me this morning about the current supply of pills and number of manufacturers, telemedicine abortion services, and also insurance coverage issues?

I am on an immediate deadline.

Best regards, Chris

Christopher Rowland Business of Health Care Reporter, The Washington Post <u>mobile, Signal:</u> 401-580-0795 <u>Twitter:</u>@PostRowland <u>USPS:</u> 1301 K Street NW [google.com] Washington DC 20071 [google.com]

This message is from an external sender. Learn more about why this matters.

--

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA [sites.utexas.edu]</u> Twitter: <u>@ProjectSANAteam [twitter.com]</u> Email: <u>araa2@utexas.edu</u>

	Page 1
From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	
CC:	<u>"Alejandra Tello Perez" <alejandratello@utexas.edu></alejandratello@utexas.edu></u>
	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	<u>"Baldwin, Aleta M." <aleta.baldwin@csus.edu></aleta.baldwin@csus.edu></u>
	<u>"Broussard, Kathleen" <rkbroussard@prc.utexas.edu></rkbroussard@prc.utexas.edu></u> <u>"Carol Ze-Noah" <carolzenoah@berkelev.edu></carolzenoah@berkelev.edu></u>
	"Melissa Madera" <mmadera@utexas.edu></mmadera@utexas.edu>
	"Rebecca Gomperts"
Date:	5/4/2022 8:24:16 AM
Subject:	Re: PLEASE TAKE ACTION - Share your article [SSMQR_100075]
wonderful a leading this Best to all, A	so late to the party (I'm still out of office and checking email only sporadically) but this is ind couldn't come at a more important time. Congrats to all and especially to Mel for effort! . Aiken, MD, MPH, PhD
Associate F LBJ School University of Principal Inv Twitter: @P	
So exciti	
	Apr 21, 2022 at 1:50 PM Alejandra Tello Perez < <u>alejandratello@utexas.edu</u> > wrote: ing and so timely. Congrats everyone, cheers!
Best, Ale	
On	Apr 21, 2022, at 12:30 PM, Baldwin, Aleta M. < <u>aleta.baldwin@csus.edu</u> > wrote:
So	exciting to have this work out there—congrats indeed!
	ta Baldwin, PhD, MPH I Associate Professor nouns: She/Her/Hers
Sola	artment of Public Health, Sacramento State ano Hall 3014 0 J Street Sacramento, CA 95819
Fro Dat To:	<u>a.Baldwin@csus.edu</u> om: Melissa Madera < <u>mmadera@utexas.edu</u> > t e: Thursday, April 21, 2022 at 10:20 AM : Abigail Aiken < <u>araa2@utexas.edu</u> >, Luisa A Tello Perez < <u>alejandratello@utexas.edu</u> >, dwin, Aleta M. < <u>aleta.baldwin@csus.edu</u> >,
	Rebecca Comperts , Carol-

Rebecca Gomperts

Armelle Ze-Noah <<u>carolzenoah@berkeley.edu</u>>, Broussard, Kathleen <<u>rkbroussard@prc.utexas.edu</u>> **Subject:** Fwd: PLEASE TAKE ACTION - Share your article [SSMQR_100075]

Yay! Paper is online. Check it out! Congrats to us all.

-------Forwarded message -------From: Elsevier - Article Status <<u>Article_Status@elsevier.com</u>> Date: Thu, Apr 21, 2022 at 1:02 PM Subject: PLEASE TAKE ACTION - Share your article [SSMQR_100075] To: <<u>mmadera@utexas.edu</u>>

ELSEVIER

Share your article!

Dear Dr. Madera,

We are pleased to let you know that the final open access version of your article *Experiences seeking, sourcing, and using abortion pills at home in the United States through an online telemedicine service* is now available online, containing full bibliographic details.

The URL below is a quick and easy way to share your work with colleagues, coauthors and friends. Anyone clicking on



the link will be taken directly to the final version of your article on ScienceDirect.

Your article link: <u>https://doi.org/10.1016/j.ssmqr.2022.100075</u>

Click on the icons below to share with your network:



You can also use this link to download a copy of the article for your own archive. It also provides a quick and easy way to share your work with colleagues, co-authors and friends. And you are welcome to add it to your homepage or social media profiles, such as Facebook, Google+, and Twitter. Other ways in which you can use your final article have been determined by your choice of <u>user</u> <u>license</u>.

To find out how else you can share your article visit<u>www.elsevier.com</u> /sharing-articles.

Kind regards, Elsevier Researcher Support Increase your article's impact Our Get Noticed guide contains a range of practical tips and advice to help you maximize visibility of your article. **Publishing Lab** Do you have ideas on how we can improve the author experience? Sign up for the Elsevier Publishing Lab and help us develop our publishing innovations! Have questions or need assistance? Please do not reply to this automated message. For further assistance, please visit our Elsevier Support Center where you search for solutions on a range of topics and find answers to frequently asked questions. You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email. © 2022 Elsevier Ltd | Privacy Policy <u>http://www.elsevier.com/privacypolicy</u> Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please addArticle_Status@elsevier.com to your address book or safe senders list.

Page 3

--

Melissa Madera, Ph.D. Research Associate & Senior Project Manager <u>Project SANA</u> LBJ School of Public Affairs University of Texas at Austin Founder & Director, <u>The Abortion Diary Podcast</u>

Alejandra Tello, MA in Global Policy Studies Junior Project Manager Research Science Associate

Project SANA LBJ School of Public Affairs University of Texas at Austin

From: jnjournals@jamanetwork.org

- To: <u>"Abigail Aiken" <araa2@utexas.edu></u>
- CC: <u>"Jennifer E Starling"</u> <u>"Rebecca Gomperts"</u> Date: 5/21/2022 9:04:48 PM

Subject: Update on your publication in JAMA Network Open



Dear Dr Aiken:

In the 12 months since your article, <u>Factors Associated With Use of</u> <u>an Online Telemedicine Service to Access Self-managed Medical</u> <u>Abortion in the US</u>, was published in *JAMA Network Open*, it has continued to attract readership and attention.

We invite you to click the title of your article in the link above to see your article's reach and usage metrics as shown in this example:



You will see the numbers of times your article has been viewed and cited by other articles. The Altmetric score shows coverage by news and social media. By clicking the Altmetric link, you can explore where your article has been mentioned in the news media, blogs, social media accounts, and more.

Please contact me if you have any questions or to discuss publication opportunities for your current and future work.

Best Regards,

Frederick P. Rivara, MD, MPH Editor in Chief, *JAMA Network Open*



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click here to unsubscribe from these emails.

From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	"James Scott" <james.scott@mccombs.utexas.edu></james.scott@mccombs.utexas.edu>
	<u>"Jennifer E Starling" <jstarling@utexas.edu></jstarling@utexas.edu></u>
	"women on web"
CC:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
Date:	8/9/2022 3:11:55 PM
Subject:	Re: Invitation from JAMA

Wow...this is a big opportunity!

Do you want to get back to them, Rebecca, and let them know we should have an original research study on requests to Aid Access post-Roe ready to submit?

Thanks so much! A

On Tue, Aug 9, 2022 at 12:56 PM women on web		wrote:
	Sent from my iPhone	
	Begin forwarded message:	
	From: "Kirsten Bibbins-Domingo (she/her/hers)" Date: 9 August 2022 at 19:53:26 CEST To: Subject: Invitation from JAMA	

CONFIDENTIAL

Please kindly confirm receipt

Dear Dr. Gomperts,

I am writing to invite you to write for a special issue of JAMA. We are planning to publish a cluster of research articles and viewpoints on health care post the Supreme Court Dobbs decision in an upcoming issue of JAMA. We are hoping you may be interested in preparing a manuscript for consideration for inclusion in this issue.

We are particularly interested your original research.

The guidelines for research articles in JAMA can be found here. I would focus your attention to the guidelines for Original Research and for the shorter Research Letters <u>https://jamanetwork.com/journals/jama/pages/instructions-for-authors.</u>Very occasionally we also publish Special Communications; these publication types require additional discussion with an editor.

Because we are planning timely publication, we would like to receive a submission by so that it can undergo peer review.

Also, while we cannot make an absolute guarantee in advance that the manuscript will be $\frac{2}{8}/2024$

accepted for publication, we can promise an enthusiastic and prompt evaluation once the manuscript is submitted.

Please let us know as soon as possible if you are interested in submitting your work for this special issue. I would also be happy to address any questions.

Thank you for considering this invitation.

Sincerely,

Kirsten Bibbins-Domingo, PhD, MD, MAS

Editor in Chief JAMA and the JAMA Network

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential, or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

--

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	"Rebecca Gomperts"
	Gomperts
	<u>"Jennifer E Starling" <jstarling@utexas.edu></jstarling@utexas.edu></u>
Date:	8/19/2022 5:50:34 AM
Subject:	Time Sensitive: Paper for JAMA
Attachments:	SMA via AA Post-Roe.docx
	Figure 1.png
	Figure 2.png

Hi there,

Attached here is the research paper in response to the invitation from JAMA. It's in the form of a research letter where the max. is 600 words, so it's pretty short, but I think the result is very clear.

The Editor asked for submissions by this Monday (August 22nd), so if you could please take a look and let me know your comments/edits before then, that would be much appreciated!

Thanks so much, A

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

Demand for Self-Managed Medication Abortion in the United States Post-Roe

Abigail R.A. Aiken PhD^{1*}, Jennifer E. Starling, PhD², James G Scott PhD³, Rebecca Gomperts PhD⁴

¹LBJ School of Public Affairs, University of Texas at Austin, Austin, TX, 78712, USA

² Mathematica Policy Research Inc., Cambridge, MA, 02139

³ Department of Statistics and Data Sciences, University of Texas at Austin, Austin, TX

78712, USA

⁴Women on Web, Amsterdam, The Netherlands

* Corresponding author: <u>araa2@utexas.edu</u>

LBJ School of Public Affairs University of Texas at Austin PO Box Y Austin, TX, 78712 USA

Word count: 600

Introduction

On June 24th 2022, the Supreme Court decision *Dobbs vs. JWHO* overturned *Roe v. Wade* creating a patchwork of state abortion laws from total pre-*Roe* bans and trigger bans to 6-week bans to no changes in existing laws.¹ This new legal landscape raises the question of whether more people now seek to self-manage their abortions outside the formal healthcare setting.

Methods

Since 2018, self-managed medication abortion has been available in the U.S. through nonprofit online telemedicine service Aid Access.² We analyzed anonymized data from Aid Access between September 1st 2021 and July 31st 2022 to assess changes in requests following the *Dobbs* decision. We omitted requests for advance provision and requests from 21 states where Aid Access provides within the formal healthcare setting. We created four state categories: 1) states that banned abortion following the decision announcement (bans in three of these were enjoined in mid-late July, so we consider them ban states in our analysis); 2) states that implemented 6-week bans; 3) states that did not enact bans but indicated that bans or restrictions are likely; and 4) states with no current or planned legal changes.³ We examined absolute changes in weekly requests per 100,000 female residents of reproductive age in each state⁴ from the baseline period (September 1st 2021-May 1st 2022) to the period after the Supreme Court decision was leaked (May 2nd- June 23rd 2022), and from baseline to the period after the decision was formally announced (June 24^{rh}-July 31st 2022). We also examined changes in requestor reasons for accessing the service for each time period.

2

Results

Between September 1st 2021 and July 31st 2022, Aid Access received 37,288 requests from 29 states. Overall, average daily requests increased from 82.6 at baseline to 135.7 following the leaked decision (64% increase, $p<10^{-6}$) and to 264.1 following its formal announcement (120% increase, $p<10^{-6}$). Requests increased in over baseline in all four state categories after the leak and after the announcement (Figure 1). The states with the largest increases in weekly requests per 100,000 female residents of reproductive age were Louisiana (5.6 to 17.3), Mississippi (2.2 to 8.9) and Arkansas (2.1 to 8.2), Texas (2.9 to 8.1), and Alabama (1.9 to 7.0), all of which implemented total bans on abortion during the study period (Figure 1). In states with total bans, the percentage of requestors citing "current abortion restrictions" increased to 62.6% post-decision from 31.4% at baseline ($p<10^{-6}$, Figure 2). In states with 6-week bans, 28.6% of requestors cited that specific ban post-decision, compared with 3.8% at baseline ($p<10^{-6}$). In states where future bans are likely, 40.2% of requestors cited "possible future legal restrictions" versus 12.5% at baseline ($p<10^{-6}$). We did not observe substantial changes in states where laws did not and are not likely to change.

Discussion

Demand for self-managed abortion through Aid Access increased substantially following the *Dobbs* decision. While states with the largest increases in requests are those that implemented total bans, we also observed increases in states where the legal status of abortion did not immediately change. In states that enacted complete or partial bans, requestors frequently cited these as their motivation for accessing the service. While we cannot pinpoint why requests increased in states where laws did not change, possible explanations include increased awareness of the service, confusion about state laws post-*Dobbs*, and disruption to in-clinic services due to increases in out-of-state patients.

2/8/2024

3

Limitations include having information on only one possible pathway to selfmanagement. However, findings support prior research suggesting that severely limiting abortion within the formal healthcare setting results in more self-managed abortions.⁵ Those provided by Aid Access are safe, effective, and supported.⁶

References

1. Guttmacher Institute. State Laws and Policies. Abortion Policy in the Absence of Roe. August 1st 2022. <u>https://www.guttmacher.org/state-policy/explore/abortion-</u> <u>policy-absence-roe</u> (Accessed August 19th 2022).

2. Aiken AR, Starling JE, Gomperts R. Factors Associated With Use of an Online Telemedicine Service to Access Self-managed Medical Abortion in the US. JAMA Network Open. 2021 May 3;4(5):e2111852-.

Center for Reproductive Rights. After Roe Fell: Abortion Laws by State.
 <u>https://reproductiverights.org/maps/abortion-laws-by-state/</u> (Accessed August 19th 2022).

4. US Census Bureau, Population Division. Annual Estimates of the Resident Population for Selected Age Groups by Sex: April 1, 2020 to July 1, 2021.

https://www.census.gov/data/datasets/time-series/demo/popest/2020s-state-

detail.html (Accessed August 19th 2022).

 Aiken AR, Starling JE, Scott JG, Gomperts R. Association of Texas Senate Bill 8
 With Requests for Self-managed Medication Abortion. JAMA Network Open. 2022 Feb 1;5(2):e221122-.

 Aiken AR, Romanova EP, Morber JR, Gomperts R. Safety and effectiveness of self-managed medication abortion provided using online telemedicine in the United States: A population based study. The Lancet Regional Health-Americas. 2022 Feb 17:100200.


Declaration of Interests

ARAA report grants from the Society of Family Planning and the National Institutes of Health. RG is Founder and Director of Aid Access. JES and JGS declare no competing interests. Neither of the sources of funding had any involvement in data collection,


2/8/2024

5

analysis or interpretation, and no role in the writing of this manuscript or the decision to submit for publication.



Per capita rates calculated as weekly average requests per 100,000 female residents of reproductive age.



	rage i
From:	<pre>"Kirsten Bibbins-Domingo \(she/her/hers\)"</pre>
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
CC:	"Rebecca Gomperts"
	"Jody Zylke"
Date:	8/20/2022 10:49:41 AM
Subject:	Re: Submission of invited paper for post-Dobbs special issue

Thank you for this submission.

We look forward to reviewing. - Kirsten

Kirsten Bibbins-Domingo, PhD, MD, MAS Editor in Chief JAMA and the JAMA Network

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential, or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

From: Abigail Aiken <araa2@utexas.edu> Sent: Saturday, August 20, 2022 5:40:36 AM To: Kirsten Bibbins-Domingo (she/her/hers) Cc:Rebecca Gomperts Subject: Submission of invited paper for post-Dobbs special issue

Dear Dr. Bibbins-Domingo,

Many thanks for your invitation to submit our original research for a special issue of *JAMA* focused on the impacts of the *Dobbs* Supreme Court Decision.

We are pleased to let you know that we have submitted a research letter than examines how state aborion laws following *Dobbs* have impacted the need for self-managed abortion, provided by the Aid Access service. The full cover letter is attached and the manuscript number is JAMA22-7172.

We look forward to your comments.

Sincerely, Abigail Aiken and Rebecca Gomperts

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: araa2@utexas.edu

	o
From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	<u>"James Scott" <james.scott@mccombs.utexas.edu></james.scott@mccombs.utexas.edu></u>
	<u>"Jennifer E Starling" <jstarling@utexas.edu></jstarling@utexas.edu></u>
	"Rebecca Gomperts"
Date:	9/2/2022 11:16:56 AM
Subject:	JAMA submission

Hi all,

I just got an email to say that we got an R&R on our submission to JAMA! It looks very doable and I will reply back to them to let them know that we will submit a revision and also advise them that it will likely take a couple of weeks (they are asking for a 1-week turnaround) since the new baby has just arrived :)

I think we will be able to incorporate the August data into the analysis and I'll send out a plan for how we'll coordinate that in the coming days. I'll also send you specific instructions for the authorship form you'll have received an email about so that they will match what we have in the paper.

So, all this is to say please hold off doing anything for now. Just wanted to let you know the good news and will be in touch with a plan shortly.

Thanks so much! A

--

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: araa2@utexas.edu

_	Page	
From:	"Lisa Hardin"	
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>	
Date:	9/14/2022 11:57:16 AM	
Subject:	RE: Out Jody Zylke	on parental leave Re: JAMA22-7172
	Decision Letter	
′ou are very	/ welcome!	
isa		
Sent: Wedn To: Lisa Har	ail Aiken <araa2@utexas.edu> esday, September 14, 2022 12:50 PM din : Out Jody Zylke</araa2@utexas.edu>	>on parental leave Re: JAMA22-7172 Decision
Warning Ex Thanks, Lisa All best, Abigail	ternal Email] a!	
Jniversity of Principal Inv Fwitter: <u>@Pr</u> Email: <u>araa2</u>	of Public Affairs Texas at Austin estigator, <u>Project SANA</u> <u>rojectSANAteam</u> <u>@utexas.edu</u> p 14, 2022 at 9:53 AM Lisa Hardin	wrote:
Hello,		
I previous	ly sent it on 9/2 and will resend it again now.	
Lisa		
From: Re Sent: We To: Lisa H Cc:		
From: Re Sent: We To: Lisa H Cc: Subject: Letter [Warning Dear Lisa	dnesday, September 14, 2022 4:26 AM lardin < James.Scott@m ; Abigail Aiken < <u>araa2</u> Re: Out Jody Zylke External Email]	2@utexas.edu>
From: Re Sent: We To: Lisa H Cc: Subject: Letter [Warning Dear Lisa Can you p	dnesday, September 14, 2022 4:26 AM lardin < James.Scott@m ; Abigail Aiken < <u>araa2</u> Re: Out Jody Zylke External Email]	2@utexas.edu>
From: Re Sent: We To: Lisa H Cc: Subject: Letter [Warning Dear Lisa Can you p Thanks so Rebecca	dnesday, September 14, 2022 4:26 AM lardin < James.Scott@m ; Abigail Aiken < <u>araa2</u> Re: Out Jody Zylke External Email]	
From: Re Sent: We To: Lisa H Cc: Subject: Letter [Warning Dear Lisa Can you p Thanks so Rebecca	dnesday, September 14, 2022 4:26 AM lardin < James.Scott@m ; Abigail Aiken <araa2 Re: Out Jody Zylke External Email] olease send me the author form o much 2 Sep 2022, at 19:48, Lisa Hardin</araa2 	2@utexas.edu> >on parental leave Re: JAMA22-7172 Decision

From: <u>"Abigail Aiken" <araa2@utexas.edu></u>

To: <u>"James Scott" <James.Scott@mccombs.utexas.edu></u> <u>"Jennifer Starling"</u> <u>"Rebecca Gomperts"</u>

Date: 9/23/2022 10:53:35 AM

Subject: Fwd: JAMA22-7172R1 Decision Letter

Hi everyone,

Great news! Congrats to all and I'll send more details about the anticipated publication date as soon as I have that info.

Very best, A

------ Forwarded message ------From: Date: Fri, Sep 23, 2022 at 10:05 AM Subject: JAMA22-7172R1 Decision Letter To: <araa2@utexas.edu>

PLEASE REPLY TO CONFIRM RECEIPT OF THIS LETTER

September 23, 2022

Dr Abigail Aiken University of Texas at Austin LBJ School of Public Affairs PO Box Y Austin, Texas 78712

RE: Requests for Self-Managed Medication Abortion Provided Using Online Telemedicine in 30 US States Before and After the Dobbs vs Jackson Women's Health Organization Decision

Dear Dr Aiken:

We have completed our review of your Research Letter, entitled "Requests for Self-Managed Medication Abortion Provided Using Online Telemedicine in 30 US States Before and After the Dobbs vs Jackson Women's Health Organization Decision", and are pleased to accept it for publication in JAMA. Your manuscript is accepted with the understanding that its contents, all or in part, have not been published elsewhere and will not be published elsewhere in print or electronic format without the consent of the editor. Also, please remember that you should not disclose the fact that your manuscript has been accepted to anyone, except coauthors and contributors and as noted below, without permission of the editor.

Any information you may receive about the publication date of your Research Letter is tentative and should be kept confidential. Prepublication distribution of the article in hard copy or electronic format without permission is grounds for rescinding the acceptance of your paper. Please note that the news media should not release any information about your article until 10 AM Central Time on Tuesday, the day of its publication date. Do not use social media to post information or "tweet" about your article before publication. If you need help in coordinating press conferences or releases, please contact the JAMA Network Media Relations Department at mediarelations@jamanetwork.org or 312-464-JAMA (312-464-5262.)

During the editing process, you may receive questions about your Research Letter. Your submission is accepted, therefore, with the understanding that it may later be necessary to consider some changes in text or ancillary material.

First and last authors (ie, those listed first and last in the article byline) may claim 10 CME credits (AMA PRA Category 1 Credit) after publication of articles in JAMA Network Journals. First and last authors will receive a subsequent email from the CME provider after the article is published with instructions about claiming CME credits.

Please verify and confirm that all conflict of interest disclosure information for you and all coauthors is accurate, complete, up-to-date, and reported in the Acknowledgment section of the manuscript in a manner that is consistent with that reported in the disclosures of potential conflicts of interest section of the JAMA's Authorship Form.

Our policy requires that all authors disclose:

Any potential conflicts of interest involving the work under consideration for publication (during the time involving the work, from initial conception and planning to present);

Any relevant financial activities outside the submitted work (during the 3 years prior to submission);

And any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what is written in the submitted work (based on all relationships that were present during the 3 years prior to submission).

Potential conflicts of interest include but are not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers' bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. For example, authors of a manuscript about hypertension should report all financial relationships they have with all manufacturers of products used in the management of hypertension, not only those relationships with companies whose specific products are mentioned in the manuscript.

Authors without potential conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests. If you are uncertain about what constitutes a relevant financial interest or relationship, please let me know. Each author will be sent an email with further instructions for submitting the Authorship Form, which includes the ICMJE Disclosure of Potential Conflicts of Interest section.

All research articles published in JAMA are made available via free public access 6 months after publication on the JAMA website (<u>https://jamanetwork.com/journals/jama</u>).

Thank you for submitting your Research Letter for our consideration and we look forward to seeing it in JAMA.

Sincerely yours,

Jody W Zylke, MD Deputy Editor, JAMA Email:

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

From: <u>"Rebecca Gomperts"</u>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 10/26/2022 12:43:37 AM

Subject: Re: TIME SENSITIVE: Authorship form for JAMA

Dear abigail

Do we know when the paper will be published?

How is

doing? How are you doing as

Lots of love R

On 14 Sep 2022, at 19:51, Abigail Aiken <<u>araa2@utexas.edu</u>> wrote:

Oops, sorry about that—attached this time. Looks like all of the author forms are in—thanks for doing it so quickly. Fingers crossed for a good response on the revision!

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

On Wed, Sep 14, 2022 at 4:26 AM Rebecca Gomperts dear abigail did not receive the author form

PDF is not attached, can you please send it? Thanks a lot rebecca

On 13 Sep 2022, at 21:43, Abigail Aiken <<u>araa2@utexas.edu</u>> wrote:

Hi there,

The revised MS for JAMA is all done! Please see PDF attached.

We now need author forms from all authors (you should have received an email request for one of these from Lisa Hardin on Sep 2nd).

wrote:

Here are instructions for completing your form:

Step 1

Check A, B, C (whole content)

For D check:

1. acquisition, analysis, or interpretation of data 2/8/2024

2. critical revision of the manuscript for important intellectual content

3. administrative, technical, or material support

Skip Step 1A

Step 2: Disclose that you are the founder and director of Aid Access. Check no for everything else.

Step 3: Check A

Step 4: Type your name as it appears at the top of the form and then type the date.

That should be it! Please let me know if you have any questions or need any help with this. Fingers crossed for a positive response on the revision...

All best, A

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

<JAMA22-7172R_Merged_PDF.pdf>

From: jnjournals@jamanetwork.org

To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
CC:	"Jennifer E Starling"
	"James G Scott" <james.scott@mccombs.utexas.edu></james.scott@mccombs.utexas.edu>
	"Rebecca Gomperts"
Date:	11/3/2022 9:01:26 PM
Subject:	Congratulations on your publication in JAMA



Dear Dr Aiken:

Thank you for sending *JAMA* your manuscript and congratulations on its publication. Below is a link to the article, which is now live on the *JAMA* website. Feel free to share the link with colleagues, and most importantly your family and friends.

Article: Requests for Self-managed Medication Abortion Provided Using Online Telemedicine in 30 US States Before and After the Dobbs v Jackson Women's Health Organization Decision Publication Date: 11-01-2022

On the online version of your article, there is a small panel at the top of the page that shows some early metrics such as views and media and social media coverage. These metrics and citations will accumulate and grow throughout this year and thereafter. Below is an example of what the metrics panel looks like:



JAMA is committed to making your author experience a positive one and to maximizing the impact and reach of your article. If you have any questions or concerns, please let us know at <u>JAMA</u>.

Best Regards,

Kirsten Bibbins-Domingo, PhD, MD, MAS

Editor in Chief, JAMA



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click <u>here</u> to unsubscribe from these emails.

From: jnjournals@jamanetwork.org

- To: <u>"Abigail Aiken" <araa2@utexas.edu></u>
- CC: <u>"Jennifer E Starling"</u> <u>"James G Scott" <James.Scott@mccombs.utexas.edu></u> <u>"Rebecca Gomperts"</u> Date: 11/9/2022 1:46:34 PM
- Subject: Congratulations on your recent publication in JAMA



Dear Dr Aiken,

Thank you for submitting your manuscript to JAMA. Your article has received some attention in the media and we're pleased to provide you a *link* to some of its news coverage.

Congratulations, and we hope you will consider publishing with us again.

Kirsten Bibbins-Domingo, PhD, MD, MAS Editor In Chief

JAMA

Page	1
rayc	

From:	"Perspectives on Sexual and Reproductive Health" <onbehalfof@manuscriptcentral.com></onbehalfof@manuscriptcentral.com>
To:	
CC:	
	araa2@utexas.edu
Date:	11/13/2022 9:57:22 PM
Subject:	Manuscript PSRH-3911.R2 has been successfully submitted to Perspectives on Sexual and Reproductive Health

13-Nov-2022

Dear Ms. Johnson:

A revision of your manuscript entitled

Michels-Gualtieri, Mira; Gomperts, Rebecca; Aiken, Abigail, has been successfully submitted online and is presently being given full consideration for publication in Perspectives on Sexual and Reproductive Health.

Co-authors: Please contact the Editorial Office as soon as possible if you disagree with being listed as a co-author for this manuscript.

Please include your manuscript ID (PSRH-3911.R2) in all future correspondence with the Editorial Office. You can view the status of your manuscript at any time by logging in to https://mc.manuscriptcentral.com/psrhand checking your Author Center.

If you need to update your e-mail address or other account information, please log in to Manuscript Central and click on your name in the upper right hand corner.

Thank you for submitting your manuscript to Perspectives on Sexual and Reproductive Health.

Sincerely,

Mariam Omar Editorial Assistant PSRH_EA@uottawa.ca

Page	1
ruge	

	1 390 1
From:	"Perspectives on Sexual and Reproductive Health" <onbehalfof@manuscriptcentral.com></onbehalfof@manuscriptcentral.com>
To:	
CC:	
Date: Subject:	araa2@utexas.edu 12/30/2022 4:54:29 PM Manuscript PSRH-3911.R3 has been successfully submitted to Perspectives on Sexual and Reproductive Health

30-Dec-2022

Dear Ms. Johnson:

A revision of your manuscript entitled

Michels-Gualtieri, Mira; Gomperts, Rebecca; Aiken, Abigail, has been successfully submitted online and is presently being given full consideration for publication in Perspectives on Sexual and Reproductive Health.

Co-authors: Please contact the Editorial Office as soon as possible if you disagree with being listed as a co-author for this manuscript.

Please include your manuscript ID (PSRH-3911.R3) in all future correspondence with the Editorial Office. You can view the status of your manuscript at any time by logging in to https://mc.manuscriptcentral.com/psrhand checking your Author Center.

If you need to update your e-mail address or other account information, please log in to Manuscript Central and click on your name in the upper right hand corner.

Thank you for submitting your manuscript to Perspectives on Sexual and Reproductive Health.

Sincerely,

Mariam Omar Editorial Assistant PSRH_EA@uottawa.ca

Page	1
ruge	

	1 490 1
From:	"Perspectives on Sexual and Reproductive Health" <onbehalfof@manuscriptcentral.com></onbehalfof@manuscriptcentral.com>
To:	
CC:	
	araa2@utexas.edu
Date:	1/6/2023 10:50:01 AM
Subject:	Manuscript PSRH-3911.R4 has been successfully submitted to Perspectives on Sexual
	and Reproductive Health

06-Jan-2023

Dear Ms. Johnson:

A revision of your manuscript entitled

Michels-Gualtieri, Mira; Gomperts, Rebecca; Aiken, Abigail, has been successfully submitted online and is presently being given full consideration for publication in Perspectives on Sexual and Reproductive Health.

Co-authors: Please contact the Editorial Office as soon as possible if you disagree with being listed as a co-author for this manuscript.

Please include your manuscript ID (PSRH-3911.R4) in all future correspondence with the Editorial Office. You can view the status of your manuscript at any time by logging in to https://mc.manuscriptcentral.com/psrhand checking your Author Center.

If you need to update your e-mail address or other account information, please log in to Manuscript Central and click on your name in the upper right hand corner.

Thank you for submitting your manuscript to Perspectives on Sexual and Reproductive Health.

Sincerely,

Mariam Omar Editorial Assistant PSRH_EA@uottawa.ca

	Page 1
From:	
To:	"Rebecca Gomperts"
	"Mira Michels-Gualtieri"
	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
Date:	1/9/2023 2:35:56 PM
Subject:	Fwd: Perspectives on Sexual and Reproductive Health - Decision on Manuscript ID PSRH-3911.R4
Attachments:	Johnson-ManuscriptR4-AFcomments.docx
Dear all, Wonderful news! ⁻ you for all your he	The second second s
Best,	
From: Perspect Date: Mon, Jan	ded message tives on Sexual and Reproductive Health < <u>onbehalfof@manuscriptcentral.com</u> > 9, 2023 at 2:31 PM ectives on Sexual and Reproductive Health - Decision on Manuscript ID PSRH-
09-Jan-2023	
Dear :	
Thank you for your revised paper	
attention to the reviewers' and editors' concerns, and I am happy to accept the paper for publication in Perspectives.	

Perspectives is now published online only, and we get most articles posted well before the quarterly publication date. An editor will be in touch to let you know when to expect edited galleys; meanwhile, feel free to check in with me if you need any updates on the schedule or anticipate being unavailable at a particular time.

After your article has been finalized and sent for typesetting, you will receive an e-mail from our publishing partner, Wiley-Blackwell, with instructions for completing a copyright assignment form and information about options for publishing your article on an open access basis. Completion of the copyright assignment form is required before the article can be published, so to avoid having this important detail fall between the cracks, please be sure to open any e-mail you get from Wiley-Blackwell.

Many thanks for this contribution.

Sincerely,

Angel M. Foster, DPhil, MD, AM Editor-in-Chief Perspectives on Sexual and Reproductive Health <u>PSRH_EIC@uottawa.ca</u>

Editor's comments: I have included a few minor comments in the attached. You can incorporate these changes during the production checklist and proof stages. Congratulations - excited to see this in



From: jnjournals@jamanetwork.org

To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
CC:	"Jennifer E Starling"
	"James G Scott" < James.Scott@mccombs.utexas.edu
	"Rebecca Gomperts"
Date:	1/30/2023 10:01:26 PM
Subject:	Update on your publication in JAMA



Dear Dr Aiken:

In the 3 months since your article, <u>Requests for Self-managed</u> <u>Medication Abortion Provided Using Online Telemedicine in 30 US</u> <u>States Before and After the Dobbs v Jackson Women's Health</u> <u>Organization Decision</u>, was published in *JAMA*, it has attracted readership and attention.

We invite you to click the title of your article in the link above to see your article's reach and usage metrics as shown in this example:



You will see the numbers of times your article has been viewed and cited by other articles. The Altmetric score shows coverage by news and social media. By clicking the Altmetric link, you can explore where your article has been mentioned in the news media, blogs, social media accounts, and more.

Note that the citations metric usually takes 6 months or more to populate.

JAMA is committed to making your author experience positive and to maximizing the impact and reach of your article. If you have any questions or concerns, please let us know.

Best Regards,

Kirsten Bibbins-Domingo, PhD, MD, MAS Editor in Chief, *JAMA*



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click <u>here</u> to unsubscribe from these emails.

	Page 1
From:	"Waves Rebecca"
To:	
CC:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
Data	"Mira Michels-Gualtieri"
Date:	2/6/2023 1:41:54 PM
Subject:	Re: Published: Your article is now published online!
they took to very timely	oo long! now though
looks like w	e will go back to misoprostol soon
xxxr	
On 6 Feb	2023, at 20:15, :
Hi All!	
The	article is like on the PSRH web page, and can be accessed
here:	
Thanks	so much,
F	Forwarded message
_	<u>s-author@wiley.com</u> > m, Feb 6, 2023 at 1:05 PM
	Published: Your article is now published online!
To:	
Dear	2
Your artic	
Reprodu	in Perspectives on Sexual and ctive Health has the following publication status: Published Online
To acces	s and share your article, please click the following link to register or log in:
https://au	Ithorservices.wiley.com/index.html#register
	also access your published article via this link:
i ou can	also access your published article via this lift.
	ove link leads to an error page, please try again later. If the link is still not working after , contact our Support team for help.

If you need any assistance, please click here to view our Help section.

Sincerely,

Wiley Author Services

To unsubscribe from these emails, <u>click here.</u>

The contents of this email and any attachments are confidential and intended only for the person or entity to whom it is addressed. If you are not the intended recipient, any use, review, distribution, reproduction or any action taken in reliance upon this message is strictly prohibited. If you received this message in error, please immediately notify the sender and permanently delete all copies of the email and any attachments.

Click here for translations of this disclaimer.



From:	jnjournals@jamanetwork.org
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
CC:	"Jennifer E Starling"
	"James G Scott" <james.scott@mccombs.utexas.edu></james.scott@mccombs.utexas.edu>
	"Rebecca Gomperts"
Date:	2/25/2023 10:03:59 PM
Subject:	Update on your publication in JAMA Network Open



Dear Dr Aiken:

In the 12 months since your article, <u>Association of Texas Senate Bill</u> <u>8 With Requests for Self-managed Medication Abortion</u>, was published in *JAMA Network Open*, it has continued to attract readership and attention.

We invite you to click the title of your article in the link above to see your article's reach and usage metrics as shown in this example:



You will see the numbers of times your article has been viewed and cited by other articles. The Altmetric score shows coverage by news and social media. By clicking the Altmetric link, you can explore where your article has been mentioned in the news media, blogs, social media accounts, and more.

Please contact me if you have any questions or to discuss publication opportunities for your current and future work.

Best Regards,

Frederick P. Rivara, MD, MPH Editor in Chief, *JAMA Network Open*



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click here to unsubscribe from these emails.

	Fage I
From:	"Rebecca Gomperts"
To:	"Kelcie Moseley-Morris"
	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
Date:	3/16/2023 3:32:27 AM
Subject:	Re: Interview request

Dear Kelcie

The statistical data are being researched by Texas University and i cannot give these at hand. I am cc ing abigail

Dana 1

At the moment we are receiving more than 1000 emails per day.

concerning payments: i checked and in february 57% of the people can only pay less than 50 euro.

It is important to continue this work, because the people we help cannot travel to other states to get a safe abortion,

On 15 Mar 2023, at 17:36, Kelcie Moseley-Morris wrote:

Hi Rebecca,

I know it might be hard to find a good time for us to talk by phone, so if you have a chance, I'd love to get your response to a few questions I have by email:

1.) How many packages of abortion pills has Aid Access mailed since July 2022?

2.) What are the most popular destinations for those packages?

3.) Has the distribution to locations within the United States increased since July 2022?

4.) Do you have an estimate of how many clients of yours need financial assistance to be able to order?

5.) Why is it important to you to continue doing this work and providing this service?

Thank you! Kelcie

On Tue, Mar 14, 2023 at 11:35 AM Kelcie Moseley-Morris wrote:

Hi Rebecca,

Warm regards

For some reason my call isn't going through to that number. Are you able to call me? My number is 208-724-9732. I'm available anytime between now and 1 p.m. Mountain Time (3 p.m. Eastern). Thank you!

On Tue, Mar 14, 2023 at 1:17 AM Rebecca Gomperts Dear Kelcie Thanks so much I am available by phone wrote:

Rebecca Gomperts On 13 Mar 2023, at 17:22, Kelcie Moseley-Morris wrote: Hello, I am a national reproductive rights reporter with States Newsroom, and I'm working on a story about abortion pill access in the U.S., particularly as we await a ruling from a Texas judge about the FDA's approval of the drug. I wanted to see if I could speak with someone from Aid Access (perhaps Dr. Gomperts, but it doesn't have to be) about the latest statistics of pill distribution and if the organization foresees any issues with continuing to distribute regardless of the outcome of the lawsuit in Texas. If possible, could we set up a time to speak this week? Thank you! Kelcie Moseley-Morris, MPA Reproductive Rights Reporter | States Newsroom call/text: 208-724-9732 email: website: newsfromthestates.com Note: I am in the Mountain Standard Time zone. Kelcie Moseley-Morris, MPA

Page 2

Reproductive Rights Reporter | States Newsroom

call/text: <u>208-724-9732</u> email: website: newsfromthestates.com

Note: I am in the Mountain Standard Time zone.

Kelcie Moseley-Morris, MPA

Reproductive Rights Reporter | States Newsroom

call/text: 208-724-9732 email: website: <u>newstromthestates.com</u>

Note: I am in the Mountain Standard Time zone.

	Page 1
From:	"Elizabeth Sully"
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	"James Scott" <james.scott@mccombs.utexas.edu></james.scott@mccombs.utexas.edu>
	"Isaac Maddow-Zimet"
	"Rachel Jones"
	"Rebecca Gomperts"
Date:	3/23/2023 9:01:24 PM
Subject:	Guttmacher/AidAccess/Abigail/James call on next steps with SMA incidence pilot work

Hi all,

Please let us know if this time still works for everyone on Monday. I've included a proposed agenda, but let me know if there is anything else you'd like to add

- 1. Update on funding, objectives and timeline for study
- 2. Data collection: recruitment options
- 3. AOB

Microsoft Teams meeting

Join on your computer, mobile app or room device <u>Click here to join the meeting</u>

Meeting ID: 271 461 787 378 Passcode: yq35JT Download Teams | Join on the web

Learn More | Meeting options

	Page 1
From:	
To:	
	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	"Rebecca Gomperts"
Date:	4/19/2023 7:10:03 AM
Subject:	Society of Family Planning 2023 Abstract
Attachments:	SFP_2023.docx

Hi Abigail, and Rebecca!

SFP extended their deadline for submitting an abstract for the annual meeting (in Seattle, WA Oct. 28-30). I thought it might be good to submit something on the physical experiences with miso alone, from our in-depth interviews, and some of the pain management strategies. Given the legal environment around mife[ristone, I think folks might be keen to know how the miso alone experiences it.

Do folks mind taking a look at this draft? **The deadline is April 21st.** Apologies for the tight turn around - and more than happy to talk through the abstract!!

The draft is attached, and the <u>call for abstracts is here</u>.

Best,

--

From:	"Mullin, Emily"
To:	"Rebecca Gomperts"
CC:	<u> "Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	<u>"Rhian Lewis" <press@aidaccess.org></press@aidaccess.org></u>
Date:	5/15/2023 9:44:25 AM
Subject:	Re: Media inquiry: Medication abortion post-Dobbs

I believe my colleague Kate Knibbs may be in touch with Abigail already (we're working together on the story). Have you spoken with her, Rebecca?

Page 1

Emily Mullin Staff writer, biotechnology WIRED wired.com/author/emily-mullin @emilylmullin

0	n Mon, May 15, 2023 at 10:32 AM Rebecca Gomperts	wrote:
	Dear Emily	
	Thank you so much	
	I am available to talk with you Lalso include Abigail Aiken professor of Texas university who has been applysing all	

I also include Abigail Aiken professor of Texas university who has been analysing all our data Warm regards Rebecca Gomperts

On 15 May 2023, at 16:30, Mullin, Emily wrote:

Hello,

I'm a reporter at WIRED magazine, and I'm working on a story tied to the one-year anniversary of the Dobbs decision on the role of medication abortion in a post-Roe world. I was wondering if anyone from Aid Access might be available to speak with me this week on whether you've seen an increase in medication requests in the past year compared to previous years.

Thanks very much,

Emily Mullin Staff writer, biotechnology WIRED wired.com/author/emily-mullin @emilylmullin

From:jnjournals@jamanetwork.orgTo:"Abigail Aiken" <araa2@utexas.edu>CC:"Jennifer E Starling"

- "James G Scott" <James.Scott@mccombs.utexas.edu>

 "Rebecca Gomperts"

 Date:
 11/1/2023 9:01:47 PM
- Subject: Update on your publication in JAMA



Dear Dr Aiken:

In the 12 months since your article, <u>Requests for Self-managed</u> <u>Medication Abortion Provided Using Online Telemedicine in 30 US</u> <u>States Before and After the Dobbs v Jackson Women's Health</u> <u>Organization Decision</u>, was published in *JAMA*, it has continued to attract readership and attention.

We invite you to click the title of your article in the link above to see your article's reach and usage metrics as shown in this example:



You will see the numbers of times your article has been viewed and cited by other articles. The Altmetric score shows coverage by news and social media. By clicking the Altmetric link, you can explore where your article has been mentioned in the news media, blogs, social media accounts, and more.

Please contact me if you have any questions or to discuss publication opportunities for your current and future work.

Best Regards,

Kirsten Bibbins-Domingo, PhD, MD, MAS Editor in Chief, *JAMA*



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click here to unsubscribe from these emails.

	Page 1	
From:		
To:	"Rebecca Gomperts"	
	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>	
Date:	11/20/2023 10:08:19 AM	

Subject: Improving measurement of abortion incidence and safety meeting

Dear Rebecca and Abigail,

I was thinking of submitting the Aid Access miso-alone safety and effectiveness paper to this call for papers - do folks have thoughts or experiences with this meeting?

https://iussp.org/en/improving-measurement-abortion-incidence-and-safety-innovations-methodology-and-recentempirical

Thanks so much!



From: "DANA M JOHNSON" <dmjohnson27@wisc.edu>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 11/19/2024 11:27:18 PM

Subject: Fw: Your Paper has been Accepted to an Oral Session at PAA2025

Dear all,

Great news! Our second Advance Provision paper was accepted to the Population Association of America as an oral session! I'm excited to get more of this work out there. The meeting will be held in Washington D.C., April 10-13th. Please let me know if you have any questions.

Best, Dana

Dana M. Johnson, PhD (she/her) Health Disparities Research Scholars Postdoctoral Fellow Department of Population Health Sciences University of Wisconsin-Madison School of Medicine and Public Health https://www.dana-johnson.com/

From: PAA@mirasmart.com <PAA@mirasmart.com> Sent: Tuesday, November 19, 2024 1:39 PM To: DANA M JOHNSON <dmjohnson27@wisc.edu> Subject: Your Paper has been Accepted to an Oral Session at PAA2025



Dear Dana Johnson,

Session organizers have completed their reviews and we are happy to inform you that your paper, *Perceptions of advance provision of medication abortion in the United States and implications for reproductive autonomy*, has been accepted for the PAA 2025 Annual Meeting program in the session below:

Title (session titles are subject to change): 917 - Reproductive Justice, Autonomy, and Coercion. Session Type: Oral

Please note that PAA 2025 is scheduled for Thursday, April 10 to Sunday, April 13. This is a shift from our typical Wednesday – Saturday pattern. Your session(s) could be scheduled for any day between Friday-Sunday.

All presenting authors a re required to pre-register for the annual meeting by February 3, 2025. Registration is scheduled to open the week of December 1, 2024. Registration information will be available on the <u>PAA Annual Meeting</u> page when it becomes available

We are very pleased that your work will be included in the program and look forward to your participation in PAA 2025!

Sincerely,

Irma T. Elo and Kyle Crowder PAA2025 Program Co-Chairs

	Page 1
From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	"Rebecca Gomperts"
Date:	3/10/2025 8:48:42 AM
Subject:	Shield law impact paper ready for your review
Attachments:	Shield Law Distribution Paper_10MAR2025.docx

Hi Rebecca,

Attached here is the research paper on the impact of shield law provision for your review. There is one green highlight on page 7 where we need some information as well.

We are thinking of submitting this to JAMA with a follow on to JAMA Internal Medicine if JAMA declines.

Thanks so much and very best, Abigail

From: "DANA M JOHNSON" <dmjohnson27@wisc.edu>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 4/7/2025 12:00:05 PM

Subject: SFP 2025 Abstract

Attachments: Codes Pulled and Axial Coding for SFP 2025 Abstract.docx SFP 2025.docx

Dear all,

Happy Monday! I write with an abstract draft of findings from the advance provision interviews. The abstract is for the <u>Society of Family Planning Annual meeting</u>, next October in Pittsburg PA.

This is a rough cut - and any suggestions are welcome. I am especially interested in folks' thoughts on the conclusion.

I am also attaching the coding excerpts in case they help provide a fuller picture of the results.

If folks are able to take a look by April 9th at 5pm cst, that would be amazing.

Thank you so much for your time and support on this project!

best, Dana

Dana M. Johnson, PhD (she/her) Health Disparities Research Scholars Postdoctoral Fellow Department of Population Health Sciences University of Wisconsin-Madison School of Medicine and Public Health https://www.dana-johnson.com/

From: "DANA M JOHNSON" <dmjohnson27@wisc.edu>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 4/14/2025 9:42:48 AM

Subject: Fw: #SFP2025 scientific abstract submission received

Hi all!

Just writing to say that our SFP Abstract was submitted. Apologies for the late note here - I was traveling for PAA and a touch behind on email.

We will hear sometime in July!

Thanks so much, and let me know if you have any questions.

Best, Dana

Dana M. Johnson, PhD (she/her) Health Disparities Research Scholars Postdoctoral Fellow Department of Population Health Sciences University of Wisconsin-Madison School of Medicine and Public Health https://www.dana-johnson.com/

From: Abstract submissions SFP2025 <no-reply@oxfordabstracts.com> Sent: Wednesday, April 9, 2025 6:05 PM To: DANA M JOHNSON <dmjohnson27@wisc.edu> Subject:#SFP2025 scientific abstract submission received

#SFP2025 scientific abstract submission received

Dear DANA JOHNSON,

Thank you for your abstract submission titled: Perspectives on over the counter and advance provision of medication abortion . Your submission has been received. Your reference number for this submission is: 253.

/view and edit up until the

Wednesday, April 9 at 11:59 pm PT/2:59 am ET deadline when it will be moved forward in the review process. You will be notified in July whether or not

this abstract submission has been accepted for presentation.

Thank you,

Society of Family Planning

OXFORD ABSTRACTS

Powered by Oxford Abstracts

From: "DANA M JOHNSON" <dmjohnson27@wisc.edu>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 4/17/2025 11:43:02 AM

Subject: Fw: FIGO Cape Town 2025 – Late-breaking abstract confi rmation

Attachments: FIGO2025-LB-5432-preview-1.pdf

Dear all,

We have submitted an abstract from the advance provision qualitative study to FIGO. We will be notified by June 2nd if our abstract is accepted.

Thank you so much, all!!

best, Dana

Dana M. Johnson, PhD (she/her) Health Disparities Research Scholars Postdoctoral Fellow Department of Population Health Sciences University of Wisconsin-Madison School of Medicine and Public Health https://www.dana-johnson.com/

From: figo.abs@mci-agency.com <figo.abs@mci-agency.com> Sent: Wednesday, April 16, 2025 2:45 PM To: DANA M JOHNSON <dmjohnson27@wisc.edu> Subject: FIGO Cape Town 2025 – Late-breaking abstract confirmation

XXV FIGO World Congress of Gynecology and Obstetrics

5-9 October 2025 Cape Town International Convention Centre

▶ figo2025.org

Final submission confirmed

Dear Dana Johnson,

Thank you for submitting a late-breaking abstract for the XXV FIGO World Congress of Gyr Obstetrics taking place 5 – 9 October 2025 at the Cape Town International Convention Centre, with workshops taking place on 4 October 2025.

WORLD CONGRESS OF GYNECOLOGY


AND OBSTETRICS

Your submission reference number is: **FIGO2025-LB-5432**. Please find a copy of this submission attached The Scientific Programme Committee will review this abstract and will let you know whether this has been not in June 2025.

If you would like to edit or withdraw this submission, please click this link: https://b-com.mci-group.com/Abs//FIGO2025/Submission/Index?AbstractSubmissionWebSiteSetupCode=LB-EN You can modify your submission until the deadline on **Wednesday 16 April 2025, 23:59 UTC**. Only submis as 'Final submission' status by this time will be reviewed by the Scientific Programme Committee.

Please do not hesitate to contact us for any further information you may require.

Kind regards, **FIGO Events Team** c/o MCI Suisse SA Geneva, Switzerland E: <u>figo.abs@mci-agency.com</u> **Office Opening Hours** Monday to Friday 09:00 to 18:00 Geneva Local Time (CET)



From:	<u>"DANA M JOHNSON" <dmjohnson27@wisc.edu></dmjohnson27@wisc.edu></u>
To:	
	"Waves Rebecca"
	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
Date:	6/9/2025 9:57:36 AM

Subject: Fw: FIGO 2025 - Abstract Notification Letter (PO)

Dear all,

Very excited to share that our abstract from the advance provision in-depth interviews was accepted as a poster to the October FIGO conference!

Congrats all - and thank you so much for your work on this project.

Best, Dana

Dana M. Johnson, PhD (she/her) Health Disparities Research Scholars Postdoctoral Fellow University of Wisconsin-Madison School of Medicine and Public Health https://www.dana-johnson.com/

Some of my recent work: <u>Abortion is back at SCOTUS</u>, OpEd in *The Hill* <u>Motivations for obtaining advance provision of medication abortion</u>, *BMJ Sexual and Reproductive Health*

From: FIGO ABS <figo.abs@mci-agency.com> Sent: Tuesday, June 3, 2025 6:23 AM To: DANA M JOHNSON <dmjohnson27@wisc.edu> Subject: FIGO 2025 - Abstract Notification Letter (PO)

Confidential



Dear Doctor Dana Johnson,

On behalf of the FIGO Cape Town 2025 Scientific Programme Committee, we are pleased to inform you that the following late-breaking abstract submission has been **accepted** for an **ePoster presentation** at the XXV FIGO World Congress of Gynecology and Obstetrics, to be held in Cape Town, South Africa, from **Sunday 5 to Thursday, 9 October 2025**:

- Submission N°: FIGO2025-LB-5432
- **Abstract Title**: Perspectives on innovations in abortion provision in a constrained policy context: Findings from US-based individuals who obtained advance provision of medication abortion

A new programme number will be allocated to your abstract after the late-breaking abstracts will have been selected (in late June 2025)

In line with the programme established by the Scientific Programme Committee, please find below the details 6/30/2025

of your presentation:

Location of display	Exhibition Area
Presenting author	Dana Johnson
Poster preparation guidelines	Please note that all accepted abstracts for ePoster presentation will be in a digital-only format. There will be no printed abstract posters at FIGO Cape Town 2025. Further instructions will be provided on the FIGO Congress website soon.

To facilitate meaningful discussions, the scientific programme committee are exploring options for designated viewing sessions, during which presenting authors may be required to present their ePoster at the ePoster stand in the exhibition hall. The schedule of viewing sessions will be confirmed once the late-breaking abstract submissions have been selected in June 2025.

REGISTRATION & CONFIRMATION

We kindly remind you that as per the <u>submission guidelines</u>, all speakers must **register** and need to pay the indicated registration fee to **attend and present at the Congress in-person**. Please make sure to register before **Wednesday 18 June**, **23h59 CET**.

You will benefit from an extension of the early bird fee until this day, by using the following special code: **ABS_early**

- 1. Access the registration platform here: <u>https://b-com.mci-group.com/CommunityPortal</u> /ProgressivePortal/FIGO2025/App/Views/InformationPage/View.aspx?InformationPageID=18040
- 2. Login by creating an account or using an existing account (if you have one)
- 3. Register (by following the instructions below) before Wednesday 18 June, 23h59 CET

Please make sure to enter the following special code in order to receive your complimentary registration: **ABS_early**

After filling in your contact information, please click **YES** to "Did you receive a special code?" and enter the code indicated above.

MEMBERSHIP OR SPECIAL CODE Are you a member or an official representative of a FIGO Member Society?* Yes No Are you a member of any other society?* Yes No Did you receive a special code?* Yes No Did you have an accepted late-breaking abstract?* Yes No Please enter the code you have received, to benefit from the early bird fee:*

MULTIPLE PRESENTATIONS

Kindly note that FIGO only authorizes the presentation of one abstract per individual. We will check the number of presentations per person, and may contact you to appoint alternative presenters if you have several abstract accepted for the congress.

If no alternative presenter can be appointed, we will ask you to withdraw your abstracts from the programme and only keep one presentation.

PUBLICATION

As per the submission guidelines, accepted abstracts will be published as a supplement to the XXV FIGO $\frac{6}{30}$

World Congress of Gynecology and Obstetrics in the International Journal of Gynecology and Obstetrics (IJGO).

A maximum of one abstract presentation and publication will be permitted to each presenting author. Only the presenting author's name will appear in the final Congress programme. All co-author names will be published in the IJGO supplement.

Failure to complete registration payment in time may result in exclusion from the programme and IJGO supplement.

PROMOTE YOUR SESISON ON SOCIAL MEDIA

We strongly encourage you to promote your participation and session at FIGO Cape Town 2025 on social media. Sharing your involvement helps build excitement around the congress and raises awareness of the important topics being discussed. Feel free to tag FIGO and use the official congress hashtag #FIGO2025 to maximize visibility @FIGOHQ.

For questions regarding the registration, please contact: <u>figo.reghot@mci-agency.com</u> For questions regarding your abstract, please contact: <u>figo.abs@mci-agency.com</u> For general enquiries, please contact: <u>figo@mci-agency.com</u>

We look forward to meeting you in Cape Town and do not hesitate to contact us for further information. Kind regards,

On behalf of the FIGO Cape Town 2025 Scientific Programme Committee.

FIGO 2025 - Abstract Management

c/o MCI Suisse SA Rue du Pré-Bouvier 9 1242 Satigny Switzerland

	Dago 1		
From:	Page 1 <u>"Essink, D.R. \(Dirk\)" <d.r.essink@vu.nl></d.r.essink@vu.nl></u>		
lo:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>		
	"Rebecca Gomperts"		
	<u>"Jennifer E Starling" <jstarling@utexas.edu></jstarling@utexas.edu></u>	—	
	"Daniëlle van Blitterswijk"		
	"Carlijn Looijen"		
	"Thijs van Vliet"		
Date:	11/6/2023 10:11:02 AM		
Subject:	RE: Good news!		
Wonderful! Congratulations! @ Rebecca, see you tomorrow			
0	il Aiken <araa2@utexas.edu></araa2@utexas.edu>		

Verzonden: maandag 6 november 2023 16:10		
0		
Aan: Rebecca Gomperts	; Essink, D.R. (Dirk) <d.r< td=""><td>.essink@vu.nl>; Jennifer E</td></d.r<>	.essink@vu.nl>; Jennifer E
Starling <jstarling@utexas.edu>; Daniëlle van Blitterswijk</jstarling@utexas.edu>		Carlijn Looijen
; Thijs van Vliet		
Onderwerp: Good news!		

Hi all,

I'm very happy to report that JAMA Internal Medicine has accepted our advance provision article! I'll be in touch to let you know the anticipated date of publication and to share a PDF of the manuscript.

Thanks so much to everyone for all of your hard work on this and congratulations!

All best, Abigail

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Twitter: <u>@ProjectSANAteam</u> Email: <u>araa2@utexas.edu</u>

From: jnjournals@jamanetwork.org

To: <u>"Abigail R A Aiken" <araa2@utexas.edu></u>

"Jennifer E Starling"
"Danielle van Blitterswijk"
"Carlijn Looijen"
"Thijs van Vliet"
<u>"Dirk Essink" <d.r.essink@vu.nl></d.r.essink@vu.nl></u>
"Rebecca Gomperts"
1/6/2024 11:01:47 PM

Subject: Congratulations on your publication in JAMA Internal Medicine

JAMA Internal Medicine

Dear Dr Aiken:

Thank you for sending *JAMA Internal Medicine* your manuscript and congratulations on its publication. Below is a link to the article, which is now live on the *JAMA Internal Medicine* website. Feel free to share the link with colleagues, and most importantly your family and friends.

Article: Advance Provision of Mifepristone and Misoprostol via Online Telemedicine in the US Publication Date: 01-02-2024

On the online version of your article, there is a small panel at the top of the page that shows some early metrics such as views and media and social media coverage. These metrics and citations will accumulate and grow throughout this year and thereafter. Below is an example of what the metrics panel looks like:

JAMA Internal Medicine is committed to making your author experience a positive one and to maximizing the impact and reach of your article. If you have any questions or concerns, please let us know at <u>JAMA Internal Medicine</u>.

Best Regards,

6/30/2025

Sharon K. Inouye, MD, MPH Editor in Chief, *JAMA Internal Medicine*



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click here to unsubscribe from these emails.

	Page 1
From:	
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
Date:	2/12/2024 3:03:33 PM
Subject:	Fwd: Authorship Form Received for JAMA23-10913
Attachments:	authorship_e_form_jama23-10913_gomperts_ezdfdy.pdf

Begin forwarded message:

From:
Subject: Authorship Form Received for JAMA23-10913
Date: 12 February 2024 at 21:03:11 CET
То:
Cc:
Reply-To:

February 12, 2024

Dear Dr Gomperts,

Thank you for submitting your Authorship form for JAMA. Your authorship form will be reviewed for accuracy and completeness. If there are any omissions, the form will be returned to you for correction and resubmission. A PDF copy of the form is attached for your reference.

Sincerely yours,

Josie Sheehy Editorial Assistant II, JAMA Email: T 312-464-4217

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

JAMA Authorship Responsibility, Funding and Conflicts of Interest, and Publishing Agreement for Coauthor

Each author must read and complete the following sections:

- 1. Authorship Responsibility, Criteria, and Contributions
- 2. Reporting of Funding and Conflicts of Interest
- 3. Publishing Agreement
- 4. Confirmation

Manuscript # JAMA23-10913

Manuscript Title: Self-managed Medication Abortions Before and After Dobbs v Jackson Women's Health Organization

Author Name: Rebecca Gomperts

Corresponding Author: Abigail Aiken

Phone:

Email:

Step 1. Authorship Responsibility, Criteria, and Contributions. Each author should meet all criteria below (A, B, C, and D) and should indicate general and specific contributions by reading criteria A, B, C, and D and checking the appropriate boxes. A contribution statement based on this form will be published with the final version of your article; please ensure the contributions are accurate.

A. I certify that

- The manuscript represents original and valid work and that neither this manuscript nor one with substantially similar content under my authorship has been published or is being considered for publication elsewhere, except as described in the journal's submission form and cover letter submitted with the manuscript, and copies of closely related manuscripts have been provided; and
- I agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; and
- If requested, I will provide the data or will cooperate fully in obtaining and providing the data on which the manuscript is based for examination by the editors or their assignees; and
- For papers with more than 1 author, I agree to allow the corresponding author to serve as the primary correspondent with the editorial office, to review the edited manuscript and proof, and to make decisions regarding release of information in the manuscript to the media, federal agencies, or both; or, if I am the only author, I will be the corresponding author and agree to serve in the roles described above.
- B. I have given final approval of the submitted manuscript.

C. I have participated sufficiently in the work to take public responsibility for (check 1 of 2 below)

• part of the content.

o the whole content.

D. To qualify for authorship, you must check at least 1 box for each of the 3 categories of contributions listed below.

I have made substantial contributions to the intellectual content of the paper as described below.

- 1. Check at least 1 of 2 below
- concept and design
- ✓ acquisition, analysis, or interpretation of data
- 2. Check at least 1 of 2 below
- □ drafting of the manuscript
- ☑ critical review of the manuscript for important intellectual content
- 3. Check at least 1 below
- statistical analysis
- obtained funding
- □ administrative, technical, or material support
- supervision

no additional contributions
 other
 ontributed to final data interpretation

Step 2. Disclosure of Potential Conflicts of Interest

The purpose of this section is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The section includes the questions from the ICMJE Form for Disclosure of Potential Conflicts of Interest and is divided into 5 subsections.

Authors are expected to provide detailed information about all relevant financial interests, activities, relationships, and affiliations (other than those affiliations listed in the title page of the manuscript) including, but not limited to, employment, affiliation, funding and grants received or pending, consultancies, honoraria or payment, speakers bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

• 2A. The work under consideration for publication.

This subsection asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party—that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation, or commercial sponsor, check "Yes."

• 2B. Relevant financial activities outside the submitted work.

This subsection asks about your financial relationships with entities in the biomedical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations, or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

• 2C. Intellectual property.

This subsection asks about patents and copyrights, whether pending, issued, licensed, and/or receiving royalties.

• 2D. Relationships not covered above.

Use this subsection to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: Government agency, foundation, commercial sponsor, academic institution, etc Grant: A grant from an entity, generally (but not always) paid to your organization Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc

Other: Anything not covered under the previous 3 boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency **Licensed:** The patent has been licensed to an entity, whether earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your patent

• 2E. Disclosure statement.

Step 2A. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc)? Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. If you have more than 1 entity, press the "Add" button to add a row. Excess rows can be removed by pressing the "Remove" button. If you have selected the "Other" checkbox, a "Comment" will be required.

No

Step 2B. Relevant Financial Activities Outside the Submitted Work

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. If you have more than 1 entity, press the "Add" button to add a row. Excess rows can be removed by pressing the "Remove" button. If you have selected the "Other" checkbox, a "Comment" will be required. You should report relationships that were **present during the 36 months prior to publication**

No

Step 2C. Intellectual Property—Patents and Copyrights

Do you have any patents, whether planned, pending, or issued, broadly relevant to the work? Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions.

No

Step 2D. Relationships Not Covered Above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

I am is the Founder and Director of Aid Access

At the time of manuscript acceptance, the journal will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, the journal may ask authors to disclose further information about reported relationships.

Step 2E. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement in the box below after you click the "Generate Disclosure Statement" button. Any subsequent changes will also update the disclosure statement automatically after clicking the "Submit" button.

Dr Gomperts reports I am is the Founder and Director of Aid Access.

Step 3. Publishing Agreement.* All authors must select only 1 of the following: A, or B, or C.

• A. Copyright Transfer. In consideration of the action of the American Medical Association (AMA) in reviewing and editing this submission (manuscript, tables, figures, video, audio, and other supplemental files for publication), I hereby transfer, assign, or otherwise convey all copyright ownership, including any and all rights incidental thereto, exclusively to the AMA, of the published article (or version of record).

• B. Federal Employment. I was an employee of the US federal government or that of another nation when this work was conducted and prepared for publication; therefore, it is not protected by the Copyright Act, and copyright ownership cannot be transferred.

• C. Work for hire. I am employed by an institution that considers this submission a "work made for hire" and that requires an authorized representative of the institution to assign copyright on my behalf. (Note: Information in the following 3 fields is required before you can submit this agreement.)

*For research articles, authors may deposit the accepted version of the manuscript (but not the final copyedited, formatted, and proofed version of record published by the journal) in a repository of their choice on or after the date of publication provided that it links to the final published article on the journal's website. JAMA Network will make the published research article (version of record) free public access 6 months after publication on the journal website and deposit it in PubMed Central for public access 6 months after publication.

Step 4. Confirmation. Confirm that all information provided is accurate by checking the box below and then enter your complete name as it appears at the top of this form and date of confirmation in the fields below.

✓ I certify that all information I have provided is accurate.

Complete Name: rebecca gomperts

Date: 12-2-2024

local_p_id: 445450 time: 1707768190 ip address: 127.0.0.1

From:	"Elisa Wells"
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	"James Scott" <james.scott@mccombs.utexas.edu></james.scott@mccombs.utexas.edu>
	<u>Gomperts</u>
Date:	2/12/2024 5:57:51 PM
Subject:	Re: R&R from JAMA

Great news! I have completed the form. Let me know if there is any help you need with revision/review.

Congrats!

From: Abigail Aiken <araa2@utexas.edu> Date: Monday, February 12, 2024 at 11:25 AM To: James Scott <James.Scott@mccombs.utexas.edu>, Elisa Wells Gomperts Subject: R&R from JAMA

Hi all,

Good news—JAMA has asked for an R&R on our paper examining sma provision before and after Dobbs. They would like the revision back within 2 weeks, so I will get to work on it shortly.

You may have already received an email about authorship forms. Please follow the link in the email to complete and submit the form. Please note that the information in the form needs to exactly match the author contributions and COI information listed in the manuscript. I've copied below what we currently have in the manuscript—please let me know if we need to make any changes based on the information you provide in your author form.

Please let me know of any questions and thanks so much for all of your work on this paper! Best to all, Abigail

ARAA conceived of the original research questions. All authors contributed to the study design. ESW and RG provided data. All authors agree to be accountable for all aspects of the work. ARAA had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. ARAA and JGS analyzed the data. JGS designed the statistical models. JGS and ARAA prepared the tables. ARAA and JGS did the initial data interpretation. ARAA wrote the first draft of the manuscript. All authors contributed to final data interpretation, revised the manuscript for important intellectual content, and approved the final version of the manuscript. No medical writers or Editors were involved in the creation of the manuscript. No AI or AI-assisted technologies were used in any aspect of this manuscript including the analysis and interpretation data, the drawing of scientific conclusions, or the writing of the manuscript. ARAA reports grant support from The Society of Family Planning (Grant # SFPRF12-MA1), The Kopcho Reproductive Freedom Fund, and The William and Flora Hewlett Foundation (Grant #2023-02900-GRA), and reports receiving infrastructure support from the National Institutes of Health (Grant # P2CHD042849). None of the funding sources had any role in the design and conduct of the study; collection, management, analysis, $\frac{6/30/2025}{2}$

and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. ESW is a Co-founder and Co-director of Plan C. RG is the Founder and Director of Aid Access. JGS declares no competing interests.

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Email: <u>araa2@utexas.edu</u>

- From: jnjournals@jamanetwork.org
 - To: <u>"Abigail R A Aiken" <araa2@utexas.edu></u>

CC:	"Jennifer E Starling"
	"DaniAlle van Blitterswijk"
	"Carlijn Looijen"
	"Thijs van Vliet"
	<u>"Dirk Essink" <d.r.essink@vu.nl></d.r.essink@vu.nl></u>
	"Rebecca Gomperts"
Date:	2/21/2024 10:54:23 AM

Subject: Congratulations on your recent publication in JAMA Internal Medicine

JAMA Internal Medicine

Dear Dr Aiken,

Thank you for submitting your manuscript to JAMA Internal Medicine. Your article has received some attention in the media and we're pleased to provide you a <u>link</u> to some of its news coverage.

Congratulations, and we hope you will consider publishing with us again.

Sincerely yours,

Sharon Inouye, MD, MPH Editor in Chief

	Page 1
From:	"Elisa Wells"
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
	<u>Gomperts</u>
	"James Scott" <james.scott@mccombs.utexas.edu></james.scott@mccombs.utexas.edu>
Date:	3/6/2024 5:22:58 PM
Subject:	Re: Good news

Congrats! Will be great to have those numbers finally out there.

From: Abigail Aiken <araa2@utexas.edu> Date: Wednesday, March 6, 2024 at 11:36 AM</araa2@utexas.edu>		
To: Gomperts	Elisa Wells	James Scott
<james.scott@mccombs.utexas.edu> Subject: Good news</james.scott@mccombs.utexas.edu>		

Hi everyone,

I just received an acceptance decision from JAMA on our paper examining the change in provision of medications for self-managed abortion pre and post-Dobbs. I anticipate having article proofs in the next week or so since the anticipated online publication date is March 25th. Everything is under embargo until then. I'll share the final copy-edited version of the article once I have it.

Congratulations to all and thank you for all of our hard work! Abigail

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Email: <u>araa2@utexas.edu</u>

From: jnjournals@jamanetwork.org

To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
CC:	"Elisa S Wells"
	"Rebecca Gomperts"
	"James G Scott" <james.scott@mccombs.utexas.edu></james.scott@mccombs.utexas.edu>
Date:	3/29/2024 10:00:51 PM
Subject:	Congratulations on your publication in JAMA



Dear Dr Aiken:

Thank you for sending *JAMA* your manuscript and congratulations on its publication. Below is a link to the article, which is now live on the *JAMA* website. Feel free to share the link with colleagues, and most importantly your family and friends.

Article: Provision of Medications for Self-Managed Abortion Before and After the Dobbs v Jackson Women's Health Organization Decision Publication Date: 03-25-2024

On the online version of your article, there is a small panel at the top of the page that shows some early metrics such as views and media and social media coverage. These metrics and citations will accumulate and grow throughout this year and thereafter. Below is an example of what the metrics panel looks like:

JAMA is committed to making your author experience a positive one and to maximizing the impact and reach of your article. If you have any questions or concerns, please let us know at <u>JAMA</u>.

Best Regards,

Kirsten Bibbins-Domingo, PhD, MD, MAS Editor in Chief, *JAMA*



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click here to unsubscribe from these emails.

From: jnjournals@jamanetwork.org

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

<u>"Jennifer E Starling"</u>
"Danielle van Blitterswijk"
"Carlijn Looijen"
"Thijs van Vliet"
<u>"Dirk Essink" <d.r.essink@vu.nl></d.r.essink@vu.nl></u>
"Rebecca Gomperts"
4/1/2024 10:01:55 PM

Subject: Update on your publication in JAMA Internal Medicine

JAMA Internal Medicine

Dear Dr Aiken:

In the 3 months since your article, <u>Advance Provision of Mifepristone</u> and <u>Misoprostol via Online Telemedicine in the US</u>, was published in *JAMA Internal Medicine*, it has attracted readership and attention.

We invite you to click the title of your article in the link above to see your article's reach and usage metrics as shown in this example:

You will see the numbers of times your article has been viewed and cited by other articles. The Altmetric score shows coverage by news and social media. By clicking the Altmetric link, you can explore where your article has been mentioned in the news media, blogs, social media accounts, and more.

Note that the citations metric usually takes 6 months or more to populate.

JAMA Internal Medicine is committed to making your author experience positive and to maximizing the impact and reach of your article. If you have any questions or concerns, please let us know.

Best Regards,

Sharon K. Inouye, MD, MPH

Editor in Chief, JAMA Internal Medicine



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click <u>here</u> to unsubscribe from these emails.

From: jnjournals@jamanetwork.org

To: <u>"Abigail Aiken" <araa2@utexas.edu></u> CC: <u>"Elisa S Wells"</u> <u>"Rebecca Gomperts"</u> <u>"James G Scott" <James.Scott@mccombs.utexas.edu></u> Date: 5/7/2024 3:19:47 PM Subject: Congratulations on your recent publication in JAMA



Dear Dr Aiken,

Thank you for submitting your manuscript to JAMA. Your article has received some attention in the media and we're pleased to provide you a *link* to some of its news coverage.

Congratulations, and we hope you will consider publishing with us again.

Kirsten Bibbins-Domingo, PhD, MD, MAS Editor In Chief

JAMA

jnjournals@jamanetwork.org From: To: "Abigail Aiken" <araa2@utexas.edu> CC: "Elisa S Wells" "Rebecca Gomperts" "James G Scott" <James.Scott@mccombs.utexas.edu> Date: 6/23/2024 10:00:34 PM

Update on your publication in JAMA Subject:



Dear Dr Aiken:

In the 3 months since your article, Provision of Medications for Self-Managed Abortion Before and After the Dobbs v Jackson Women's Health Organization Decision, was published in JAMA, it has attracted readership and attention.

We invite you to click the title of your article in the link above to see your article's reach and usage metrics as shown in this example:

You will see the numbers of times your article has been viewed and cited by other articles. The Altmetric score shows coverage by news and social media. By clicking the Altmetric link, you can explore where your article has been mentioned in the news media, blogs, social media accounts, and more,

Note that the citations metric usually takes 6 months or more to populate.

JAMA is committed to making your author experience positive and to maximizing the impact and reach of your article. If you have any questions or concerns, please let us know.

Best Regards,

Kirsten Bibbins-Domingo, PhD, MD, MAS Editor in Chief, JAMA



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click here to unsubscribe from these emails.

Page 1
"Dana Johnson"
"Waves Rebecca"
araa2@utexas.edu
7/2/2024 1:40:36 PM
Fwd: Information about your #SFP2024 scientific abstract

Hi all,

Bummer news, SFP did not accept our abstract regarding the advance provision interviews. But..this only lights a fire under me MORE to get that manuscript out this summer. Stay tuned all!

If you have any questions, please feel free to send me a note.

Hope everyone is staying cool and taking care!

best, Dana

------ Forwarded message ------From: Date: Tue, Jul 2, 2024 at 2:08 PM Subject: Information about your #SFP2024 scientific abstract To:



Dear Dana,

Thank you very much for your interest in the 2024 Society of Family Planning Annual Meeting and for submitting an abstract. After careful consideration, we regret to inform you that your abstract, "You wouldn't live in a house without a fire extinguisher" Motivations for ordering medication abortion pills in advance in the United States (#204), was not selected for presentation. Please inform the other authors of this abstract.

We hope that you will still consider attending <u>#SFP2024</u>, and we encourage you to submit a scientific abstract for next year's meeting. The Annual Meeting will be taking place in Detroit on October 19-21, preceded by two days of business meetings, pre-conference workshops, and a welcome reception.

Best,

Christine

Christine Hence, MS

Events Manager

866.584.6758, ext. 402 (eastern time zone)

Pronouns: she/her/hers

www.SocietyFP.org

Dana M. Johnson, PhD

https://www.dana-johnson.com/

	Page 1	
From:	"Dana Johnson"	
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>	
	"Waves Rebecca"	
Date:	8/14/2024 9:53:46 AM	
Subject:	Draft of Advance Provision Manuscript 1 (Motivations)	
Attachments:	Manuscript1_Motivations.docx	

Dear All,

I hope everyone is going well! I am writing with draft of the Advance Provision in-depth interviews manuscript. This manuscript focuses on "motivations" for obtaining advance provision, and our second manuscript (in progress) will focus on who is ordering advance provision.

Two quick points:

1. Please take a look at the track changes, I left a few comments specific to folks (ie, Abigail for the funder, **burner** for a second eye on our methods)

2. Abigail and I discussed trying BMJ Sexual and Reproductive Health first, but I am certainly open to any all suggestions!

Thank you SO much for all your work on this project!

best, Dana

Dana M. Johnson, PhD

https://www.dana-johnson.com/

	3	
From:	"Dana Johnson"	
To:		
	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>	
	"Waves Rebecca"	
Date:	9/10/2024 5:34:28 PM	
Subject:	Fwd: The Lancet Regional Health - Americas: Submission Confirmation	
Attachments:	TLRHAMERICAS-S-24-00753.pdf	

Dear all,

We have submitted the first manuscript from the advance provision in-depth interview study to Lancet Regional Health - Americas! Please see full PDF submission for your records (and Abigail, updated on the Project SANA box as well).

Page 1

Congratulations, all! Thank you so much for all your work on this project!!

Have a wonderful rest of your tuesday.

Best, Dana

------ Forwarded message ------From: **The Lancet Regional Health - Americas Team** <<u>em@editorialmanager.com</u>> Date: Tue, Sep 10, 2024 at 5:32 PM Subject: The Lancet Regional Health - Americas: Submission Confirmation To: Dana M Johnson

Dear Dr Johnson,

We have received your article "Motivations for obtaining advance provision of medication abortion in the United States: a qualitative study" for consideration for publication in *The Lancet Regional Health - Americas*.

Thank you for submitting your work to this journal.

Kind regards,

The Lancet Regional Health - Americas

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. <u>(Remove my information/details)</u>. Please contact the publication office if you have any questions.

Dana M. Johnson, PhD

https://www.dana-johnson.com/

The Lancet Regional Health - Americas

Motivations for obtaining advance provision of medication abortion in the United States: a qualitative study --Manuscript Draft--

Manuscript Number:	
Article Type:	Article (Original Research)
Section/Category:	
Keywords:	Abortion, advance provision, mifepristone, misoprostol, medication abortion, qualitative study, United States
Corresponding Author:	Dana M Johnson, PhD University of Wisconsin-Madison School of Medicine and Public Health UNITED STATES
First Author:	Dana M Johnson, PhD
Order of Authors:	Dana M Johnson, PhD
	Rebecca Gomperts, MD, PhD
	Abigail RA Aiken, MD, MPH, PhD
Manuscript Region of Origin:	UNITED STATES
Abstract:	Background: Advance provision of medication abortion, or the prescription of mifepristone and misoprostol before pregnancy occurs, is an unexplored care model aimed at expanding abortion access. We examine motivations for obtaining advance provision from the online telemedicine service Aid Access, which supports people in the United States. Methods: Between May and November 2023, we conducted semi-structured in-depth interviews with 39 people who obtained advance provision between January 2022 and April 2023. Interviews were transcribed and thematically coded to assess individual motivations. Findings: 1) Participants were motivated to obtain medications because of the Dobbs vs. Jackson Women's Health Organization (Dobbs) draft opinion leak and eventual decision. Participants expressed concerns about access to abortion under current and future abortion restrictions. 2) Concerns about restrictions prompted people to make a back-up plan for themselves and loved ones, and participants were motivated to have medications on hand because pregnancy would be either unsafe or difficult. Others were trying to become pregnant, but because of their health histories they were cognizant of the health risks of a desired pregnancy. 4) Participants had an active desire to take back control of their reproductive autonomy in the face of inevitable abortion bans. Interpretation: The need for autonomy, resistance and reassurance were woven throughout participant's motivations for obtaining advance provision. The Dobbs decision acted as a catalyst for action to take back reproductive autonomy and prepare for lack of access to abortion care.

Date: 9/13/2024 7:11:41 AM

Subject: A Comment Has Been Added to SSRN Abstract ID 4953282

SSRN

Motivations for Obtaining Advance Provision of Medication Abortion in the United States: A Qualitative Study (Abstract ID 4953282):

Thank you for opting in to share your preprint with Preprints with The Lancet on SSRN.
 Your paper has not been accepted for posting on SSRN. The decision by Preprints with The Lancet is separate from the Lancet Group's editorial process at the journal where you submitted your paper.

 Please also refer to our FAQ page for more information: https://www.thelancet.com /preprint-faq
 <br

Questions or need further assistance? Reply to this email or visit the SSRN Support Center at https://service.elsevier.com/app/home /supporthub/ssrn/ or call 877-SSRNHelp (877 777 6435) in the United States or +1 212 448 2500 outside of the United States.

Thank you, The SSRN Team

Search the SSRN eLibrary | Browse SSRN | Top Papers

	Page 1	
From:	"Dana Johnson"	
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>	
	"Waves Rebecca"	-
Date:	9/16/2024 8:52:16 AM	
Subject:	Fwd: Your Submission TLRHAMERICAS-D-24-00618	

Hi all!

I hope you had a nice weekend! Sorry to start off your Monday morning this way, but bummer news from Lancet Regional Health Americas, but not too unexpected? It looks like they have not published too much qual work..

I am a little unsure where to try next!

Sexual and Reproductive Health Matters seems great, but we have a miso-only in-depth interview paper under review there, does that matter?

Perspectives on Sexual and Reproductive Health also seems good, but I have been hearing from other folks that they are quite backed up - have folks heard anything about this?

Finally, perhaps mostly a question for Abigail, do you think BMJ Sexual and Reproductive Health has flexibility on word count? Happy to cut words as well!

If folks have any thoughts, please let me know!

best, Dana

------ Forwarded message ------From: **The Lancet Regional Health - Americas Team** <<u>em@editorialmanager.com</u>> Date: Mon, Sep 16, 2024 at 8:15 AM Subject: Your Submission TLRHAMERICAS-D-24-00618 To: Dana M Johnson

Manuscript reference number: TLRHAMERICAS-D-24-00618 Title: Motivations for obtaining advance provision of medication abortion in the United States: a qualitative study

Dear Dr Johnson,

Many thanks for submitting your manuscript to *The Lancet Regional Health - Americas*. We read your paper with interest, but I regret to say that we are unable to proceed with it, after careful consideration. We currently receive far more submissions than we have space to publish and therefore have to reject many otherwise worthy papers.

We are sorry to disappoint you on this occasion and would like to suggest two alternative journals we believe might be suitable options:

Dialogues in Healthhttps://www.editorialmanager.com/DIALOG/Public Health in Practicehttps://www.editorialmanager.com/PUHIP/

If you would like your paper to be considered by one of these alternative journals, we can transfer it directly on your behalf. To do this, please either accept or decline the transfer by clicking on the links below:

Accept to Transfer: Agree to Transfer

Decline to Transfer: Decline to Transfer

Please note, the transfer links will expire on Oct 16, 2024. Should this expire, please contact the alternative journal directly to submit your paper.

Although this decision has not been a positive one, we thank you for your interest in the journal and hope it does not deter you from considering us again in the future.

Yours sincerely,

Dr Taissa Vila Editor-in-Chief, *The Lancet Regional Health - Americas* Email:

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. <u>(Remove my information/details)</u>. Please contact the publication office if you have any questions.

Dana M. Johnson, PhD

https://www.dana-johnson.com/

	Page 1
From:	"Sharie Mae Cruz" <onbehalfof@manuscriptcentral.com></onbehalfof@manuscriptcentral.com>
To:	
	araa2@utexas.edu
Date:	9/19/2024 9:52:35 AM
Subject:	BMJ Sexual & Reproductive Health - Manuscript ID bmjsrh-2024-202580

19-Sep-2024

Dear Dr. Johnson:

Your manuscript entitled "Motivations for obtaining advance provision of medication abortion in the United States: a qualitative study" has been successfully submitted online and is presently being given full consideration for publication in BMJ Sexual & Reproductive Health.

Your manuscript ID is bmjsrh-2024-202580.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at https://mc.manuscriptcentral.com/bmjsrh and edit your user information as appropriate.

Author names will be taken directly from the information held in ScholarOne and not from the article file. Please check that all names are correctly entered as this will be the name displayed on the final published article and in any indexes affiliated with the journal.

You can view the status of your manuscript at any time by entering your manuscript ID bmjsrh-2024-202580 into Where Is My Paper https://whereismypaper.bmj.com/, our fast and easy-to-use manuscript tracking tool or by checking your Author Center after logging in to https://mc.manuscriptcentral.com/bmjsrh.

Any individuals listed as co-authors on this manuscript are copied into this submission confirmation email. If you believe that you have received this email in error, please contact the Editorial Office.

Thank you for submitting your manuscript to BMJ Sexual & Reproductive Health.

Kind regards,

Prof. Sharon Cameron Editor in Chief, BMJ Sexual & Reproductive Health

P.s. What did you think of the article submission process?

At BMJ, we constantly strive to improve our services for authors. We value your feedback and we'd be grateful if you could take 5 minutes to fill out our short survey. Your responses will remain confidential and you won't be identified in any results.

Please click on this link to access the survey https://www.surveymonkey.co.uk/r/6DGV97V:

We are constantly trying to find ways of improving our peer review system and continually monitor processes and methods by including article submissions and reviewers' reports in our research. If you do not wish your paper or review entered into our peer review research programme, please let us know by emailing papersadmin@bmj.com as soon as possible

	Page 1
From:	"Sharie Mae Cruz" <onbehalfof@manuscriptcentral.com></onbehalfof@manuscriptcentral.com>
To:	
	araa2@utexas.edu
Date:	9/20/2024 12:54:00 PM
Subject:	BMJ Sexual & Reproductive Health - Manuscript ID bmjsrh-2024-202580

20-Sep-2024

Dear Dr. Johnson:

Your manuscript entitled "Motivations for obtaining advance provision of medication abortion in the United States: a qualitative study" has been successfully submitted online and is presently being given full consideration for publication in BMJ Sexual & Reproductive Health.

Your manuscript ID is bmjsrh-2024-202580.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at https://mc.manuscriptcentral.com/bmjsrh and edit your user information as appropriate.

Author names will be taken directly from the information held in ScholarOne and not from the article file. Please check that all names are correctly entered as this will be the name displayed on the final published article and in any indexes affiliated with the journal.

You can view the status of your manuscript at any time by entering your manuscript ID bmjsrh-2024-202580 into Where Is My Paper https://whereismypaper.bmj.com/, our fast and easy-to-use manuscript tracking tool or by checking your Author Center after logging in to https://mc.manuscriptcentral.com/bmjsrh.

Any individuals listed as co-authors on this manuscript are copied into this submission confirmation email. If you believe that you have received this email in error, please contact the Editorial Office.

Thank you for submitting your manuscript to BMJ Sexual & Reproductive Health.

Kind regards,

Prof. Sharon Cameron Editor in Chief, BMJ Sexual & Reproductive Health

P.s. What did you think of the article submission process?

At BMJ, we constantly strive to improve our services for authors. We value your feedback and we'd be grateful if you could take 5 minutes to fill out our short survey. Your responses will remain confidential and you won't be identified in any results.

Please click on this link to access the survey https://www.surveymonkey.co.uk/r/6DGV97V:

We are constantly trying to find ways of improving our peer review system and continually monitor processes and methods by including article submissions and reviewers' reports in our research. If you do not wish your paper or review entered into our peer review research programme, please let us know by emailing papersadmin@bmj.com as soon as possible

- From: <u>"DANA M JOHNSON" <dmjohnson27@wisc.edu></u>
 - To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 10/1/2024 11:20:08 AM

Subject: Fw: Submission 4286 Confirmation

Dear all,

I am sending along our confirmation (see below) that we submitted our abstract to the Population Association of America Annual Meeting! Thanks so much for your swift review of this abstract.

Best, Dana

Dana M. Johnson, PhD (she/her) Health Disparities Research Scholars Postdoctoral Fellow Department of Population Health Sciences University of Wisconsin-Madison School of Medicine and Public Health https://www.dana-johnson.com/

From: PAA2025 Site <PAA@mirasmart.com> Sent: Tuesday, October 1, 2024 10:44 AM To: DANA M JOHNSON <dmjohnson27@wisc.edu> Subject: Submission 4286 Confirmation

Congratulations on the successful submission of your Submission to the PAA2025 Site. For your records, please print a copy of this email.

Start the Visa Process Now: You can download a letter about the conference with information on your submission that you can use to request a visa. A more detailed letter will be available for all accepted submissions. To access the letter, click edit from the Author Home, and choose the manage button (number 6). Click the "**Submission Completed Letter**" button to get your letter. Submission ID: 4286

Submission Title: 'Perceptions of advance provision of medication abortion in the United States and implications for reproductive autonomy'

First Choice Submission Topic: 9. Fertility, Family Planning, Sexual Behavior, and Reproductive Health Session: 902 - Abortion

Second Choice Topic: 9. Fertility, Family Planning, Sexual Behavior, and Reproductive Health Session: 917 - Reproductive Justice, Autonomy, and Coercion

Please use the Submission ID in all communications about your Submission.

This email is being automatically sent to you from the PAA2025 Site.

	Page 1
From:	"Waves Rebecca"
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
Date:	10/11/2024 3:15:52 AM
Subject:	Re: New grant opportunity

yes!

On 10 Oct 2024, at 19:22, Abigail Aiken <<u>araa2@utexas.edu</u>> wrote:

Hi there,

This grant opportunity has just come out and I would like to apply:<u>https://societyfp.org/wp-content/uploads/2024/09/2024-remote-provision-of-medab_rfp.pdf</u>

I think there are some very interesting questions we could look at with AA data. Would you be supportive of this? Maybe you will have some interns in the spring who could be part of the research?

Thanks and hope all is well, A

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Email: <u>araa2@utexas.edu</u>

	Page 1
From:	gomperts
To:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
CC:	"Rebecca Gomperts"
Date:	10/29/2024 3:20:26 AM
Subject:	Re: Update on SFP grant proposal

great i am available tomorrow wednesday

Sent from my iPhone

On 28 Oct 2024, at 22:13, Abigail Aiken <araa2@utexas.edu> wrote:

Hi there,

Just an update that I am currently working on the SFP proposal. The idea for the grant is to explore: 1) multiple ordering of pills across services (how often and the reasons why); 2) the abortion experiences of people living in ban vs. non-ban states, particularly with respect to seeking and accessing in-person follow-up care if needed or desired; 3) the cost of shield law services: what proportion of people pay a reduced amount and what their circumstances are. So there would be both a quantitative and qualitative component to the work

It would be great to talk about the budget as well—would you have time for a call sometime soon?

Thanks so much and all best, A

Abigail R.A. Aiken, MD, MPH, PhD Associate Professor LBJ School of Public Affairs University of Texas at Austin Principal Investigator, <u>Project SANA</u> Email: <u>araa2@utexas.edu</u>

	Page 1
From:	<u>"Sharie Mae Cruz" <onbehalfof@manuscriptcentral.com></onbehalfof@manuscriptcentral.com></u>
To:	
	araa2@utexas.edu
Date:	11/22/2024 6:06:26 AM
Subject:	BMJ Sexual & Reproductive Health - Manuscript ID bmjsrh-2024-202580.R1

22-Nov-2024

Dear Dr. Johnson:

Your manuscript entitled "Motivations for obtaining advance provision of medication abortion in the United States: a qualitative study" has been successfully submitted online and is presently being given full consideration for publication in BMJ Sexual & Reproductive Health.

Your manuscript ID is bmjsrh-2024-202580.R1.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at https://mc.manuscriptcentral.com/bmjsrh and edit your user information as appropriate.

Author names will be taken directly from the information held in ScholarOne and not from the article file. Please check that all names are correctly entered as this will be the name displayed on the final published article and in any indexes affiliated with the journal.

You can view the status of your manuscript at any time by entering your manuscript ID bmjsrh-2024-202580.R1 into Where Is My Paper https://whereismypaper.bmj.com/, our fast and easy-to-use manuscript tracking tool or by checking your Author Center after logging in to https://mc.manuscriptcentral.com/bmjsrh.

Any individuals listed as co-authors on this manuscript are copied into this submission confirmation email. If you believe that you have received this email in error, please contact the Editorial Office.

Thank you for submitting your manuscript to BMJ Sexual & Reproductive Health.

Kind regards, Editor in Chief, BMJ Sexual & Reproductive Health

P.s. What did you think of the article submission process?

At BMJ, we constantly strive to improve our services for authors. We value your feedback and we'd be grateful if you could take 5 minutes to fill out our short survey. Your responses will remain confidential and you won't be identified in any results.

Please click on this link to access the survey https://www.surveymonkey.co.uk/r/6DGV97V:

We are constantly trying to find ways of improving our peer review system and continually monitor processes and methods by including article submissions and reviewers' reports in our research. If you do not wish your paper or review entered into our peer review research programme, please let us know by emailing papersadmin@bmj.com as soon as possible

- From: <u>"Sharie Mae Cruz" <onbehalfof@manuscriptcentral.com></u>
 - To: dmjohnson27@wisc.edu
 - CC: <u>dmjohnson27@wisc.edu</u>

araa2@utexas.edu

- Date: 11/27/2024 9:16:26 AM
- Subject: Your submission to BMJ Sexual & Reproductive Health has been accepted

27-Nov-2024

bmjsrh-2024-202580.R1 - Motivations for obtaining advance provision of medication abortion in the United States: a qualitative study

Dear Dr. Johnson:

We are pleased to accept your article for publication in BMJ Sexual & Reproductive Health.

Your article will now be sent for copyediting and typesetting. We will email you a proof to check via our online tool usually within 10-15 days of acceptance; please check your junk mail folder.

The proof is your opportunity to check for typesetting errors and the completeness and accuracy of the text; including author names and affiliations, tables and figures; including legends, numerical, mathematical, or other scientific expressions. We ask that you only make minor corrections at this stage. Please provide any comments within 48 hours. There will be no further opportunities to make corrections prior to publication.

See https://authors.bmj.com/after-submitting/accepted/ for more information about what to expect once your article has been accepted.

If you have selected open access or colour printing (if applicable) as an optional addition for your paper, within 2-3 working days, you will receive an email with payment options and instructions from BMJ's e-commerce partner, Copyright Clearance Center. You will be able to choose either to pay by credit card or invoice. If you are not making the payment yourself, you may forward the email to the person or organisation that will be paying on your behalf. Your article will not be published by production until you have paid the article processing charge or requested an invoice. If you no longer require open access or colour printing, please let us know at info.bmjsrh@bmj.com For more details on open access publication please visit our Author Hub: https://authors.bmj.com/open-access/.

Please note, that if your institution is part of one of BMJ's Publish and Read or prepay agreements your request for funding will be automatically processed based on this acceptance and you will only receive an email accepting or denying your funding request. To find out if your institution is part of a Publish and Read or prepay agreement visit BMJ's open access agreements page: https://authors.bmj.com/open-access/institutional-programme/.

We publish most articles online in their final form around three weeks after acceptance. See https://authors.bmj.com/after-submitting/online-first-publication/ for more information about online publication. BMJ will deposit your article in all indexes affiliated with the journal.

BMJ Sexual & Reproductive Health has a popular blog (https://blogs.bmj.com/bmjsrh/) that is free to read. We would encourage you to consider contributing a short blog post of <u>500-1000</u> words to help promote your published article to the widest possible audience. Please contact the Social Media Editor at social.srh@bmj.com for further information.

Any final comments from the reviewer(s) are included at the foot of this email. The comments are for your information only, but in the case of minor requests (e.g. typos) these can be corrected when you $\frac{6/30}{2025}$

receive your proof.

If your article is selected for press release by BMJ's Press Office you will be informed as soon as possible.

If you have any queries, please contact the Editorial Office at info.bmjsrh@bmj.com.

Kind regards, Prof. Sharon Cameron Editor in Chief, BMJ Sexual & Reproductive Health

Dr. Hang Wun Raymond Li Associate Editor, BMJ Sexual & Reproductive Health

https://bmjsrh.bmj.com/ @BMJ_SRH Facebook: https://www.facebook.com/BMJ.SRH Blog: http://blogs.bmj.com/bmjsrh/

Reviewer(s)' Comments to Author (if any):

From: <u>"Waves Rebecca"</u>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 12/19/2024 6:22:21 AM

Subject: Re: SFP grant support letter

Attachments: Aid Access_Support letter_Aiken .pdf

Abigail R. A. Aiken, MD, MPH, PhD Lyndon B. Johnson School of Public Affairs University of Texas at Austin 2300 Red River Street Austin, TX, 78713

December 10th, 2024

Dear Dr. Aiken,

Hereby I would like to express the support of Aid Access for our research project "Patient experiences seeking, securing, and managing medication abortion provided through online asynchronous telemedicine across states with abortion bans, restrictions, and protections". I am very happy to be Co-I on this project and as Founder and Director of Aid Access, I will provide access to the de-identified data required to fulfil our specific aims and will be happy for the service to let patients know about the opportunity to take part in in-depth interviews.

Having worked for over two decades providing early medication abortion in countries where safe abortion is not available, I have a wealth of knowledge and experience to contribute to our project. I look forward to collaborating on the design of data collection instruments for the examination of patient experiences and in discussing, interpreting, and preparing our findings for publication. I will also provide insights that will help place our results in the wider context of abortion access in the US and will assist in disseminating findings through national and international networks of advocates and activists.

It has been a pleasure to work closely with you in the past and I hope we will have the chance to continue to work together on this critically important study for women in the United States.

Sincerely,

Dr Rebecca Gomperts

From: jnjournals@jamanetwork.org

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

CC:	"Jennifer E Starling"
	"Danielle van Blitterswijk"
	"Carlijn Looijen"
	<u>"Thijs van Vliet"</u>
	<u>"Dirk Essink" <d.r.essink@vu.nl></d.r.essink@vu.nl></u>
	<u>"Rebecca Gomperts"</u>
Date:	1/1/2025 11:02:32 PM

Subject: Update on your publication in JAMA Internal Medicine

JAMA Internal Medicine

Dear Dr Aiken:

In the 12 months since your article, <u>Advance Provision of</u> <u>Mifepristone and Misoprostol via Online Telemedicine in the US</u>, was published in *JAMA Internal Medicine*, it has continued to attract readership and attention.

We invite you to click the title of your article in the link above to see your article's reach and usage metrics as shown in this example:

You will see the numbers of times your article has been viewed and cited by other articles. The Altmetric score shows coverage by news and social media. By clicking the Altmetric link, you can explore where your article has been mentioned in the news media, blogs, social media accounts, and more.

Please contact me if you have any questions or to discuss publication opportunities for your current and future work.

Best Regards,

Sharon K. Inouye, MD, MPH Editor in Chief, *JAMA Internal Medicine*



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click here to unsubscribe from these emails.

From: "DANA M JOHNSON" <dmjohnson27@wisc.edu>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 1/2/2025 12:03:44 PM

Subject: Fw: Congratulations on your publication with BMJ Sexual & Reproductive Health

Hi all!

The first paper from the advance provision in-depth interview study is live online!

Thanks all for your work on this - I'm so excited to get the first paper from this project out into the world!

Best, Dana

Dana M. Johnson, PhD (she/her) Health Disparities Research Scholars Postdoctoral Fellow Department of Population Health Sciences University of Wisconsin-Madison School of Medicine and Public Health https://www.dana-johnson.com/

From: bmjjournals-mailer@alerts.stanford.edu <bmjjournals-mailer@alerts.stanford.edu> Sent: Wednesday, January 1, 2025 1:10 AM To: DANA M JOHNSON <dmjohnson27@wisc.edu> Subject: Congratulations on your publication with BMJ Sexual & Reproductive Health

We are pleased to confirm that your article is now published online in BMJ Sexual & Reproductive Health:

Article: Motivations for obtaining advance provision of medication abortion in the United States: a qualitative study

Read our tips on how to promote your content. to help boost your article's usage; from sharing it with your colleagues to posting on social media. How you share your article depends on your chosen licence type; find out more about <u>author permissions</u>.

You can access you<u>article performance metrics</u> – including downloads, citations and Altmetric score – and sign up to receive alerts if a response to your article is published.

Visit our <u>Author Hub</u> to access more information on what to expect now that your article is published online, including when you can expect your article to be available in indexing databases.

BMJ is committed to improving its service to authors and we value your feedback: please tell us about your experience in this short survey.

From: "DANA M JOHNSON" <dmjohnson27@wisc.edu>

To: <u>"Abigail Aiken" <araa2@utexas.edu></u>

Date: 1/2/2025 12:03:44 PM

Subject: Fw: Congratulations on your publication with BMJ Sexual & Reproductive Health

Hi all!

The first paper from the advance provision in-depth interview study is live online!

Thanks all for your work on this - I'm so excited to get the first paper from this project out into the world!

Best, Dana

Dana M. Johnson, PhD (she/her) Health Disparities Research Scholars Postdoctoral Fellow Department of Population Health Sciences University of Wisconsin-Madison School of Medicine and Public Health https://www.dana-johnson.com/

From: bmjjournals-mailer@alerts.stanford.edu <bmjjournals-mailer@alerts.stanford.edu> Sent: Wednesday, January 1, 2025 1:10 AM To: DANA M JOHNSON <dmjohnson27@wisc.edu> Subject: Congratulations on your publication with BMJ Sexual & Reproductive Health

We are pleased to confirm that your article is now published online in BMJ Sexual & Reproductive Health:

Article: Motivations for obtaining advance provision of medication abortion in the United States: a qualitative study

Read our tips on how to promote your content to help boost your article's usage; from sharing it with your colleagues to posting on social media. How you share your article depends on your chosen licence type; find out more about <u>author permissions</u>.

You can access you<u>article performance metrics</u> – including downloads, citations and Altmetric score – and sign up to receive alerts if a response to your article is published.

Visit our <u>Author Hub</u> to access more information on what to expect now that your article is published online, including when you can expect your article to be available in indexing databases.

BMJ is committed to improving its service to authors and we value your feedback: please tell us about your experience in this short survey.

From: <u>"Abigail Aiken" <araa2@utexas.edu></u>

To: <u>"James Scott" <James.Scott@mccombs.utexas.edu></u> <u>"Rebecca Gomperts"</u> <u>"Angel Foster" <Angel.Foster@uottawa.ca></u>

Date: 3/7/2025 5:52:00 PM

Subject: Fwd: Congratulations from the Society of Family Planning

Hi all,

Some great news from SFP, please see below!

I'll be in touch shortly to get the ball rolling. For now, thank you all for your willingness to collaborate in this research and looking forward to getting started.

Best to all, Abigail

------ Forwarded message ------From: **SFP Grants** <<u>grants@societyfp.org</u>> Date: Fri, Mar 7, 2025 at 2:31 PM Subject: Congratulations from the Society of Family Planning To: Abigail Aiken <<u>araa2@utexas.edu</u>>

Dear Dr. Aiken,

Congratulations! It is my pleasure to share that the Society of Family Planning will be funding your proposal for the *Understanding people's experiences with remote provision of medication abortion* funding opportunity. We are delighted to be partnering with you around this important work.

Peer review was essential to the decision-making related to this funding opportunity. All proposals were reviewed by individuals with specific expertise in this topic. Recognizing how valuable peer review feedback can be, we are committed to sharing it with applicants. **Your application's reviews are now visible in the <u>online application portal</u>.**

Keep in mind that each review reflects one individual's feedback on your proposal. As is often the case in peer review processes, perspectives may diverge between reviewers. All applications and feedback are evaluated holistically.

We will be announcing grant recipients publicly in the coming week, so please look out for an email announcement.

In the meantime, **please visit the link<u>here</u> to schedule youronboarding call**, ideally before April 1, to walk briefly through the administrative elements of your award, including a learning community for grantees.

Congratulations again! Please don't hesitate to be in touch with any questions in the interim.

All the best,

Rachel

Grants staff

Rachel Brooks, Senior Grants Manager (she/her)

Patty Fernandez Piñeros, Senior Grants Manager (she/her) Ruth Manski, Director of Research Programming and Organizational Learning (she/her)

Ohvia Muraleetharan, Research Program Manager (she/her) Jenny O'Donnell, Senior Director of Research and Evaluation (she/her)

Eunice Ruiz, Grants Administration Coordinator (he/him) Grants@SocietyFP.org www.SocietyFP.org SFP

From: jnjournals@jamanetwork.org To: "Abigail Aiken" <araa2@utexas.edu>

CC:	"Elisa S Wells"
	"Rebecca Gomperts"
	"James G Scott" <james.scott@mccombs.utexas.edu></james.scott@mccombs.utexas.edu>
Date:	3/25/2025 10:01:21 PM
Subject:	Update on your publication in JAMA



Dear Dr Aiken:

In the 12 months since your article, <u>Provision of Medications for Self-Managed Abortion Before and After the Dobbs v Jackson Women's</u> <u>Health Organization Decision</u>, was published in *JAMA*, it has continued to attract readership and attention.

We invite you to click the title of your article in the link above to see your article's reach and usage metrics as shown in this example:

You will see the numbers of times your article has been viewed and cited by other articles. The Altmetric score shows coverage by news and social media. By clicking the Altmetric link, you can explore where your article has been mentioned in the news media, blogs, social media accounts, and more.

Please contact me if you have any questions or to discuss publication opportunities for your current and future work.

Best Regards,

Kirsten Bibbins-Domingo, PhD, MD, MAS Editor in Chief, *JAMA*



This message was sent to araa2@utexas.edu by tjnjournals@jamanetwork.org.

The JAMA Network | 330 N. Wabash Avenue | Chicago, IL 60611

Click here to unsubscribe from these emails.

From:	<u>"Abigail Aiken" <araa2@utexas.edu></araa2@utexas.edu></u>
To:	"Rebecca Gomperts"
	<u>"Angel Foster" <angel.foster@uottawa.ca></angel.foster@uottawa.ca></u>
Date:	5/19/2025 4:27:12 PM
Subject:	Connecting on SFP grant

Hi Rebecca and Angel,

As the start date for the SFP grant approaches, I was hoping we might be able to schedule a meeting for the three of us sometime in early June.

Would you all please be able to share some good dates/times for the week of June 9th? I know you're both very busy and that the time difference may be a challenge, so I will do my best to work around you all's schedules.

Thanks so much and all best, Abigail